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  Abstract 
2 
 
Integrin α7β1 plays an important role in maintaining adult skeletal muscle 
integrity and like dystrophin, provides anchorage and bidirectional signaling as a 
laminin receptor. The expression of α7β1 integrin was upregulated upon dystrophin 
deficiency arguing for the molecular compensation and thus considered as potential 
candidate for treatment of Duchenne Muscular Dystrophy (DMD). 
 
The existence of developmentally regulated alternative splice variants makes the 
α7β1 integrin a complex integrin to study its function in skeletal muscle. In this study 
we show that increased levels of the adult extracellular variant X2 interfere with muscle 
integrity, while the presence of embryonic integrin α7 extracellular variant X1 results in 
normal skeletal muscle architecture. Furthermore, detailed analysis of mdxα7tg mice 
suggests that overexpression of integrin α7 made no difference on the dystrophic 
phenotype, in fact mdx α7X2 mice show a more severe phenotype compared to mdx mice.  
 
Our study also shed light on the importance of integrin α5 during the 
development of the skeletal muscle by means of generati g conditional knockout (cKO) 
mice using HSA-Cre and Pax3-Cre promoter systems. Our findings show no obvious 
difference in the Itga5 cKO when the HSA promoter drives Cre recombinase, however 
conditional loss under the control of the Pax3 promoter leads perinatal lethality.  
 
In addition we investigate the dosage effect of integrin α5 in integrin α7 
knockout (KO) mice to understand the cross talk betwe n these two integrins and to co-
relate with previous data suggesting a gain of functio  phenotype by that existence of 
integrin α5 at the myotendinious junction (MTJ) in α7KO muscle (Nawrotzki et al., 
2003) 
 
From our data we know that gene therapy with integrin α7 is a challenge and is 
not a suitable alternative to cure dystrophy, at lest not in mdx mice, we therefore switch 
our focus on looking into cell based therapies for DMD by investigating the potential 
role of perivascular cells (PVCs) using transplantation experiments in mice by 
artificially inducing muscle damage. 
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1. Introduction 
1.1 Skeletal Muscle:  
 
Muscle is a specialised tissue that has both the ability to contract and to conduct 
electric impulses. There are three types of muscle tissue - skeletal, cardiac and smooth 
muscle. Skeletal muscle moves the body with the help of muscle fibre contraction, 
which is a result of the force generated by ATP consumption. The contractile force 
generated in the muscle must be passed through the muscle cell membrane, the 
sarcolemma, to the muscle surrounding basement membrane before being transferred 
through the tendon to the bone allowing for a joint movement.  The complexity of 
muscle function requires a high degree of specialisation and organisation of muscle cell 
components, but this also leaves muscle susceptible to the effect of mutations. This is 
exemplified by the muscular dystrophies, of which many are caused by the disruption of 
the muscle cell anchorage between inside and outside of the cell. 
Skeletal muscle integrity and its function are maintained by the interaction of the 
muscle cell with the surrounding extracellular matrix. Cell adhesion molecules, like 
integrin α7β1 and the Dystrophin Glyoprotein Complex (DGC) link the muscle cell to 
the surrounding basement membrane and thus play an important role in transferring 
signals between inside and outside of the muscle cel . It has been shown that in the 
absence of either of these cell-adhesion molecules mu cle integrity is compromised 
leading to muscle wasting disease and myopathies. In order to develop potential 
therapies for the diseases it is important to understand the role cell-matrix interaction 
plays in normal development and maintenance of the adult muscle cell. 
 
 1.2 Muscle fibre development, structure and function  
 
The first sign of commitment to the myogenic lineag in the mouse is seen 
around 8 days post coitum ( Ott et al., 1991)  when the precursor cells in the paraxial 
mesoderm (those adjacent to the notochord and neural t be) start to express the 
myogenic regulatory factors (MRFs). The promoter elements that control the specific 
temporo-spatial expression of the MRFs coordinating myogenesis have yet to be fully 
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elucidated, though it is known that the transcription of muscle specific proteins is a 
complex network of feedback loops and cascades allowing the precise control of the 
differentiation state. 
Once committed to muscle cell lineage, myoblasts (muscle cell precursors) 
migrate to regions of muscle formation and start to pr liferate. Some align with each 
other, withdraw from the cell cycle and fuse to form multi-nucleated primary myotubes. 
Subsequent migrating myoblasts then fuse to this primary structure and this process is 
termed secondary myogenesis. The fusion of myoblasts to form myotubes is termed 
terminal differentiation. The secondary myotubes continue to grow and elongate by cell 
fusion before eventually separating and maturing into adult muscle fibres (Fig. 1.1).  
 
 
Figure 1.1: Schematic representation of myogenesis. Myoblasts withdraw from the cell cycle 
and fuse to form primary myotubes. Further myoblast fu ion is termed secondary myogenesis 
 
 
Over the course of this process, structural proteins a d enzymes are synthesised 
and assembled into structural components or secreted to contribute to the specialised 
extracellular matrix surrounding muscle. 
Secondary myotubes grow as a result of cell fusion and eventually separate and 
mature into adult skeletal muscle fibre. They are multinucleated and cylindrical in 
shape. A single myofibre contains bundles of myofibrils, which are divided into a 
serially arranged contractile apparatus called sarcomers. Each myofibre is surrounded 







Terminal Differentiation  
- Adult 
   





Figure 1.2: Adult skeletal muscle structure. The myofilament proteins constituting the 
contractile apparatus are found within each individual myofibril. Myofibrils are bundled within 
the muscle fibre and encased by the sarcolemma (the muscle fibre plasma membrane) and a 
specialised extracellular matrix (ECM), the basement membrane, to form muscle fibres. The 
nuclei of each fibre lie just under the surface of the sarcolemma. Between muscle fibres is an 
interstital connective tissue termed the endomysium. A bundle of muscle fibres termed the 




Myofibres are attached to the sarcolemma at Z-disks by focal adhesion points 
called costameres. The muscle fibre is linked to the skeleton via the fibrous connective 
tissue called tendon. The site where the tendon meets the muscle fibre is called 
myotendinious junction (MTJ). At the MTJ the sarcolemma forms digit-like extensions 
into the tendon to increase the surface area of the MTJ and thus transferring tension into 
shear stress.  
Myofibres are further classified into fibre types, oxidative/slow (type I) and 
glycolytic/fast (type II) fibres, depending upon their morphology, metabolic and 
physiological properties. Glycolytic fibres are further divided in the mouse, into 
subtypes IIa, IIb and IId.  Each fibre type differs in the expression of the myosin heavy 
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muscle has its own population of stem cells called satellite cells found between the 
muscle fibre sarcolemma and the basement membrane (Bishoff, 1994). They mediate 
repair of the adult muscle, being mitotically quiesc nt they are activated to re-enter the 
cell cycle in response to stress, induced for example by injury (Grounds, 1991) or 
diseases such as muscular dystrophies (Webster and Bl u, 1990). 
The main function of muscle fibres is to contract and as a result produce body 
movement. The contractile unit of the muscle is termed the sarcomere and is defined as 




Figure 1.3: The contractile unit of muscle. Muscle fibres are striated due to the structure of 
the contractile unit. The alignment of actin and myosin gives skeletal muscle its characteristic 
striations.  Myosin fibres are thick and constitute th  dark A-band, in the centre of which is the 
lighter H-Zone. Adjacent to the A-band is the lighter I-Band, this also contains the darker Z-
line. The portion between two Z-lines is a single contractile unit, termed the sarcomere. 
Stimulation by a nerve impulse causes the globular head of myosin to bind actin. Once bound, 
ATP consumption results in movement of this head region, which pulls the actin into the centre 
of the sarcomere. The myosin head then releases the actin filament and the cycle is repeated. 
The sliding of myofilament components over each other via the consumption of ATP reduces 
muscle length by 70%. (Taken from Rogers and Mayer, 2005) 
 
 
Skeletal muscle function integrity and the transmision of chemical and 
mechanical signals are maintained by the interaction of the muscle cell with the 
surrounding extracellular matrix. As muscle cell contraction generates the force 
required for movement, muscle cell attachment to its surrounding matrix at the sites of 
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interaction of muscle fibres with their surrounding matrix is also significant in the 
regulation of cell survival, proliferation and differentiation (Hynes, 2002). The correct 
attachment to a normal basement membrane is therefor  as important to muscle fibre 




Figure 1.4: Anchorage of the contractile apparatus in adult skeletal muscle. Contraction of 
muscle results when the myosin and actin filaments of he myofilaments slide over each other. 
The Z-line is the point at which the actin filaments are anchored. Myosin also has a base plate 
to which it is anchored, termed the M-line. The Z-line and to a lesser extent the M-line are the 
points at which the contractile unit attaches to the sarcolemma and therefore the basement 
membrane. These linkage points are termed the costameres (Pardo, Siliciano and Craig, 1983) 
and are rich in proteins such as vinculin, α-actinin, talin and the transmembrane adhesion 




Cell-matrix contact is predominantly maintained through the interaction of 
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1.3 Basement membrane  
Basement membranes (BM) are a highly specialised elment of extracellular 
matrix structure, which surrounds the skeletal muscle fibre and play an important role in 
muscle fibre regeneration. It was first described in 1840 by the histologist and surgeon 
Sir William Bowman (Bowman, 1940). In his publication Bowman described what is 
known as a BM to be highly delicate, transparent and elastic sheath encircling 
individual muscle fibres. Analysis at the level of electron microscopy revealed that the 
basement membrane is made up of two layers. The first being a sheet-like structure 
directly linked to the sarcolemma, called basal lamina (Figure 1.5) and the second an 
underlying fibrillar reticular lamina. The basal lamina consists of members of the 
laminin family, members of the type IV collagen family, the heparan sulphate 
proteoglycan perlecan, nidogen and additional molecules such as growth factors and 




Figure 1.5: The basal lamina- A) Scanning electron micrograph of the basal lamina taken from 
the cornea of the chick embryo, where the epithelial cells have been removed to reveal the 
sheet-like structure. B) The networks of collagen type IV and laminin connected through 
nidogen and perlecan. Integrin α7β1 and DGC (not shown in here) connect the basal lamin  to 
the plasma membrane in skeletal muscle. (Adapted from Alberts, 2002). 
 
 
Within the ECM protein family, laminin has been shown to have a significant 
effect on cell behaviour. Laminin induces changes in myoblast cell shape, enhances 
migration and stimulate proliferation (Ocalan et al., 1988; Timpl and Brown 1996). 
Laminin is a trimer, composed of α, β and γ chains. Laminins-2, -4, -8, -9, -10 and -11, 
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containing the α2, α4 and α5 chains, respectively, are those predominant in skeletal 
muscle basement membranes during development. In the adult, laminin α4 and α5 
chains become confined to the neuromuscular junctio (NMJ) and blood vessels, while  
the α2 chain containing laminins (laminins-211 and -221) become the predominant 
forms (reviewed in Gullberg et al., 1999; Sanes, 2003). 
Basement membranes are important for cell polarisation in the embryo and 
adult, for cell migration during development and for cell migration and adhesion in 
wound healing (Yurchenco et al., 1993). The change i  expression pattern of basement 
membrane components reflects the degree of specialisat on of the muscle ECM to 
muscle cell development and function. For example, terminal differentiation is 
characterised in part by a switch from a fibronectin-rich ECM to a laminin-rich 
basement membrane (Kuhl et al., 1986). 
Fibronectin has pronounced effects on cell behaviour. It is implicated in many 
processes in the developing embryo such as gastrulation, migration of neural crest cells 
and germ cells, somitogenesis and the development of the heart and vasculature. Its 
importance is reflected by the embryonic lethality of functional null mutant mice. These 
mice have mesodermal defects and fail to develop notoch rds or somites (Georges-
Labouesse et al., 1996). Fibronectin is first present at the blastocyst stage of 
development in mouse embryos and is abundant at sites of active cell migration (Hynes 
and Yamada, 1982). Within the adult, fibronectin is involved in processes such as 
wound healing and pathological processes such as thrombosis, fibrosis and neoplastic 
transformation (George et al., 1993). In muscle, fibronectin is down regulated in the 
basement membrane surrounding newly formed muscle fibres at terminal 
differentiation, though its expression remains in the endomysium between them. 
The effects of various BM components on cell functions are mediated via cell 
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1.4 Transmembrane receptors: 
Transmembrane receptors are necessary to induce migration, differentiation and 
fusion of myogenic cells as well as provide important cellular interactions between the 
actin cytoskeleton and the extracellular matrix in adult skeletal muscle. The two major 
transmembrane receptors expressed in skeletal muscle, which link laminin of the 
basement membrane to the actin cytoskeleton are the Dystrophin-Glycoprotein-
Complex (DGC) and integrin α7β1.  
1.4.1 Dystrophin-Glycoprotein-Complex (DGC): 
The DGC is a multi-functional protein complex made up of membrane 
associated proteins and plays an important role in maintaining the integrity of the 
skeletal muscle fibre. This multi-subunit protein complex is comprised of structurally 
organised 3 distinct sub-complexes namely, the intracellular proteins, dystrophin, 
syntrophins, the sarcolemmal localised β-dystroglycan, sarcoglycans (α, β, γ and δ), 
sarcospan and the extracellular α-dystroglycan. Dystroglycan is a ubiquitously 
expressed large glycoprotein, which is distributed at the cell surface. It is a product of a 
single gene and the protein is further processed into two non- covalently linked sub-
units called α -and β- dystroglycan. α- dystroglycan acts as a receptor for ECM 
components on the extacellular side, whereas β-dystroglycan is inserted into the plasma 
membrane where it binds to dystrophin inside the cell. Early studies demonstrate that 
dystroglycan plays an important role in BM formation f embryoid body; thus mice 
deficient for dystroglycan die early in development prior to gastrulation (Williamson et 
al., 1997).  
 Dystrophin binds to the actin cytoskeleton with its N-terminal end and with its 
C-terminal end to β-dystroglycan, which then links to the extracellular matrix by α- 
dystroglycan and laminin interaction (Durbeej and Campbell, 2002) thereby providing a 








   




Figure1.6: The Dystrophin-Associated Protein Complex (DAPC). This simplified cartoon 
represents the major components of the DGC, the extracellular laminin 211 ligand and 
intracellular binding partners. The DGC is made up of two subunits α and β. α-DG is located 
on the extracellular side of the membrane, where it binds to laminin-211 and the 
transmembrane -bound, β-DG. Β-DG then binds intracellularly to dystrophin, linkig DG to γ-
actin. Associated with DG is the sarcoglycan complex, which is composed of multiple subunits. 




The DGC is critical in maintaining skeletal muscle. Mutations in the genes 
encoding components of DGC and the laminin α2 chain cause a class of hereditary 
myopathies, known as muscular dystrophy, characterised by muscle degeneration and 
regeneration, which is typically progressive and manifests in different severities 
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1.4.2 Integrins: 
Integrins constitute a large family of glycosylated heterodimeric transmembrane 
adhesion receptors mediating cell-cell, cell-matrix and cell-pathogen interactions. The 
name “integrin” comes from the “integrating” nature of these adhesions (Tamkun et al., 
1986) as they integrate the cell’s exterior (ECM) to the cell’s interior (cytoskeleton). All 
integrins are αβ heterodimers. There are 8 known β subunits and 18 known α subunits 
that can associate to form 24 different integrins (Gullberg, and Lundgren-Akerlund, 
2002). The β1 subunit is associated with at least 12 different α subunits to form the 
largest sub family of integrin (figure 1.7). The complexity is increased by the existence 






Figure 1.7: The integrin family. Integrins consist of two subunits α and β. Together they form a 
heterodimer. 24 heterodimers are known to exist in vertebrates. Each heterodimer interacts 
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There are two intracellular splice variants known for the integrin β1 subunits in 
the mouse, namely β1A and β1D. They are also the most abundant form of β1 integrins 
in human (Baudoin et al., 1998). The β1A variant is ubiquitously present, while the β1D 
is restricted to skeletal and cardiac muscle (van der Flier et al., 1995; Zhidkova et al., 
1995). The β1A subunit is expressed during primary myogenesis; it  then replaced by 
β1D during secondary myogenesis (Brancaccio et al., 1998).  
 
1.4.2. 1 Integrin structure: the extracellular domains 
The integrin α and β subunits show no homology to each other. The α subunits 
are 130-180 kD in size and β subunits are approximately 90 kD. Both subunits are in 
contact with each other via their N-terminal domains, which form globular head. This is 
the region at which the subunits interact with each other and with their ligands (Nermut, 
et al., 1988; Weisel et al., 1992) (Figure 1.8).  
 
 
Figure 1.8: A Schematic and simplified portrayal of integrin α and β subunit domain 
structures. Domains of the α subunit include, the β-propeller, three β-sandwich domains that 
make a ‘thigh’ domain and two similar domains forming the ‘calf’ module (Xiong et al., 2001). 
Within the β subunit there is a PSI domain, so termed because it is present in plexins, 
semaphorins and integrins (Bork et al., 1999), four epidermal growth factor domains and a β-
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The globular head domain of the integrin is a region at which the subunits 
interact with each other and with their ligands (reviewed in Humphries, 2000). Ligand 
binding is complicated and requires an understanding of subunit structure. Ligand 
binding of integrins requires the presence of divalent cations. The way in which the α 
subunits contribute to the co-ordination of the cations divides them into two groups. 
This classification depends on the presence of an I-domain (Inserted domain) (Lee et al., 
1995; Michishita and Arnaout, 1993)   
 
The α subunits are structurally divided into two different groups, those with and 
those without an inserted “I’’ domain (Lee et al., 1995). The domain is also referred to 
as the A-domain as it is homologous to the van Willebrand factor A domain (Arnaout et 
al., 1988; Corbi et al., 1987; Larson et al., 1989). A similar domain constitutes the 
globular head in the β subunit. The globular head of both types of α subunits is made up 
of seven repeated structures, which fold to form a seven-bladed β-propeller (Springer, 
1997; Xiong et al., 2001), which is connected to a thigh and the calf-1 and calf-2 
domains. Some of the β-propeller repeats assembles EF-hand like Ca2+ binding sites 
(Leitinger et al., 2000) (repeats 4-7 in non I domain α chains and repeats 5-7 in I domain 
α chains). A typical EF-hand repeat contains 12 amino acid residues, with oxygen 
containing residues at positions 1, 3, 5, 9 and 12 and these provide coordination sites for 
divalent cations (Strynadka and James, 1989). However, the EF-hand-like repeats in all 
integrin α subunits lack the coordination site at position 12, but still appear to be able to 
coordinate a cation (Gulino et al., 1992; D’Souza et l., 1991). The specific role of these 
sites has proven difficult to study as their mutation often leads to a lack of cell surface 
expression (Wilcox et al., 1995; Masumotp and Hemler, 1993). However, it has been 
shown that coordination at these sites may not be involved in the ability to bind ligand, 
but rather in the regulation of cell adhesion in a lig nd binding-independent manner 
(Pujades et al., 1997). The Ca2+ binding to these sites allosterically affects the ligand 
binding (Humphries et al., 2003; Oxving and Springer, 1998). Half of the 18 known 
integrin α subunits have an inserted I domain. The α1, α2 α10 and α11 subunits 
associate with β1 subunit and form ECM-binding integrin. The αD, αM, αL, αX (β2 
associated) and αE (β7 associated) mediate cell binding in cells of the immune system. 
The crystal structure of I domain from αM, αL, α1 and α2 revealed that the central β-
sheet is surrounded by seven α-helices to form a Rossman fold (Emsley et al., 1997; Lee 
et al., 1995; Nolte et al., 1999; Qu and Leahy, 1995; Rich et al., 1999).  
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The extracellular domain of the β-subunit consists of an I domain (βI- domain) 
linked by a hybrid domain to the stalk region. The N-terminal also forms a separate 
domain called plexin-sempahorin-integrin (PSI) domain, which folds back from the βI 
domain to hybrid domain (Bork et al., 1999). The βI domain is involved in ligand 
binding. It consists of an Mg2+ coordinating MIDAS and a site adjacent to MIDAS 
(ADMIDAS) binding and inhibitory Ca2+ ion. βI domain is also involved in the folding 
of α-chain β-propeller. βI domain is responsible for the conformational changes by 
binding to the Mn2+ ion (Humphries et al., 2003). The β-chain cytoplasmic tail is 
longer than that of the α chain and is involved in the anchorage to cytoskeleton. The α 
subunits lacking an A domain lack the MIDAS, so an alternative method of metal ion 
co-ordination must be achieved. This is via the β-propeller domain and an I-like domain 
found in the β integrin subunit, as exemplified by the αVβ3 integrin crystal structure 
(Xiong et al., 2001). It seems that aromatic residues within the β-propeller of the αV 
interact with the β subunit to form an interface for cation co-ordinaton and therefore 
ligand binding (Xiong et al., 2001). 
The two different groups of integrin α subunit (I-domain containing or not) also 
differ in that those not containing an I-domain (α3, α5, α6, α7, αv and αIIb) also have 
an endogenous proteolytic cleavage site, close to the transmembrane domain. These 
integrins exist as an N-terminal heavy chain and a 20-30kDa C-terminal light chain, 
held together by a disulfide bridge. Proteolytic cleavage is vital for the functional 
activation of cell surface receptors, adhesion molecules and extracellular matrix proteins 
(Seidah et al., 1998; Seidah and Chretien, 1997). 
Limited investigation into the function of proteolytic cleavage in integrin α 
subunits has been carried out. Integrin α6 was expressed in the LoVo cell line, which 
expresses a mutated, non-functional form of the proteolytic cleavage enzyme Furin 
(Lehmann et al., 1996). The un-cleavable α6 integrin was able to associate with the β 
subunit and the attachment of these cells to laminin-1 was indistinguishable to cell lines 
expressing the cleaved form of integrin α6. 
Similarly, mutation of the cleavage site of integrin αIIbβ3 did not affect cell 
surface expression or adhesion on fibrinogen (Kolodziej et al., 1991). In fact, the role of 
integrin α subunit cleavage has as yet, remained elusive. It has however been shown 
that disruption to the cleavage site of integrin α6 affected its inside-out signalling in 
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terms of affinity modulation by phorbol 12-myristate 13-acetate (Diamond and Springer 
1994). 
Integrins are major carriers of N-glycans and it is well known that cell surface 
carbohydrates contribute greatly to the interaction between a cell and its extracellular 
environment. This includes processes such as cell-cell communication, cell signalling, 
protein folding and stability. Both the α and β subunits of integrins are glycosylated. 
The α5β1 integrin is one of the best characterised integrins, it has been shown that N-
glycans are a requirement for αβ dimerisation, proper integrin-matrix associations a d 
probably lateral association of integrins with membrane associated proteins and 
glycolipids (Gu and Taniguchi 2004; Bellis 2004; Zheng and Hakomori 1994). 
Abnormal changes to N-glycosylation of integrins can modulate biological functions 
such as cell spreading and migration, which makes th m of particular importance in 
disease, processes such as cancer (Dennis et al., 2002; Jasiulionis et al., 1996; Miyoshi 
et al., 1999).  
The ligands that β1 integrins interact with are mostly components of the ECM 
and counter receptors on other cells. Integrins interact with defined recognition sites 
within their ligands. The first to be elucidated was Arg-Gly-Asp (RGD), present in 
fibronectin and vitronectin and recognised by α5β1, αIIbβ3 and αVβ3 integrins (Charo 
et al., 1990; D’Souza et al., 1988). RGD-reactive int grins are quite closely related and 
all contain α subunits that are without an I-domain and which are p oteolytically 
cleaved. Within the group of laminin-recognising integrins two groups seem to have 
independently evolved. One recognises the E8 fragment containing the long arm of 
laminin (Gehlson et al., 1989) and is recognised by proteolytically processed α subunits, 
α3β1, α6β1 and α7β1. The other group recognises part of the short arm of the α chain in 
laminins, they have uncleaved α subunits with I domains and include α1β1 and α2β1 
(Hall et al., 1990). 
 
1.4.2.2 Integrin: intracellular domains  
Ligand binding conveys a signal to the cell interior through the membrane 
spanning region and cytoplasmic portion of each chain within the dimer. Cytoplasmic 
tails are short in length and there is high sequence similarity between the different α and 
β cytoplasmic tails. The conveyance of an integrin-mediated signal involves the 
coordination of components of the cell cytoskeleton or associated signal transduction 
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molecules. The main difference between integrins and other adhesion receptors is their 
ability to regulate their signalling from the inside and the outside. Integrin modulation 
from within allows the cell to have some control over the ECM that surrounds it. The 
interaction of intracellular proteins with the cytoplasmic domains of the integrin dimer 
can regulate integrin function (Liu, Calderwood and Ginsburg, 2000). This could be by 
‘activating’ them to increase their affinity for ligand (Schwartz, Schaller and Ginsberg, 
1995). The interaction of the α and β cytoplasmic domains can also alter the affinity of 
the receptor (Lu, Takagi and Springer, 2001). It has been suggested that the receptors 
may be kept in a default low-affinity state, which may help to protect cells from 
opportunistic pathogens able to utilise the receptors (Hauck, 2002). It was suggested 
that the activation state of the integrin αVβ3 may be controlled by its extracellular 
conformation that a ‘bent’ inactive state may exist, where the globular head folds over 
to lie close to the cell membrane (Xiong et al., 2001; Beglova et al., 2002).  
Ligand binding to integrins is associated with the clustering of integrins and the 
recruitment of actin filaments and signalling proteins (Hynes, 2002). The specialised 
complexes formed at the membrane are termed focal adhesions. The structures are 
dynamic and can dissociate and reform at different sites and this phenomenon is 
involved in processes such as wound healing and cell migration (Grose et al., 2002; 
Ballestrem et al., 2001). This provides an affinity independent mechanism of regulation 
through changes to integrin clustering and the diffus on rate of integrins within the 
membrane (Kim et al., 2004). 
The correct localisation of integrins also requires a connection to the actin 
cytoskeleton via the integrin β1 cytoplasmic domain. This connection can be a direct or 
in-direct association of intermediary proteins including vinculin, talin, α-actinin, tensin 
and paxillin (reviewed in Brakebusch and Fassler, 2003). Mutations to the cytoplasmic 
domain of integrin β1, prevent the localisation of the heterodimer to focal adhesions, 
cause reduced ligand binding and impaired activation of downstream signalling 
molecules (Marcantonio et al., 1990; Hayashi et al., 1990; Solowska et al., 1989).  
As integrin cytoplasmic domains have no detectable enzymatic activity, as well 
as providing an achor to the actin cytoskeleton, proteins binding the integrin β tails also 
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1.4.3: Bidirectional signalling of integrins 
Integrins are bidirectional signalling molecule. Extracellular stimuli can induce 
intracellular signalling cascades (outside-in signalli g) and intracellular stimuli can 
regulate extracellular changes (inside-out signallig). These will be discussed in detail 
below. 
 
1.4.3 I Inside-out signalling 
Integrins are expressed on the cell membrane in both inactive and active 
conformations. The active conformation of integrins is controlled by pathways that act 
on the interactions between the cytoplasmic tails of the α and β subunits (Constantin et 
al., 2000; Dustin and Springer, 1989; Lollo et al.,1993). In the absence of intracellular 
stimuli the cytoplasmic tails of the α and β subunits are bound together constraining the 
integrin in an inactive conformation. In this low affinity state the integrin assumes a 
bent conformation (Figure 1.9A) (Takagi et al., 200). Binding of talin to the 
cytoplasmic tail of the β subunit leads to the separation of the α and β cytoplasmic tails 
(Tadokoro et al., 2003). This causes a separation of the transmembrane domains and the 
membrane proximal extracellular domain. This conformational change destabilises the 
interface between the headpiece and the tailpiece of integrins inducing a switch-blade 
like opening of the integrin into an extended, active conformation (Figure 1.9B) (Takagi 
et al., 2002). In the extended conformation integrins have a high- affinity towards their 
extracellular matrix ligands (Takagi et al., 2002). Active ligand-bound integrins then 
cluster on the cell membrane and, together with various cytoplasmic adaptor proteins, 
form complexes known as focal adhesions. Following the formation of focal adhesions, 
integrins modulate a vast array of intracellular changes. 
 
   




Figure 1.9: Inactive and extended integrin conformations. Electron micrographs and ribbon 
diagrams of (A) bent/inactive and (B) extended/ active integrin conformations. Bending occurs 
at the junction between the tailpiece and the headpiece in the extracellular domains, 
corresponding to α position between the thigh and calf-1 domain of the a subunit and between 
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1.4.3.II Outside-in signalling: 
Approximately 150 different molecules have been shown to interact with 
integrins at focal adhesions, including growth factor receptors, kinases phosphatases, G 
protein regulators, proteases, actin modulators and multiple adaptor proteins (Zamir and 
Geiger, 2001). Integrin-mediated signalling is therefo e a complex event, which is 
required to modulate a diverse array of cellular behaviours such as cell proliferation, 
cell survival, cell shape, cell polarity, cell migration, gene expression and 
differentiation. It is well established that signalling pathways rely on a cascade of 
phosphorylation events, however integrins do not contain any intrinsic kinase activity 
and therefore depend on kinases associated with their cytoplasmic tails. The two main 
kinases, which associate with the cytoplasmic tail of the β subunit and elicit 
downstream signalling effects are focal adhesion kinase (FAK) and integrin linked 
kinase (ILK). The importance of FAK and ILK has been stablished. Both are critical 
for development and their absence leads to embryonic lethality (IIic at al., 1995; Sakai 
et al., 2003). There are many additional binding proteins and downstream signalling 
pathways including membrane extension by the integrin-mediated dissociation of GTP-
bound Rho-GTPases (Del Pozo et al., 2002) or the activation of Src-like kinases 
involved in pathways regulating microtubular re-organisation (Etienne-Manneville and 
Hall, 2001). Mitogenic signalling proteins can also be recruited including growth factor 
receptors (Miyamoto et al., 1996; Plopper et al., 1995), mitogen-activated protein kinase 
(MAPK), lipid second messengers and protein phosphatases (Miyaamoto et al 1995).  
Most integrin heterodimers are expressed on a wide variety of cell types and 
most cells express several integrins. The wide variety of integrins and their ligands 
mean a cell can modulate its adhesiveness by changing the pattern of integrin 
expression. In addition, cells can even modulate the binding properties of the specific 
integrins they express (Elices and Hemler, 1989; Kirchhofer et al., 1990; Staatz et al., 
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1.5 Integrins during skeletal muscle development 
Within adult mammalian skeletal muscle, members of the β1 family of integrins 
are expressed at areas important to muscle function. These include the costameres, 
neuromuscular junction (NMJ) (where the nerve meets the myofibre), the MTJ and the 
sarcolemma. Though their expression patterns at each of these sites vary depending on 
the stage of development. As described previously, myogenesis involves the migration 
of myoblasts to areas of muscle formation followed by their differentiation into adult 
muscle fibres. Regulation of this is controlled by cytokines, cell adhesion receptors and 
ECM components.  
During and following the development of skeletal muscle the expression pattern 
of integrin subunits and their splice variants are tightly regulated (Figure 1.10). The 
predominant integrin subunits expressed in skeletal muscle are α4, α5, α6, α7, αv and 
β1. The integrin subunit α7 is alternatively spliced in both the cytoplasmic (α7A and 
α7B) and the extracellular (α7X1 and α7X2) domains (Collo et al., 1993; Song et al., 
1993; Zober et al., 1993). Splicing of integrin β1 gives rise to two variants expressed in 
muscle β1A and β1D (van der Flier et al., 1995). The β1 integrins have been shown to 
be important at the specific step of plasma membrane breakdown and subsequent to 
this, in the assembly of the muscle fibre cytoskeleton (Schwander et al., 2003). By the 
time secondary myotubes have formed the integrin β1D cytoplasmic splice variant has 
replaced integrin β1A. Integrin β1A staining has disappeared from the sarcolemma of 
adult muscle fibres (Belkin et al., 1996). The β1D variant is specifically restricted to 
skeletal and cardiac muscle (van der Flier et al., 1995; Zhidkova, Belkin and Mayne, 
1995) where it is enriched at sites of force transmis ion (Belkin et al., 1996; van der 
Flier et al., 1995). It is thought to provide a stronger connection at this site than the 
integrin β1A variant, and this has been exemplified in vitro by the improved 
cytoskeleton-ECM connection of non-muscle cells transfected with integrin β1D 







   




Figure 1.10: Integrin and extracellular matrix protein expression during myogenesis. During 
primary myogenesis the integrin β1 splice variants β1A is predomintantly expressed while 
during the secondary myogenesis it was replaced by integrin β1D and remains predominantly 
expressed in adult skeletal muscle. Integrins α4, α5, α6 and αv are mainly expressed during 
primary myogenesis. Integrin α7 is expressed during primary myogenesis and is up-regulated at 
the onset of secondary myogenesis. The α7B variant is expressed both during primary and 
secondary myogenesis whereas α7A expression is induced at secondary myogenesis. The 
extracellular variant X1 and X2 are expressed during primary myogenesis. In the secondary 
myogenesis the expression of α7X1 decreases and is no longer seen in the adult. (From Rogers 
and Mayer, 2006) 
 
 
Despite the specific enrichment of integrin β1D at the myotendinous junction, 
the muscle specific knockout of integrin β1D, and replacement with integrin β1A 
showed no defect at this site, only a mild cardiac phenotype was seen. Yet, the two 
integrin β1 variants are clearly not functionally equivalent as the ubiquitous expression 
of integrin β1D resulted in embryonic lethality (Baudoin et al.,1998).  
 
Crossing the integrin β1D knock-in mouse into a less penetrant genetic 
background attenuated the embryonic lethality and revealed low muscle mass at birth 
caused by impaired primary myogensis. Integrin β1D has subsequently been shown to 
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interfere with cell migration and proliferation, and this is in line with its onset of 
expression and the effect seen in the knock-in mouse model (Belkin and Retta, 1998; 
Gimond, Baudoin and Sonnenberg, 2000).  
From the time of terminal differentiation and on into adult skeletal muscle, the 
level of α5 and α6 integrins has dropped significantly (Blaschuk and Holland, 1994; 
Boettiger et al., 1995; Bronner-Frase et al., 1992). The integrin α7 is restricted to 
skeletal and cardiac muscle and is strongly up regulated from terminal differentiation 
onwards (Song et al 1993; Yao et al., 1996). The α7β1D integrin is the only integrin 
expressed at the sarcolemma and MTJ, but at the NMJs the α7; α3 and αV integrin 





Figure 1.11: Schematic representation of integrin location during muscle development. 
During the primary myogenesis integrins α4, α5, α6, α7, αv and are expressed β1A are present 
in the myoblast, which are then retained at the MTJ during the secondary myogenesis. 
However, in the adult skeletal muscle only integrin α7β1D is predominatly expressed at MTJ as 
well as at sarcolemmaof the muscle fibre. Integrin αv and α3 expression can be seen at NMJ 
along with expression of integrin α7 (Taken from Mayer, 2003) 
 
 
The changes in integrin expression occurring at the transition into adult muscle 
described above are numerous. It is therefore not surpri ing that the expression of their 
ligands also changes at this time. As described earlier, there is a switch from a 
fibronectin- rich ECM to a laminin-rich basement mebrane during myogenesis. The 
expression pattern of integrin therefore fits with this pattern of ligand expression, 
MTJMTJmyoblasts
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whereby integrin α5β1 dominates when fibronectin is present in the ECM and the 
switch to the laminin-rich basement membrane coincides with the increase of integrin 
α7β1.  
It is unknown whether the changes to integrin expression cause the switch in 
ligand or vice versa, but it does however appear tht t e two are linked. Mice 
homozygous null for the laminin β2 chain express reduced amount of α7B at the MTJ 
and NMJ and in patients, while mice lacking the laminin α2 chain the presence of the 
α7β1 receptor at MTJs, NMJs and sarcolemma is also reduced (Vachon et al., 1997; 
Hodges et al., 1997). 
 
 
1.5.1 Integrin α7 in skeletal muscle  
α7β1 integrin is the most highly expressed integrin in adult skeletal muscle, 
where it localises at the sarcolemma, the NMJ and MTJ (Bao et al., 1993). This 
localisation implies its function in providing the t rminal and peripheral cohesion that 
plays a role in muscle integrity, neuromuscular connectivity and force transmission. 
Integrin α7 is involved in many processes throughout the development of limb 
musculature including migration, proliferation and the connection of primary and 
secondary myotubes with the ECM (Yao et al., 1996; Crawley et al., 1997; Echtermeyer 
et al., 1996; Foster, Thompson and Kaufman 1987; Kaufm n and Foster 1988) The role 
of integrin α7 seems more prominent in the adult as its expression i  up-regulated at 
terminal differentiation and levels remain elevated hroughout adulthood (Song et al., 
1993; Yao et al., 1996).  
Integrin α7β1 is functionally a diverse integrin because of thepr sence of 
different splice variants whose expression are temporally and spatially controlled. The 
α7 subunit has two major intracellular and two major extracellular splice variants. The 
intracellular variants are α7A and α7B (Figure 1.12) and they both differ in sequence, 
size and their phosphorylation (Collo et al., 1993).  
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Figure 1.12: Alternative splicing of the integrin α7 intracellular domain. The A variant is 
generated by splicing of exons XXV,XXVI and XXVII. The stop codon is located at base pair 
position 3536in exon XXVII.  In the B variant exon XXV is followed by XXVII with skipping of 




Integrin α7B is expressed in proliferating myoblasts and in the adult, whereas 
the A variant is induced specifically in skeletal muscle, upon terminal differentiation 
(Collo, Starr and Quaranta 1993; Ziober et al., 1997). However, the B variant remains 
the predominantly expressed variant. Both associate with the integrin β1D subunit in 
adult skeletal muscle (Belkin et al., 1996). The integrin α7B variant localises to the 
muscle fibre membrane and the MTJ, and staining for the integrin α7A variant is also 
seen at the MTJ (Hayashi et al., 1998; Velling et al., 1996; Cohn et al., 1999). 
The α7B variant includes a serine/threonine protein kinase homology region, a 
putative actin-binding site and a receptor-like protein tyrosine phosphatase homology 
region (Song et al., 1993). But despite the apparent differences between the A and B 
variants, no functional differences have as yet been identified (Yao et al., 1996; 
Echtermeyer et al., 1996). A third cytoplasmic splice variant has also been identified 
namely the α7C variant. It is rat specific and exclusive variant to be expressed at rat 
sarcolemmal (Song et al., 1993). 
There are two major extracellular variants described, the X1 and X2 (Figure 
1.13) though other minor variants have also been described (Hodges and Kaufman 
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Figure 1.13: Alternative splicing within the extracellular domain. The X1 variant contains 
exon IV, V and VII with exon VI skipped. The X2 variant contains exons IV, VI and VII with 
exon V skipped. 
 
 
In contrast to the cytoplasmic splice variants, only the α7X2 variant is found in 
adult skeletal muscle (Hodges and Kauffman 1996; Ziober, et al., 1993). The expression 
of these splice variants is also developmentally regulated (Figure 1.10). Both the α7X1 
and α7X2 are expressed during primary myogenesis. In secondary myogenesis the 
expression of α7X1 decreases and is no longer seen in the adult. 
The X1 and X2 variants are functionally distinct. The X2 variant has been 
shown to have a preference towards binding to laminin-111 whereas the X1 variant 
prefers to interact with laminin-411 (von der Mark et al., 2002) and it requires β1 
activating monoclonal antibody to make X1 variant to bind laminin-111 (Ziober et al., 
1997). However both X1 and X2 variants show equal affinity towards laminin-211. 
Distinct functions within adult muscle fibres have b en described for integrin α7 
splice variants. Integrin α7 expression at the lateral surfaces of muscle fibrs increases 
when adult muscle regenerates (Kaariainen et al., 2000). The expression of splice 
variants is regulated during this time so that in early regeneration the X1 and A variants 
are expressed whereas as the fibre is repaired the X2 and B variants again become 
predominant (Kaariainen et al., 2002). 
Though it is seen that the α7β1 integrin plays an important and diverse role in 
muscle development, myogenesis occurs normally in its absence. This could be due to 
redundancy or overlap in function as using β1 inhibiting antibodies does disrupt the 
formation of myotubes in vitro (Menko and Boettiger 1987) and mice lacking β1 
integrin specifically in muscle die immediately after birth having poorly developed 
muscle fibres (Schwander et al., 2003).  
IV V VI  VII  
IV V VII  X1 
VI  IV VII  X2 
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These findings highlight a fundamental difference between the α and β integrin 
subunit functions in the development of skeletal muscle. It appears that the α subunits 
are able to functionally compensate for each other or alternatively, have some 
redundancy in their functions. In contrast the integrin β1 subunit is vital to the 
development of muscle. 
That is not to say that the absence of integrin α7 has no effect on skeletal 
muscle, as mice lacking the functional integrin α7 subunit develop a progressive 
muscular dystrophy (Mayer et al., 1997). Mice showed typical dystrophic symptoms in 
the soleus muscle such as variable muscle fibre size and centrally located nuclei. Also 
the MTJ where α7 integrin is normally concentrated was severely disrupted in the 
gastrocnemius (GC) and tibialis anterior (TA) muscle , where a high level of fibre 
necrosis was seen (Mayer et al., 1997). Whereas in  normal MTJ the muscle fibre folds 
to form interdigitations covered by a thin basement membrane, in the α7 null muscles 
this folding was greatly reduced and the normal sarcomere structure was disrupted.  
At later stages the interdigitations of the muscle fibre were not visible at all and 
myofilaments had retracted from the sarcolemma. Most of these changes were specific 
to the α7 integrin absence as in mdx mice, in which dystrophin is lacking, the 
interdigitations remain and myofilaments do not retract from the sarcolemma. Also the 
basement membrane at the MTJ was doubled in thickness i  integrin α7 null mice and 
its components were not localised normally (Miosge et al., 1999). In the wildtype 
controls nidogen-1, collagen type IV and the laminin α2 chain were only present in the 
basement membrane at the MTJs, yet in the α7 null MTJs nidogen-1 was found in the 
basement membrane but also in the muscle fibre cytoplasm and within the tendon. Both 
nidogen-1 and collagen type IV were increased as seen by immunogold labelling. The 
laminin α2 chain had become undetectable in the basement membrane and was found 
instead in the neighbouring matrix of the tendon. It seems that the integrin α7 is not a 
prerequisite of basement membrane assembly at the MTJ, as all the correct components 
were present, but that it is important to its maintenance 
In Duchenne Muscular Dystrophy (DMD) patients and i mdx mice it was found 
that the expression of α7β1 integrin is up regulated (Cohn et al., 1999). In addition, the 
overexpression of α7β1 integrin in mdx/utr -/- double mutant mice that lack both 
dystrophin and its analogue utrophin leads to increased life span (Burkin et al., 2001). 
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This finding suggests that the integrin can physiologically compensate for the absence 
of the DGC and could be a potential therapeutic target for DMD. 
 
1.5.2 Integrin α5 in skeletal muscle  
α5β1 integrin goes through specific changes in distribu ion, activation and 
expression during myogenesis (Blaschuk et al., 1994). α5β1 and α6β1 are widely 
expressed during myogenesis and then down-regulated af r myotube formation, but 
they are ligand opposing receptors, integrin α5 binds to fibronectin whlile integrin α6 is 
a laminin receptor and the reason they co-exist during myogenesis is not yet known. 
α5β1 has been shown to promote proliferation, while α6β1 has been shown to induce 
differentiation (Sastry et al., 1996). 
Integrin α5β1 is a receptor for fibronectin which binds to the RGD region of 
fibronectin (Pytela et al., 1985). Studies carried out using various cell culture systems 
suggest the role of integrin α5β1 in many cellular processes. Integrin α5β1 is also 
important during embryonic development and its defici ncy leads to embryonic lethality 
(Yang and Hynes, 1993). The effects seen are mesodermal, most prominently in the 
posterior region of the embryo, which is truncated, lacks a notochord and somites and 
has severely kinked neural tube. Integrin α5 knockout (KO) mice die before muscle 
differentiation begins; therefore the KO model does not shed any light on the role on 
integrin α5β1 in this process. 
To study the function of integrin α5 by avoiding the embryonic lethality, 
chimeric mice were derived from integrin α5 -/- embryonic stem (ES) cell. Integrin α5 -
/- ES cells were injected into wild type (WT) blastocysts to obtain α5 -/-, +/+ chimeric 
animals (Taverna et al., 1998). In vitro, neither α5-null ES cells nor α5-null myoblast 
showed any deficit in myogenesis and in chimeric mie, muscle with high proportion of 
α5- null cell could form (Taverna et al., 1998). This would initially suggest that integrin 
α5 is not required for primary or secondary myogenesis. However, further analysis of 
these mice revealed characteristics of muscular dystrophy with onset at late embryonic 
stages (Taverna et al., 1998). This could be explained by the fact that the muscle fibres 
are able to survive in α5-null chimeric mice by the fusion of -/- cells with WT 
myoblasts, which able to convey survival or anti-apoptotic signals and thus masking the 
absolute function of α5 integrin. 
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In the chimeric mice the expression of α5 integrin was shown to be greatly 
reduced, yet the expression of fibronectin remained unchanged in comparison with the 
wildtype muscles. Integrin α5 null cells assembled a fibronectin-rich matrix, formed 
focal contacts on fibronectin and even migrated on fibronectin-coated surfaces (Yang, 
Rayburn and Hynes, 1993). This implies that the assembly of the fibronectin-rich 
matrix, was achieved by compensation via other integrins. It has been shown that in the 
absence of integrin α5β1 both αVβ3 (Wennerberg et al., 1996; Wu et al., 1996) and 
activated integrin αIIbβ3 (Wu et al., 1995; Hughes et al., 1996) can direct fibronectin 
matrix assembly. Though it remains unclear as to whether such integrins would be 
expressed in muscle. It would therefore have been interesting to see if changes to the 
expression pattern of other integrin subunits were observed in muscle of the chimeric 
mice.  
The reason for the degenerative changes observed in the muscle deficient in 
integrin α5 remains unclear and much more work in this field is required to fully 
understand the molecular defects behind it. Knocking out integrin α5 is embryonically 
lethal and conclusions drawn from the α5 -/- chimeric mice were limited. An ideal tool 
in the investigation of the role of integrin α5 during muscle development would be to 
generate a conditional knock out of integrin α5 where the deletion of integrin α5 is 
achieved by a muscle-specific promoter. 
1.5.3 Association between integrins α7 and α5 during skeletal muscle development 
In wildtype muscle integrins α5 and α7 are co-expressed at the MTJ up until 
postnatal day 5 and by postnatal day 10, α5 integrin expression is no longer seen at this 
site. In the absence of integrin α7 in the knock-out model, integrin β1D persists at the 
MTJ in the adult and is found to specifically co-localise with integrin α5 at this site. 
Integrin α5, was also the only α subunit to co-precipitate with the β1D integrin in the α7 
deficient muscle (Nawrotzki et al., 2003). 
The α5 integrin was shown to localise in place of α7 in the α7 lacking muscle. 
This data suggest that initial expression of both α5β1D and α7β1D integrins is followed 
by the down-regulation of α5β1D at the MTJ and the preservation of α7β1D. When the 
α7 subunit is absent in mutant muscles the down-regulation of the α5β1D integrin is not 
seen. 
There is no transcriptional up-regulation of integrin α5 in the integrin α7 
deficient muscle, in fact integrin α5 mRNA decreases by 3 weeks after birth in both 
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wildtype and α7-deficient muscle. The absence of integrin α7 is the cause of the integrin 
α5 persistence, as in MTJs of mdx muscles α5 integrin is not present and does not co-
localise with integrin β1D (Nawrotzki et al., 2003). As the decrease in integrin α5 at the 
MTJs of normal muscle does not appear to be transcriptionally controlled, it is likely 
that the integrin α7 mediated displacement of integrin α5 will be complex. 
The α5β1 integrin is a fibronectin receptor and its persistence at the MTJs of α7 
integrin null muscles results in the deposition of fibronectin in the basement membranes 
of adult muscle fibres. It is thought that the α5β1-fibronectin link is inferior to the α7β1-
laminin connection and results in muscle wasting seen in α7-deficient muscle 
(Nawrotzki et al., 2003). If this were the case, the disruption to the integrin α5-
fibronectin link by integrin α7 and the setting up of the α7-laminin connection are vital 
to the integrity of wildtype adult muscle. 
A negative co-cooperativity between integrin α7 and α5 subunits has been 
described, whereby α7β1 integrin is able to functionally inactivate the α5β1 integrin by 
the reduction of its surface expression and binding affinity (Tomatis et al., 1999). The 
binding affinity was defined as the ability of CHO cells to bind to a fibronectin matrix 
when α7 was overexpressed. This could be due to a simple competition between α 
subunits for integrin β1 binding, resulting in more α7β1 receptors than α5β1 and 
therefore lower fibronectin binding affinity.  
The suggestion that the interaction of α5β1 and α7β1 is simply competitive 
could explain why the α5 subunit binds to β1D in the absence of integrin α7 in the 
knock out muscle. But, what it does not explain is why it is specifically the α5 integrin 
that co-localises with the β1D subunit at the MTJ. This is an especially interesting 
question when one considers that integrin α6 is also present in the muscle at this time. 
Integrin α6 is highly homologous to integrin α7 and its pairing with integrin β1 would 
create a laminin receptor. 
The fact that integrin β1D is retained at the MTJ of integrin α7 deficient muscles 
further underlines its importance at this site. Despit  the integrin α subunit that partners 
it, integrin β1D remains at the MTJ. 
Perhaps the switch from integrin α5 to integrin α7 involves components binding 
the α or β cytoplasmic domains able to regulate activity or cnfirmation in a subunit 
specific manner. Proteins able to bind integrin cytoplasmic domains and regulate 
integrin α5β1 and α7β1 receptor function in muscle fibres could be of interest.  
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To investigate the relation between these both these integrins, it is important to 
design a tool by which the function and importance of integrin α7 is elucidated in 
integrin α5 deficient mice.  
 
1.6 Muscular Dystrophies  
  As mentioned earlier, the high degree of muscle fibre specialisation and 
organisation makes muscle susceptible to the effect of mutations that lead to diseases of 
muscle wasting, termed the muscular dystrophies (MDs). 
Muscular Dystrophies (MD) are a group of inherited disorders with clinical and 
molecular heterogeneity resulting in progressive muscle wasting (Cohn and Campbell, 
2000). The highly organised and specialised structue of the muscle fibre makes it 
susceptible to the effects of mutations leading to congenital defects or late onset 
progressive muscle weakness. A previous study suggets that inherited or spontaneous 
mutations in approximately 100 different genes could potentially leads to MD. So far 
more than 40 genes have been identified causing various myopathies in both human and 
mice (Spence et al., 2002). The primary defects that cause the various myopathies 
identified in both man and mice highlight the importance of the myofibril-sarcolemma-
basement membrane connection to muscle function. 
As discussed before, the most important genes are those encoding 
transmembrane proteins such as dystrophin and integr s (Koenig et al., 1987; Mayer et 
al., 1997). Disruption of the link between the cytoskeleton and extracellular matrix 
makes the sarcolemma to lose its stability, which in turn renders the muscle fibres 
susceptible to necrosis (Cohn and Campbell, 2000). Similar to transmembrane protein 
mutation in their ligands also cause muscle-related disorders, for example mutation in 
the laminin α2 chain leads to congenital muscular dystrophy 1A (MDCIA) (Helbling-
Leclerc et al., 1995). Less obvious candidates also exist, including cytoplasmic 
proteases, cytoplasmic proteins associated with organelles and sarcomeres and even 
nuclear membrane proteins, all of which are linked to diseases of muscle wasting (for 
reviews see Rando 2001; Spence et al., 2002).  
The varying phenotypes and severities of different muscular dystrophies imply 
that some components of the anchorage link are moreimportant than others, or perhaps 
that some can be compensated for more easily than others. The dual role of 
transmembrane proteins in mechanical linkage and signal transduction suggest they 
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would be very important to muscle fibre function and i tegrity, and this is confirmed by 
the severe muscular dystrophies occurring upon mutations in their genes.  
The functional importance of the DGC in skeletal muscle is demonstrated by 
mutation of the human dystrophin gene as seen in Duchenne Muscular Dystrophy 
(DMD) and Becker muscular dystrophies (BMD) (Cohn and Campbell, 2000; Mayer et 
al., 1997). Mutations of the associated sarcoglycan family are observed in some limb-
girdle muscular dystrophies (Bushby, 1999). 
 
1.6.1 Duchenne Muscular Dystrophy 
Duchenne muscular dystrophy (DMD) is an X-linked degenerative muscle 
disorder affecting about 1 in 3500 males.  DMD is caused by mutations in the 
dystrophin gene (Kapsa et al., 2003).   Dystrophin is a 427 kDa cytoskeleton protein 
which localises to the sarcolemma contributing 5% of sarcolemmal protein. In DMD the 
mutation of dystrophin leads to loss of functional protein thus leading to sarcolemmal 
instability and disruption of the DGC. In patients the clinical symptoms are not obvious 
until the age of 3-5 years when proximal muscle weakn ss is first observed leading to 
constant loss of muscle.  
Clinical progression of the disease is confirmed by the onset of 
pseudohypertrophy of calf muscle and proximal limb uscle weakness, resulting in 
wheel-chair dependence by the age of 12. DMD patients suffer from respiratory 
complications due to weakness of intercostal muscles, which leads to premature death at 
early twenties. In some cases death may also be caused by cardiac dysfunction 
(Hoffman et al., 1987; Blake et al., 2002).  
Normal skeletal muscle fibre is multinucleated with nuclei located at the 
periphery of the fibre. In diseased condition the muscle fibre undergoes cycles of 
degeneration and regeneration, which results in fibres with centrally located myonuclei. 
When the regenerative capacity of muscle is not adequat  to the rate of damage then the 
muscle fibre is replaced by adipose and connective tissue resulting in 
pseudohypertrophy, which ultimately leads to muscle wasting. 
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1.6.2 Complexity of the disease phenotype 
Certain characteristic pathological changes to skeletal muscle allow the 
categorisation of a muscular dystrophy, and these are present in DMD and the mdx 
mouse. The primary consequence of the genetic defect is degeneration of muscle fibres, 
but the extent of this varies between muscles, betwe n muscle fibre types within 
muscles, at different ages and between species. In addition, various secondary 
consequences add to the disease phenotype such as an inflammatory cell response and 
chronic degeneration of tissue (characterised by the replacement of muscle tissue by 
adipose and connective tissues). To further complicate matters, it is difficult to separate 
some responses from a direct result of the primary defect and a secondary consequence 
of its effect. For example, fibre hypertrophy can be a direct consequence of the primary 
defect (Hardiman, 1994) or it can be a secondary response of one fibre to the 
degeneration of its neighbour.  
Muscular dystrophy disease processes can be identified histologically in muscle 
cross sections. Degenerating fibres are often identified as a high concentration of nuclei 
or gaps in the tissue. Centrally located nuclei (CLN) mark a fibre, which has undergone 
repair, by the fusion of satellite cells (skeletal muscle stem cell) to the site of damage. In 
mice, once a fibre has been repaired the nuclei remains at the centre of the fibre. The 
percentage of fibres with centrally located nuclei is therefore an accumulative indication 
of the amount of damage and repair that has occurred in the muscle. However, it should 
be noted that every day wear and tear of muscle results in approximately 2% of normal 
muscle fibres having CLN. 
 
1.6.3 Animal models available for study DMD: 
Crucial to the study of DMD has been the mdx mouse, a naturally occurring 
genetic and biochemical model of the human disease (Stedman et al., 1991; Petrof et al., 
1993). A point mutation in exon 23 of the dystrophin gene results in the disruption of 
the reading frame and therefore the absence of functional protein (Sicinski et al., 1989). 
The mdx mouse model has provided both insight into the disase pathology of DMD 
and a basis on which potential therapies can be test d. However, although both DMD 
patients and the mdx mouse have the same primary defect, the mdxmouse has a much 
less severe phenotype, with a later onset than seen in DMD and a normal life span. 
Histological analysis in mdx mice has shown similar features of muscle regeneration 
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such as centrally placed nuclei, necrosis, inflammation, loss of muscle fibre and 
accumulation of adipose tissue (Stedman et al., 1991). In the diaphragm the muscle 
fibre loss and collagen deposition is significant ad the severity of the phenotype is 
comparable to human. Elsewhere, it appears that active regeneration is able to 
compensate for the repeated cycles of muscle degeneration. A phenotype more closely 
resembling that of the human one can be generated in mice lacking a combination of 
both utrophin (a dystrophin orthologue) and dystrophin (Grady et al., 1997) or integrin 
α7 and dystrophin (Guo et al 2006). The reasons for the species- specific differences 
remain unknown. 
Overall the mdx mouse model is a very good tool for the studies of DMD. Other 
than mdx, there is a dog model available to study the DMD. The golden retriever dog 
model shows the closest similarity in phenotype to DMD patients and has a reduced life 
span. Keeping in mind the ease factor of maintenance, the mdx mouse remains the most 
popular mouse model. 
 
1.7 Therapeutic strategies for DMD 
Treatments able to slow the progression of DMD and improve quality of life do 
exist (van Deutekom and Ommen, 2003; Kapsa, Komberg and Byrne, 2003; Voisin and 
de la Porte, 2004; Tidball and Wehling-Henricks., 2004; Chakkalakal et al., 2005), but 
there is no cure. Routes that are currently being investigated can be classified into 
genetic, cell based and pharmacological. In people with DMD, corticossteroid (steroid) 
medication has been shown to improve muscle strength and function for six months to 
two years and slow down the process of muscle weakening. In addition, recent research 
has also shown that a creatine suppliments can help improve muscle strength in some 
people with MD. 
The severity and prevalence of the disease means potential cures are being 
heavily investigated, but delivery methods and problems with immunogenicity have so 
far prevented the application of some of the most promising therapies  (for recent 
review see Deconinck and Dan, 2007; Zhou et al., 2006; Engvall and Wewer, 2003).  
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1.7.1 Gene based therapy  
If an alternative receptor, which is able to perform the same function as the DGC 
could be identified, many of the therapeutic setbacks could be avoided. Increasing levels 
of an endogenous alternative would avoid the problems of the large size of the 
dystrophin gene, the immunogenicity issues and delivery methods.  
Utrophin is a member of the dystrophin-related protein family and an autosomal 
homologue of dystrophin, sharing both sequence and fu ctional motif similarities with 
dystrophin (Tinsley et al., 1992; Pearce et al., 1993). It is speculated to be the foetal 
form of dystrophin, as its expression declines as dystrophin is up-regulated around birth 
(Clerk et al., 1993). There also appears to be functio al redundancy in the adult between 
the two homologues. This is exemplified by the comparatively mild phenotypes of the 
mdx and utrophin-null mice as compared to the severe muscular dystrophy of the 
utrophin null-mdx double knockout (DKO) mouse (Deconinck et al., 1997). The DKO 
mouse has progressive muscle weakness, contractures, kyphoscoliosis and lethality 
within weeks of birth, in other words, a phenotype much more reminiscent of the human 
DMD disease, where there may be non-muscle effects contributing towards the adverse 
phenotype. 
Further confirming its potential as an alternative to dystrophin are observations 
made in mdx mice, endogenous utrophin is redistributed to the sarcolemma and is 
expressed at high levels in regenerating muscle fibr s (Khurana et al., 1991).  
Indeed, the adenoviral delivery of utrophin did improve the mdx phenotype 
(Gilbert et al., 1999). It restored the histochemical staining pattern of the DGC, reduced 
the number of fibres with centrally located nuclei and made muscle fibre membranes 
impermeable to Evan’s blue dye, indicative for improved muscle fibre membrane 
integrity. Similarly, in DKO mice, a marked decreas in CLN (from 80 to 12%) and 
fibre necrosis was seen on delivery of utrophin (Wakefield et al., 2000). 
 Transcriptional up-regulation of utrophin expression by glucocorticoids has 
been investigated with some success (Courdier-Fruh et al., 2002) and the search 
continues for small molecule pharmacological compounds that may also increase 
transcription. 
Utrophin has shown potential as a candidate for the treatment of DMD. But the 
more candidates investigated, the higher the chance of finding a successful treatment. 
With this in mind, it is worth considering proteins, which may indirectly be able to 
improve dystrophic phenotypes. For example, Myostatin is a negative regulator of 
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muscle development and crossing myostatin null mice with mdx mice resulted in 
increased muscle mass and strength, with improved regeneration in the diaphragm 
(Wagner et al., 2002). 
In terms of DMD, an additional candidate to be considered could be the integrin 
α7β1 receptor. Although the role of integrins in muscle function and development is 
less well documented, recent findings are revealing them as essential to the correct 
development and maintenance of adult muscle functio. As mentioned before, like the 
DGC, integrin receptors are capable of forming extracellular - cytoskeletal connections 
through adaptor molecules that link their cytoplasmic tails to actin filaments (Liu, 
Calderwood and Ginsberg, 2000). Integrin α7β1 has been identified as a cellular 
receptor for laminin-111 (Kramer et al., 1991; von der Mark et al., 1991) and the α7 
subunit is mainly expressed in skeletal and cardiac muscle (Song et al., 1992). In fact, 
its importance to skeletal muscle integrity is exemplified in mice with a targeted 
deletion of integrin α7, which develop a progressive muscular dystrophy (Mayer et al., 
1997). Subsequently, human patients with previously unclassified myopathies were 
shown to have mutations in the integrin α7 gene (Hayashi et al., 1998). 
These findings show the important role of integrin α7 in muscle fibre integrity, 
but of interest in this context are the changes that occur to integrin α7β1 levels in 
various muscular dystrophies. For example, in DMD patients and in the corresponding 
mdx model the level of integrin α7 is elevated (Vachon et al., 1997; Hodges et al., 
1997). Also in dystroglycan-depleted chimeric mice increased amounts of integrin α7 
have been observed (Cote, Moukhles and Carbonetto, 2002).  
These natural elevations in the disease state make integrin α7 an obvious 
therapeutic target for further investigation and some studies have addressed this. In mice 
lacking dystrophin and its paralogue utrophin, transgenic overexpression of the integrin 
α7X2B splice variant increased life span and mobility (Burkin et al., 2005; Burkin et al 
2001). Though, a seemingly contradictory outcome of this study showed no real 
improvement in the level of muscle degeneration (Burkin et al., 2005; Burkin et al 
2001).  
Encouraging results also came from a study involving transgenic overexpression 
of the ADAM12 metalloproteinase in mice. This resulted in elevated levels of integrin 
α7, and when it was overexpressed on the mdx background it resulted in an amelioration 
of the phenotype (Kronqvist et al., 2002; Moghadaszadeh et al., 2003). 
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These studies are by no means proof that integrin α7 could provide a therapeutic 
alternative to dystrophin, but they certainly highlt a promising avenue for further 
study. In this study I am exploring the idea of overexpressing integrin α7 in mdx mice, 
to demonstrate the capacity of integrin α7 splice variants to ameliorate the phenotype 
seen in these mice. 
 
1.7.2 Cell based therapies 
As discussed above, available therapies may improve the quality of life of 
patients, however, there is no definitive cure to date. Various stem cell-based strategies 
have been tested with no long-term success, but recently muscle-resident pericytes 
attracted attention for their potential to contribute to muscle regeneration.  
Translational studies in the late 1970s and early 1980s first showed that donor 
myogenic cells can contribute to muscle regeneration (Watt et al., 1982; Blau et al., 
1983; Morgan et al., 1988). It was not until the late 1980s that myoblast transplant was 
first used as a treatment in mdx mice (Partridge et al., 1989). After several more positive 
studies using both mouse and human myoblast, the first cl nical trials were attempted to 
alleviate DMD in humans through cell transplantation (Negromi et al., 2006). 
Unfortunately, these efforts were largly ineffective. On the whole, there was a low level 
of donor cell incorporation, generally attributed to poor survival of transplanted cells or 
lack of dispersion from the injected site. As a result there was only minimal 
improvement in the recipients (Partridge et al., 1998; Peault et al., 2007). Although the 
cell based therapy approach has some limitations, there is still lot of potential which 
needs to be explored and thus we need to study the stem cell population not only from 
skeletal muscle but also from other sources which may contribute to muscle 
regeneration.  
Canadian scientists McCulloch and Till first discovered the potential of stem 
cells by injecting bone marrow cells into the spleen of irradiated mice. They observed 
nodules arising from single bone marrow cells, which they speculated were stem cells 
(Siminovitch, McCulloch and Till, 1963). Stem cells are characterised by their ability to 
self-renew through cell division after being in a quiescent state. They also exhibit the 
capacity to differentiate into other lineages under c rtain physiological conditions and 
thus become tissue or organ- specific cells with special functions (Morrison et al 
1997,Weissman 2000; Till and McCulloch 1961).  
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There are two categories of stem cells, embryonic stem cells and adult stem 
cells. Embryonic stem cells are present as the inner cell mass in blastocysts, at very 
early embryonic development. They are pluripotent and can form all the cell types from 
the three germ layers, endoderm, ectodem and mesoderm. On the other hand adult stem 
cells are active post nataly and are multipotent. There are adult stem cells unique for 
almost all tissues Relevant to my study here are the population of stem cells residing in 
skeletal muscle and the blood vessels surrounding the muscle fibre. 
1.7.2.1 The Satellite Cell: the principal skeletal muscle stem cell 
In the early 19th century it was claimed that multinucleated myofibres may be 
formed by the fusion of multiple mononucleated cells. The proof of which came in 
1960s by a pair of scientists Bintliff and Walker. They performed a simple experiment 
on the mouse hind limb and demonstrated that following a muscle injury to the muscle, 
a pool of mononucleated cells assemble at the site of injury and these fuse together to 
form myofibres (Bintliff and Walker 1960). In 1961, based on observations of frog 
muscles under the electron microscope, Alexander Mauro provided the first description 
of the satellite cell (Mauro, 1961). He described a cell that, due to its small cytoplasmic 
volume, appeared indistinguishable from myonuclei except for the unique position that 
it occupied, ‘wedged’ between the plasma membrane and the basement membrane of 
the muscle fibre. These findings were verified by another paper of the same year that 
observed such a cell within muscle spindles (Katz, 1961). 
Vertebrate skeletal muscle has a remarkable capacity for regeneration, following 
repeated or complete destruction of the tissue, and for this reason, it is the best-studied 
tissue in regenerative medicine in recent years (Gayraud-Morel et al., 2009). The stem 
cells that establish the muscle prenatally also give rise to a distinct lineage of quiescent 
muscle stem cells perinatally; these are the satellite cells (SC), which are now accepted 
as the principal regenerative cell type responsible for the post-natal growth, repair and 
regeneration of skeletal muscle (Gayraud-Morel et al., 2009). Muscle Satellite cells 
(MSCs) are a distinct, small population of myogenic precursor cells (MPCs) found in 
adult skeletal muscle. The primary role of these SCs is repair of a damaged myofibre 
upon injury (Relaix and Zammit, 2012). This small population of MPCs only contribute 
2-7% of the total muscle nuclei and resides in the protected niche environment beneath 
the basal lamina but outside of sarcolemma of associated muscle fibres (Relaix et al., 
2005). Stem cells give rise to myogenic precursor cells in adult muscle, which then 
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contribute to postnatal tissue growth and repair (Asakura, 2003; Seale, Asakura and 
Rudnicki , 2001). Stem cells reside in a highly specifialised niche, in close contact to 




Figure 1.14: Satellite cell location and niche. Satellite cells occupy a sub-laminar position in 
adult skeletal muscle. In the uninjured muscle fiber, the satellite cell is quiescent and rests in an 
indentation in the adult muscle fiber. The satellit cells can be distinguished from the myonuclei 
by a surrounding basal lamina. (Taken from Gayraud-Morel et al, 2009)  
 
The key protein determining the presence and myogenic determination of the 
SCs is the transcription factor Pax7, which appears to be crucial for maintenance of the 
SC population in the post-natal life (Seale et al., 2000). Further studies revealed that 
muscle of Pax7-/- mice contained a reduced number of SCs and exhibited impaired 
muscle regeneration, confirming its essential role in myogenesis (Oustanina et al., 2004) 
(Figure 1.15). Although Pax7 null mice die post-natally they do not show severe 
skeletal muscle pathology. This is likely due to the functional redundancy that Pax7 
shares with its paralogue Pax3 (Relaix et al., 2004). Pax3 is expressed in the embryonic 
precursors of satellite cells. Accordingly, Pax3/Pax7 double-mutant mice die mid-
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Figure 1.15: The Satellite cell niche. An isolated EDL myofibre from a wildtype Pax7-ZsGreen 
transgenic mouse, immunostained with Pax7 (Red) to identify SCs (Top row) which colocalise 
with Zs-green (fluorescent protein derived from Zoanthus Sp. reef coral 1) (green) of the 
transgene driven by the Pax7 promoter Zs-green-positive SCs are also readily identifiable in 
muscle sections of the GC muscle (bottom row) where nidogen staining (red) marks the 
basement membrane defining the exact location of SCs in the muscle fibre (Divekar D. and 
Mayer, U, unpublished results). 
 
 
MRFs are basic helix loop helix transcription factors. Myf5 is the first MRF 
expressed in the embryo and is critical for muscle determination (Ott et al., 1991; 
Buckingham, 1992). Upon entrance into the cell cycle adult satellite cells express a 
second MRF, MyoD (Beauchamp et al., 2000). MyoD is expressed throughout the 
proliferative phase before being down regulated upon differentiation (Figure 1.16) 
(Tajbakhsh & Buckingham, 2000). 
 
Figure 1.16: Satellite cell differentiation during myogenesis. Upon muscle fibre injury, 
satellite cells undergo differentiation and proliferation cycle. During this time they express 
myogenic differentiation markers like Myf5, MyoD and Myogenin. Pax7 expression begins 
during activation and then down regulated in later stages of differentiation. (Taken from 
McCullagh and Perlingeiro, 2014). 
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Although Myf5 acts upstream of MyoD they share a degre  of redundancy 
(Kassar- Duchossoy et al., 2004; Rudnicki et al., 1993) as individual deficiency did not 
result in impaired skeletal muscle formation, while Myf5/MyoD double knockout mice 
lack skeletal muscle completely and die soon after birth (Rudnicki et al., 1993). Myf5 
and MyoD are critical determinants of the myogenic lineage and are indispensable for 
satellite cell specification and differentiation. MyoD null mice show a severe 
regeneration deficiency due to an inability of the satellite cells to differentiate and a 
failure of these cells to exit the cell cycle (Megeney et al., 1996; Sabourin et al., 1999; 
Yablonka-Reuveni et al., 1999). The majority of satellite cells down regulate MyoD and 
up-regulate the muscle specific transcription factor, and marker of differentiation 
Myogenin. Crucially however, a small minority of cells down-regulate MyoD, thus exit 
from the cell cycle, but re-express Pax7 returning to a quiescent, undifferentiated state. 
This is a good evidence to suggest that satellite cells are able to undergo self-renewal 
and maintain their own numbers (Zammit et al., 2004). In mature muscle, SCs are in 
quiescent state. However, in response to certain stimuli, such as myofibre necrosis as a 
result of trauma or damage, surviving SCs get activted and enter the cell cycle to 
proliferate. They generate new myoblasts, which prolife ate, migrate to the site of injury   
and fuse with damaged myofibre, forming regenerated an  functional myofibres. 
Following their activation in the first stage of this regeneration process, a subset of SC 
progeny return to the quiescent state in the process of elf-renewal (Dahwan and Rando, 
2005) (Figure1.17). 
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Figure 1.17: Satellite cell response to myotrauma. Upon injury, satellite cells become activated 
and proliferate. Some of these satellite cells re-establish a quiescent cell pool through a process 
of self-renewal while others migrate to the site of damage and, depending on the severity of the 
injury, fuse to the existing myofiber or align and fuse to produce a new myofiber. (Taken from 
Hawke and Garry, 2001) 
 
Representing the principle endogenous cells with regen rative function in 
skeletal muscle and their great capacity for regeneration outlines satellite cells as the 
prime cell for therapies.  Yet, by nature they exhibit a number of characteristics that 
limit their effectiveness. The number of possible SCs/myoblast division is limited. In 
humans, adult myoblast divide only 25-30 times, a number that has shown to decline 
with age and some diseases such as DMD. While a small minority of SCs is thought to 
withstand the aging process and retain the intrinsic capacity for regeneration (Collins et 
al., 2007), aged muscle displays a notable reduction in number and regenerative 
capacity of SCs. SCs also lack the ability to cross the muscle endothelium when 
delivered systemically. Even so intramuscular injections of SCs (110 injections per cm2 
of muscle surface) had some success (Skuk et al; 2007), the problem remains that the 
majority of injected cells are lost within the first day. Furthermore, in vitro expansion of 
SCs for transplantation has been shown to reduce their potency for differentiation in 
vivo (Dellavalle et al., 2007). Trials of myoblast transplantation in DMD patients 
enabled delivery of dystrophin and improved muscle tr ngth, but the approach is still 
plagued by immune rejection, poor cell survival rates and limited spread of injected 
cells (Farini et al., 2009; Huard et al., 2003). For these reasons there has been a growing 
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interest in the field of developing alternative, more efficient cell-based therapies for 
conditions such as DMD. 
 
1.7.3 Other resident skeletal muscle stem cells 
It is established that the satellite cells are a source of myoblasts, but this does not 
answer whether satellite cells are the solely or just one of many sources for muscle 
myoblasts. Additionally, the source of the satellit cells themselves was until recently 
largely a mystery. There is evidence to suggest that satellite cells are not bona fide stem 
cells but rather muscle precursor cells themselves, r newed from another stem cell 
source. 
Further evidence describes population of cells thatare able to contribute to 
muscle regeneration. Ferrari et al. suggested in 1998 that bone marrow derived and 
skeletal muscle stem cells are of the same lineage. In transplantation experiments in 
immunocompromised mice, they demonstrated that genetically marked bone marrow 
derived cells migrated into degenerating areas, underwent myogenic differentiation and 
participated in the repair of the damaged fibers.  
This data further suggested a potential role of genetically modified, bone 
marrow-derived myogenic progenitors to target therap utic genes to muscle tissue, thus 
providing an alternative strategy for treatment of muscular dystrophies (Ferrari et al., 
1998).  
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Figure 1.18: Other stem cell populations associated with skeletal muscle. Skeletal muscle 
contains several types of cells with myogenic potential, including satellite cells, myogenic 
precursor cells, pericytes, mesoangioblasts (MAB), muscle-derived stem cells (MDSC), side 
population (SP) cells, muscle interstitial cells (MIC), fibro-adipogenic progenitor cells (FAP), 
Pw1+ interstitial cells (PIC) and hematopoietic cells. In addition, other non-muscle tissue-
derived stem cells, including mesenchymal stem cells (MSC), hematopoietic stem 
cells/hematopoietic progenitor celsl (HSC/ HPC), embryonic stem cells/induced pluripotent 
stem cells (ESC/iPSC), AC133+, adipose-derived stemc lls (ASC) and amnion fluid stem cells 
(AFSC) have been shown to be able to differentiate into myogenic cells, and thus these cells 
may be utilized for therapeutic stem cell transplantation (taken from Biressi and Asakura, 2012) 
 
In addition, experiments performed in 1999 underscored the remarkable capacity 
of adult skeletal muscle-derived cells. When injected into irradiated mice they 
contributed to all major blood lineages (Jackson, Mi and Goodell, 1999). Similar data 
were obtained by Gussoni et al. 1999, which indicated that intravenous injection of 
either normal haematopoietic stem cells or a novel population of muscle-derived stem 
cells into irradiated animals resulted in the reconstitution of the haematopoietic 
compartment of the transplanted recipients. In addition, it also revealed the 
incorporation of donor-derived nuclei into muscle, and the partial restoration of 
dystrophin expression in mdx muscle. These outcomes suggest that transplantation of 
stem cell populations, might provide an unanticipated avenue for treating muscular 
dystrophy as well as other diseases (Gussoni et al., 1999).  
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Apart from the bone marrow-derived cell population ther cells of various 
origin, like dermal fibroblasts, mesangioblasts, and neural tube derived cells, have been 
a focus of investigation in the late 1990s. These stem cell-like populations have been 
shown to convert to the myogenic lineage after a period in culture and to contribute to 
muscle regeneration in the dystrophic mouse (Gibson et al., 1995; Saito et al., 1995; 
Tajbakhsh et al., 1994). More recently, it has been shown that a variety of circulating 
cells, including AC133-expressing cells and blood vessel-derived pericytes, when 
transplanted can contribute to muscle regeneration in mdx mice (Torrente et al., 2004, 
Sampaolesi et al., 2003, Dellavalle et al., 2007). These blood vessel associated cells 
attracted a lot of attention, due to evidence that suggests that they have mesenchymal 
stem cell-like properties and as such could be an easy accessible reserve cell population 
in the body. However, a detailed understanding of the identity and regulation of these 
progenitor cells as well as the final fate of their descendants is a crucial prerequisite for 
using and manipulating these cells in medical applications. There are many technical 
and practical challenges, which need to be overcome before they can be used to combat 
disease. For example, the method of cell extraction is crucially important to avoid any 
contaminating cells, which would make the results inconclusive. Furthermore, it is also 
vital to avoid any rejection from the donor cells from the host immune system. To 
overcome this obstacle most studies use the nude mdx mouse as a host model system.  
 
1.7.3.1 Mesenchymal Stem Cells (MSCs) 
Mesenchymal stem cells (MSCs) were first discovered in 1968 by the pioneering 
studies of Friedenstein. During in vitro culturing of hematopoatic stem cells (HSCs) it 
was discovered that there was a different type of cells in the bone marrow with a 
fibroblastic morphology. These cells could form colonies on the culture plate and were 
named as colony forming unit fibroblasts, CFU-F by Lanotte et al in 1981. Furthermore, 
they had the ability to generate cartilage, bone, muscle, tendon, ligament and fat (figure 
1.19). 
 
   




Figure 1.19: Mesenchymal Stem cells (MSCs) and their multilineage differentiation 
potential. MSCs are capable of differentiating in multiple lineages displayed in the picture. 
Dependent on the stimuli provided in the medium they maintain the same differentiation 




Owen described them in 1988 as stromal cells due to their fibroblastic 
phenotype in 1988, but finally they were named MSCs by Caplan in 1991. Pittenger   et 
al. performed the first experiments with MSCs from human bone marrow aspirates in 
1999, and showed that they expressed CD29, CD90, CD71 and CD106 but were 
negative for CD45, CD14 and CD34. MSCs were also isolated from many other sources 
such as adipose tissue, umbilical cord blood, placent  and even from the dental pulp. 
However, MSCs from these sources differed in their CD marker expression. In 2006 the 
International Society for Cellular Therapy published a position paper by Dominici et al. 
and set the following features for MSCs. MSCs should be positive for CD73, CD90 and 
CD105, but be negative for CD19, CD34, CD45, CD11a and HLA-DR. 
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MSCs, chemokines and cytokines and their surface rec ptors were also shown to 
be important during inflammation and injury (da Silva Meirelles et al 2008). 
Inflammation at the injury site triggers a gradient of cytokines and chemokines, which 
mediates migration of MSCs to the injured site (Salem and Thiermann 2010). Especially 
CD44 was found to be important in homing of both mouse and human MSCs (Herrera 
et al., 2004; Sackstein et al., 2008). In addition, t was shown that CXCR4 and CD106 
play an important role in the migration of MSCs (Segers et al., 2006; Shi et al., 2007; 
Hung et al., 2007).  
MSCs are considered for cellular therapies for various reasons. Firstly, they can 
be isolated as a pure population due to the defined markers they express. Secondly, they 
can easily be cultured in vitro to obtain high numbers without loosing their properties. 
MSCs can migrate to the injured site n vivo and thus became a popular candidate in 
regenerative medicine and cellular therapies. Currently MSCs are being investigated 
extensively in clinical trials, mostly in the United States, Europe and East Asia studying 
their use in neurological, liver, bone, heart, graft versus host and some autoimmune 
diseases like diabetes and Crohn’s disease. 
 
1.7.3.2 Pericytes   
Following their initial description by Charles Rouget in late 19th century, 
perivascular cells found in close association with capillaries were first referred to as 
‘Rouget cells’ (Rouget 1873). They have since been given a variety of names including 
mural or vascular smooth muscle cells. The term pericyt  (peri; around, cyte; cell) was 
introduced by Zimmerman in 1923 and remains the widely preferred idiom to denote 
these now extensively studied cells (Bergers and Song, 2005). 
Pericytes (perivascular cells/ PVCs), microvascular mu al cells, were originally 
identified for their primary function in angiogenesis. Formation of new blood vessels 
requires the mutual interaction of two cell types; ndothelial cells which constitute the 
internal lining, and PVCs. They can be classified as microvasculature, or vascular 
smooth muscle cells in larger blood vessels; althoug  this distinction is not absolute and 
there appears to be a continuum of pericyte-like phnotypes depending on morphology 
and location (Armulik, Abramsson and Betsholtz, 2005; Brachvogel et al., 2005). 
Capillaries and microvessels are enclosed by pericyt s. The endothelial cells and 
pericytes associated in this way both synthesise and share the same basement membrane 
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within the microvasculature (Mandarino et al., 1993). Although different in location, 




Figure 1.20: Interaction of Pericytes and endothelial cells in microvessels. (A) Cartoon 
representing pericytes surrounded by a basement membrane establish direct contact with 
endothelial cells (taken from Armulik, Abramsson and Betsholtz, 2005), (B) Electron 
micrograph showing the close interaction between a pericyte and an endothelial cell (EC). 
Cytoplasmic foot processes (fp) surround and envelop the EC establishing intimate physical 
relationship between the Pericyte and EC allowing for crosstalk (Taken from Hayden et al., 
2008). 
 
The reciprocal communication and interaction between th  two is dependent on 
signaling through soluble factors such as platelet-derived growth factor (PDGF) and 
transforming growth factor β (TGF-β), in addition to physical contact mediated by 
adhesion plaques, integrin and peg/socket and gap junctions (Hirschi and D’Amore, 
1996; Armulik et al., 2005).  
Traditionally, perivascular cells are thought to act merely as scaffolding to 
stabilise blood vessels; but are now recognized to have an active role in vessel 
formation. They may sense the presence of angiogenic stimuli in the tissue, 
communicate via paracrine signaling to induce proliferation and differentiation of 
endothelial cells, deposit or degrade extracellular matrix and regulate blood vessel 
contractibility (Armulik, Abramsson and Betsholtz, 2005; Bergers and Song, 2005).  
Despite extensive research the complex ontogeny and plasticity of pericytes is 
still incompletely understood and molecular markers r main controversial (Bergers and 
Song, 2005). Pericytes are thought to perform various functions throughout the body 
during different stages of development and a difference in morphology and distribution 
among vascular beds indicates adaptations for tissue- pecific function. Furthermore, 
there is increasing evidence to suggest that pericyt s are precursors for a number of 
A B 
   
  Chapter 1  
59 
different cell types. They have been shown to differentiate into osteogenic, 
chondrogenic, adipogenic and myogenic lineages in vitro (Caplan, 2007; Farrington-
Rock et al., 2004). A landmark publication by Crisan et al in 2008 denoted their close 
similarity to human mesenchymal stem cells (MSCs). This led to the provocative 
speculation that pericytes represents a population of MSCs and can contribute to tissue 
regeneration (Doherty et al., 1998; Caplan et al., 2008; 2011). Caplan et al. in 2008 even 
hypothesized that all MSCs are pericytes.  This was further supported by studies 
showing that skin pericytes have MSC-like properties (Paquet-Fifield et al., 2009) 
Finally, Dellavelle et al showed in 2007 that perivascular cells from the 
microvasculature of human skeletal muscle are able to differentiate with high efficiency 
into myofibres in vivo, suggesting a potential option for DMD treatment.  
Unfortunately, there is not a specific molecular marker with which pericytes can 
be defined without ambiguity and the lack of highly specific genetic tools for pericyte 
labeling limits the interpretation of FACS data and fate mapping (Armulik et al., 2011). 
There are a handful of markers that are commonly used for detection of pericytes, but 
they are not exclusive for them. Markers include th intracellular protein alpha smooth 
muscle actin (αSMA), NG2 proteoglycan, PDGFRβ, desmin and the regulator of G 
protein signaling-5 (RGS-5) (Bergers and Song, 2005). In addition, several mouse 
models have been generated in order to study and identify pericyte-like cells (Table 
1.1). 
Table 1.1: Available mouse models to study the pericyte.  
 
Of interest is the discovery that annexin A5 has recently been identified as a 






Name Mouse model Locus Reference 
XlacZ4 Transgenic Unknown Tidhar et al., 2001 
AP-Cre/LacZ Knock-In Alkaline Phosphatase  Cossu et al., 2001 
Anxa5-LacZ Knock-In Anxa5-KI Brachvogel et al., 2005 
PDGFRβ-Cre/LacZ Knock-In PDGFRβ Betsholtz et al., 2007 
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1.8 Annexins 
Annexins represent a large family of calcium-dependent phospholipid-binding 
proteins, characterised by a unique architecture that allows their peripheral and 
reversible docking onto membranes. This family of structurally related proteins 
comprises over 500 different gene products expressed in most species. In vertebrates 12 
annexin subfamilies have been identified (A1- A11 and A13) (Rescher and Gerke, 
2004). 
 
Annexin V (Anxa5) presents the prototype and has proved fundamental in the 
investigation and analysis of other members of the family (Liemann and Huber, 1997). 
First purified from chondrocytes as a potential receptor for collage type II (Mollenhauer 
and von der Mark, 1983), further studies demonstrated its ability to attach membranes 
through calcium-dependent binding of phospholipids (Huber et al., 1990; Rojas et al., 
1990), what is also the hallmark for its ability to detect apoptotic cells, which present 
phosphatidylserine on their surface (Koopman et al., 1994). Anxa5 has been implicated 
in the mineralisation process during endochondral ossification (Kirsch et al., 2000; 
Brachvogel et al., 2001), and in membrane repair (Sk ahina et al., 2008). 
Most functions of Anxa5 have only been identified in vitro. However in 2003, 
an Anxa5-deficient mouse model has been generated, which showed that Anxa5 is 
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1.9 Aims 
In order to develop successful strategies to ameliorate muscle wasting diseases 
and delay muscle loss with ageing, it is (1) critical to understand the function of all 
major skeletal muscle proteins and (2) potential new therapies need to be extensively 
tested. Although loss of integrin α7β1 has been shown to result in a congenital muscular 
dystrophy in mice and human, the function of integrins in skeletal muscle development 
and the adult is not well understood. Particularly the role of integrin α5β1, whose loss in 
chimeric mice led to dystrophic symptoms, and its relationship to integrin α7β1 remains 
elusive. 
Objectives addressed in chapter 3: Integrin α5β1 in development and adult 
skeletal muscle 
1. To investigate the role of integrin α5 in skeletal muscle 
Knocking out integrin α5 is embryonically lethal and conclusions drawn from 
the α5 -/- chimeric mice were limited and therefore we aim to KO integrin α5 
conditionally using Pax3 and HSA promoter driving expression of Cre recombinase. 
2. To investigate the relationship between integrin α5 and α7 in skeletal muscle. 
Integrin α7 displaces integrin α5 at the MTJ of developing muscle, suggesting a 
crosstalk between these two receptors exists. The mechanism for which is unknown. 
Revealing this mechanism will provide insight into the role and relationship of integrin 
α subunits in skeletal muscle development. To understand the relationship between 
integrin α5 and α7, we aim to study the double knockout (DKO) mice. 
 
Objectives addressed in chapter 4: Could integrin α7β1 be a therapeutic target for 
DMD? 
3. Could integrin α7 play a role in the ameliorating of dystrophic phenotype? 
There is still not a successful therapy available to ameliorate myopathies. 
It is therefore necessary to continue research on ide tifying new therapeutic 
strategies or to improve current strategies. Integrin α7β1 has been suggested as 
potential therapeutic target for DMD as it is upregulated in DMD patients and in 
mdx mice.  
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This raises the following question, which we aim to answer by generating 
transgenic mice overexpressing integrin α7 intra and extra cellular splice variants. 
 
• Is it possible to increase the levels of integrin α7 while maintaining the correct 
processing, localisation and function? 
• Could the different integrin α7 splice variants have different abilities in improving 
the muscle phenotype seen in DMD? 
Objectives addressed in chapter 5: Do pericytes contribute to skeletal muscle 
regeneration? 
In recent years, pericytes attracted a lot of attention due to their mesenchymal 
stem cell-like properties and, more specifically, their potential to participate in muscle 
regeneration. Pericytes are a poorly defined cell population, and it is not clear whether 
these cells commit to the myogenic lineage when in co tact with regenerating muscle, 
or whether there is a mutual relationship between pricytes and satellite cells, in which 
both cell types can adopt both phenotypes when exposed to stimuli provided by the 
environment. Understanding contribution of endogenous and exogenous pericytes to 
muscle regeneration is therefore pivotal in further defining pericytes and their 
relationship with satellite cells and to do so we aim  
 
4. to generate the pericyte reporter mouse strain for cell lineage tracing 
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Chapter 2 Materials and Methods 
2.1 Mouse lines 
 
During this study we used different mouse models to investigate the role played 
by integrins and pericytes during the skeletal muscle regeneration. Some of the mouse 
stains were generated in the laboratory, while others were obtained from collaborators.  
 
2.1.1 Integrin α7 overexpressing transgenic mouse line 
Integrin α7 overexpressing strains were generated in our laboratory before the 
start of this study. In brief, integrin α subunit cDNAs had been generated in the 
laboratory from murine myoblast RNA by RT-PCR. The Human Skeletal α-actin (HSA) 
promoter element was added 5’ to the integrin α7 cDNAs. After linearisation the DNA 
was injected into pronuclei of fertilised mouse embryos, these were transferred into the 
oviduct of pseudopregnant fosters mothers. Mice harbouring the transgene were 
detected by PCR using a sense primer (table 2.6) hybridising with the HSA promoter 
and antisense primers hybridising within the α subunit coding sequence and also cDNA 
specific primer pairs (table 2.6). The mice born following oocyte injection that were 
positive for the transgene were termed ‘Founder’ mice. Each Founder was backcrossed 
into the 129Sv wildtype strain. One positive offspring from this F1 generation was 
picked and crossed again with the 129Sv wildtype. The strain was then maintained by 
the crossing of subsequent generations with the 129Sv wildtype. Within a strain all mice 
are therefore heterozygous for the transgene, and every member is derived from a single 
‘F1 deriver’ mouse. For each overexperssing integrin splice variant more than one stain 
were analysed according to the expression levels of the integrin overexpressed (Table 
2.1) These transgenic mice were studied for the effct of overexpression of integrin on 
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Table 2.1: Summary of Integrin α7 Splice Variant Overexpressing Transgenic Strains. Each 
construct corresponds extracellular splice variant and intracellular splice variant as shown. 
The various strains derived for each construct are named after the Founder mouse. An average 
relative level of overexpression/expression as compared to the wildtype is shown, the standard 
deviation for these values is found in Appendix 1. Strains crossed out in grey are those which 
























Construct 1 HSA X2 A 
Susie 31.7 80.7 
Chris 33.2 80.7 
Tina 0 - 
Construct 3 HSA X1 A 
Lydia 53.4 6.5 
Maria 164.8 19.9 
Judith 10.4 1.9 
Elke 19.0 1.6 
Construct 5 HSA X1 B 
Xaver 20.4 9.3 
Karin 24.3 10.5 
Construct 7 HSA X2 B 
Max 14.4 22.3 
Moritz 1.7 0.3 
Fritz 28.7 5.7 
Hans 0 - 
Babette 21.7 3.2 
 
 
2.1.2 Integrin α7 overexpressing transgenic mdx mouse line 
To investigate the role of integrin in muscle wasting disease like DMD, integrin 
α7 overexpressing mice were crossed with dystrophin-deficient mdx mice. The F2 
generation was named mdxtg. The four integrin α7 splice variant combinations were 
studied and documented in result chapter 4. 
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2.1.3 Integrin α5 conditional knockout mouse line 
Integrin α5 conditional mice were a kind gift of Prof R.O Hynes (MIT, USA). 
The principal behind the homologous recombination and design of the targeting 
construct is included in chapter 3 (Figure 3.1). To study the role of integrin α5 during 
muscle development, heterozygous integrin α5 mice were crossed with mice, expressing 
Cre recombinase under the control of the HSA or the Pax3 promoter. The breeding 
strategy is explained in detail in chapter 3 (Figure 3.2). The outcome from these 
experiments is discussed in chapter 3. 
2.1.4 Integrin α5/ α7 double knockout mouse line 
  In order to study the combined contribution of integrin α5 and α7 to muscle 
development Itga7 +/- mice were crossed with Itga5 +/- Cre mice to generate Itga7+/- // 
Itga5 +/-Cre mice. Males from the F1 generation were then crossed with Itga7+/-// Itga5 
FL/FL or Itga7 -/-// Itga5 FL/FL females to obtain Itga7 -/-// Itga5 FL/-Cre mice for 
analysis.  
2.1.5 Anaxa5 -Cre –KI mouse line 
To investigate the role played by pericytes in muscle regeneration, we generated 
the Anxa5-Cre-KI mouse strain. Based on the previously generated Anxa5-LacZ fusion 
strain (Brachvogel 2001), the targeting construct for homologous recombination was 
designed in a way that activity of Cre- recombinase was controlled by the endogenous 
Anxa5 promoter.  
2.1.6 Reporter mouse lines   
For lineage tracing of pericytes, Anxa5-Cre-KI mice were crossed with 
ROSA26-EYFP and ROSA26-LacZ mice. ROSA-26-td-Tomato mice were used for in 
vitro labeling of pericytes using Adeno-Cre viral induction.  
 
2.2 Molecular biology techniques 
The general molecular biology methods used for Escheri ia Coli (E. Coli) 
culture and preparation of competent cells, agarose gels and DNA extraction, 
precipitation, electrophoresis and digestion were all done according to Maniatis et al. 
(1982). Concentration of DNA was measured using NanoDrop. For preparation of large 
amounts/high quality plasmid DNA, the Quiafilter mini-, midi- and maxiprep kits 
(Qiagen) were used according to the manufacturer’s protocols. 
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2.2.1 Bacterial growth 
The competent E. coli strain DH5α was used to propagate plasmids. E. Coli 
were grown on sterile Luria and Bertani minimal medium (LB medium, Roth). All 
cultures were grown overnight at 37ºC, either on solid medium or shaken at 200rpm in 
liquid cultures. Selection for transformed bacteria was carried out in the presence of 100 
µg/ml Ampicillin (Roche) unless otherwise stated. 
2.2.2 Preparation of competent cells 
For preparation of competent cells DH5α were plated on antibiotic free LB-agar 
plates and grown at 37°C overnight. A single colony was picked with a sterile toothpick 
and transferred to 2 ml LB media containing 0,02M MgSO4 and 0,01M KCl in 15 ml 
polystyrene round bottom test tube (BD Falcone) and incubated in a shaker (200rpm) at 
37°C overnight. The overnight culture was used to in culate 100 ml of LB media 
containing 0,02M MgSO4 and 0,01M KCl (1:100 dilution) in a 1000ml conical 
Erlenmeyer flask and left shaking at 37°C till at a w velength of 600 nm an O.D. of 
approximately 0.3-0.55 was reached. The flask was left on ice with gentle shaking from 
time to time to prevent precipitation of the bacteria. The cells were then transferred to 
pre-cooled centrifugation bottles and were centrifuged at 6000 rpm for 10 min at 4°C in 
a pre-cooled centrifuge. The pellet was then re-suspended carefully in 50 ml of TFB-I 
(table 2.2) buffer taking care not to produce any air bubbles and was then centrifuged 
again same as above. The cells were then re-suspended again this time in 4 ml TFB-II 
(table 2.2) buffer and 100 µl aliquots were on a mixture of dry ice and acetone. The 
cells were then stored at -80°C and checked for competency at a later date. In general 
competency of 106 to 108 was achieved. When using these cells for transformations, 
each tube was split in two and transformations were done using 50 µl of competent 
cells.  
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Table 2.2: Composition of buffers used for preparation of competent cells. All solutions are 




2.2.3 Transformation of Plasmid DNA 
Chemical competent DH5α E. Coli cells were thawed gently on ice. 50 µl was 
taken and transferred to a new tube to which 0.5 µl of plasmid DNA was added. The 
sample was then mixed by hand before incubating on ice for 30 minutes. Bacteria were 
then heat-shocked for 45 seconds 42ºC. Bacteria were th n grown in 900 µl of LB broth 
without ampicillin for one hour at 37ºC with shaking and then plated onto an LB plate 
with ampicillin (100 µg/ml) and grown overnight at 37ºC.  Single ampicillin resistant 
colonies were then picked using a sterile toothpick and incubated in 2 ml LB broth with 
ampicillin at 37ºC for 6-8 hours. For long term preservation of bacteria DMSO stocks 
were made by adding 20% DMSO to bacterial overnight cultures, snap frozen on dry ice 
and then stored at -80ºC. When appropriate, blue-white selection was performed at this 
stage by adding 40 µl of XGal (2% in DMF) and 40 µl of Isopropyl β-D-1-
thiogalactopyranoside (IPTG) (100 mM) to the plates prior to plating. 
 
2.2.4 Isolation of plasmid DNA by alkaline lysis 
For isolation of plasmids, 2 ml LB media in a 15 ml Polystyrene round bottom 
test tube was inoculated after picking a single colony from an LB-agar plate and 
incubated overnight at 37°C in a shaker (200 rpm). The bacterial suspension was then 
transferred to a 1.5 ml eppendorf tube and centrifuged gently at 3000 rpm. Most of the 
media was removed and the remaining pellet was re-suspended in the residual media. 
TENS buffer (Table 2.3) was added at a volume of 300 µl followed by 150 µl of 3M 
Na-acetate/pH 5.2 and then mixed by inverting the tubes several times. The tubes were 
Reagent Composition 
TFB I buffer  
 
30 mM K acetate, 50 mM Mn2Cl, 100 
mM RbCl, 10 mM CaCl2, 15 % (v/v) 
Glycerine (pH 5.8), filter sterile  
TFB II buffer  
 
10 mM MOPS/NaOH (pH 7.0), 75 mM  
CaCl2, 10 mM RbCl, 15 % (v/v)  
Glycerine, filter sterile  
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then centrifuged at full speed (14,000 rpm) for 15 min and the supernatant was 
transferred to a new tube. Next, 900 µl of 100% ethanol was added and the tubes were 
stored at -20°C for 20 min followed by centrifugation for 20 min at full speed. The 
supernatant was discarded and the pellet was washed with 70% ethanol, air dried and re-
suspended in 100 µl of TE buffer containing 0.1 mg/l RNase. 
 
  Table 2.3: Composition of buffers used for plasmid isolation. All solutions are made up in    
dH2O unless otherwise stated.  
 
 
2.2.5 Plasmid purification by Qiagen kit 
A Qiagen plasmid purification midi kit was used for purification of plasmid 
DNA. Bacterial cultures were grown under the conditions stated above until reaching 
stationary growth phase, typically after 16 hours of incubation. Cells were then 
harvested by centrifugation (4000 rpm for 15 minutes at 4°C in a Beckman centrifuge 
with the rotor JA-25-50). The supernatant was discarded and the cell pellet carefully re-
suspended in 4ml re-suspension buffer (P1). 100 µg/ml of RNase A was added to the 
buffer P1 prior to the re-suspension to prevent RNA contamination of purified plasmid 
DNA. 4 ml of lysis buffer (P2) was then added to the cell suspension, which was mixed 
gently to avoid the bacterial DNA contamination and then incubated at room 
temperature for 5 minutes. Following lysis, 4ml of pre cooled neutralisation buffer was 
added (P3), which was then gently mixed and incubated on ice for 20 minutes. Next, the 
solution was centrifuged (15000 RPM for 30minutes at 40 C in a Beckman centrifuge 
with the rotor JA 16-25), the supernatant was retain d and the pellet discarded. The 
solution was then filtered through a damp tissue to remove any particulate material 
before passing over a Qiagen column, previously equilibrated with 4ml of buffer QBT. 
The plasmid DNA bound to the column was then washed twice with 10ml of medium 




10 mM Tris/HCl (pH 8.5), 1 mM EDTA  




10 mM Tris/HCl (pH 8.5), 1 mM EDTA  
(pH 8.0) ,1 M NaOH, 10 % SDS 
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and then precipitated by adding 3.5 ml of isopropanl. DNA was then recovered by 
centrifugation (at 15000 RPM for 30 minutes at 40 C in Beckman centrifuge with a 
rotor JA-16-25), which was then washed with 2 ml 70% ethanol. The solution was then 
centrifuged (at 15000 RPM for 10 minutes at 40 C in Beckman centrifuge with a rotor 
JA-16-25) and supernatant was carefully decanted off. The DNA pellet was allowed to 
dry before being dissolved in 200µl of filter sterilised TE buffer (Table 2.3). 
 
2.2.6 DNA digestion by restriction enzymes  
Digestions were made using Roche restriction enzymes with corresponding 
Roche buffers. For every 1 µg of DNA to be digested, 1 Unit of restriction enzyme was 
used. The ratio of enzyme to buffer was kept below 10% (v/v). All restriction digests 
were carried out at 37°C unless otherwise stated.  
 
2.2.7 Agarose gel electrophoresis  
DNA samples were mixed with 5x Orange G neutral loading dye (Table 2.4) and 
loaded onto a 0.6% agarose gel (made by diluting agarose in 1 X TAE buffer (Table 
2.4). The gel was then run for approximately 40 minutes at a constant voltage of 150V. 
The DNA gel was then stained with 0.5-µg/ml ethidium bromide for 30 minutes and 
visualised using a UV trans-illuminator (UVP BioDocIt Systems) 
 






50 X TAE buffer 
 
40 mM Tris Acetate, 2 mM EDTA  
(pH 8.5)  
DNA gel loading dye 
 
50% (v/v) Glycerol, 1X TAE buffer, 
0.5% (w/v) Orange G powder 
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2.2.8 Isolation of DNA fragment from agarose gels 
For isolating DNA from agarose gel, the gel was runat 100 volts for ideal 
separation of restricted DNA fragments or PCR products. DNA was purified from 
agarose gel using the Gene-clean kit (MP-Biochemicals). After the gel was stained in 
Ethidium bromide, the desired size DNA was visualised under the UV hand lamp and 
cut out using a scalpel. It was then transferred in a pre-weighed eppendorf tube. Next, 
the amount of Nal was calculated according to the weight of the gel and was added to 
the eppendorf tube, which was then incubated in a thermo mixer at 550C for 5-10 
minutes until the gel was completely dissolved. 5µl of glass beads were added to the gel 
solution, mixed and incubated on ice for 5 minutes with mixing regularly ensuring the 
glass beads stayed suspended. The solution was then centrifuged at 14000 rpm 10 
seconds to recover the DNA bound to glass beads. The supernatant was decanted and 
the pellet was washed with 500µl of New wash buffer supplied with the kit. After re-
suspension the solution was centrifuged at 14000 rpm for 10 seconds and the 
supernatant was discarded. The washing steps were repeated three times. The DNA 
pellet was dissolved in 10µl of ddH2O and incubated at 550C for 4 minutes to elute the 
DNA. The solution was then centrifuged at 14000 rpm 10 seconds to recover the DNA 
in the supernatant. The process was repeated one more ti e by adding 10µl of ddH2O. 
The concentration of DNA was then measured with a NanoDrop. 
2.2.9 Quantification of DNA  
DNA concentration gel was measured by spectrophotometry using a NanoDrop. 
Briefly 1µl of TE buffer was used to create a zero value before DNA concentration and 
quality (OD260/OD280 ratio) was determined for each sample.  
 
2.2.10 Ligation of DNA fragment 
For ligations, the Ready-To-Go kit (Amersham) was used; equal ratios of vector 
to insert (250-500 ng) were used in a final volume of 20 µl, with sticky-end ligations 
left for 30 minutes and blunt-end ligations for 45 minutes in a 16°C water bath which 
was maintained at constant temperature in the cold room. The ligated product was then 
used straight for transformation in competent E.Coli DH5α (2.2.3) or was frozen at -
20°C for later use. 
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2.2.11 Phenol-chloroform extraction and ethanol precipitation of plasmid DNA 
Equal volumes of phenol- chloroform were added to the plasmid DNA, vortexed 
and centrifuged at 14000 RPM for 2 minutes at room te perature (RT)). The upper 
layer (aqueous phase) was then collected into a fresh eppendorf before adding an equal 
volume of phenol and the centrifugation process was repeated. The upper layer was then 
transferred to a fresh eppendorf before an equal volume of chloroform was added and 
centrifuged. The upper aqueous layer was then treated with 1/10 volume of 3M sodium 
acetate and 2.5 volumes of absolute -200 C ethanol and incubated at -200 C for 20 
minutes. The precipitated DNA was pelleted by centrifugation, washed with 70% 
ethanol and dissolved in an appropriate amount of TE buffer.  
2.2.12 Cloning of PCR fragment into pUC18/19 vector 
PCR products were cloned into pUC18 or pUC19 vectors using the Sure clone 
kit (Amersham). The PCR fragments were blunted using Klenow enzyme (Roche). This 
was achieved by adding 1 µl of Klenow fragment (5900 U/ml) to the DNA diluted in 1x 
blunt/kinase buffer and left at 37°C for 30 minutes after which the DNA was extracted 
by phenol-chloroform extractionThe PCR products were then separated on an agarose 
gel, cut and purified as described (2.2.7). The DNA was then cloned into linerarised and 
dephosporylated pUC18/19 
2.2.13 Sequencing  
Sequencing reactions were performed at TGAC at the John Innes Centre, 
Norwich. For plasmids <5kb in length 200ng and 500 ng of DNA for >5kb in length 
was sent for sequencing. Sequences were verified and aligned using the online tools 
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2.3 Polymerase Chain Reaction (PCR) 
2.3.1 Amplification of plasmid DNA fragment by PCR 
700ng of plasmid DNA was amplified using the high-fidelity Taq polymerase 
(Roche) in total volume of 200µl. The reaction mixture was then divided in 4 tubes 
containing 50 µl each and subjected to the following PCR conditions. 
 
 
Denaturation at 94°C for 2 min 
  94°C for 45sec  
Annealing     at 55°C for 1 min      35 cycles 
Extension      at72°C for 1min/1kb + 3 seconds each cy le  
  72°C for10 min 
   4°C for 15 min 
 
PCR products were then separated on an agarose gel and purified with Gene Clean. 
 
2.3.2 Genotyping of mouse tissue by PCR 
Mouse ear biopsies were lysed (table 2.5) overnight at 55°C and 1:10 diluted for 
the PCR reaction according to table 2.6.  










Proteinase K lysis buffer 
 
 0.1 M Tris/HCl, 0.2 M NaCl, 0.2 % 
(w/v) SDS, 5 mM EDTA, 0.1 mg/ml  
Proteinase K  
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Table 2.6: Master mix for genotyping by PCR. 
 
 
The standard touchdown programme used for genotyping is detailed below, 
followed by modifcations for itga5 mutant mice and m x mice  
 
a) Touchdown programme 
 
Denaturation at 95°C for 5 min 
  95°C for 1 min  
Annealing     at 65°C for 1 min /minus one degree each cycle 10cycles
  
Extension      at72°C for 1 min  
                         95°C for 1 min  
                         55°C for 2 min     30 cycles 
                         72°C for 1 min 
  72°C for10 min 






Reagents Concentr ation Volume per  reaction  
Forward and Reverse 
primer mix 
20 pM per primer 1µl 
10x Buffer with detergent 100mM tris-HCL(pH 8.8 
at 25°C), 500 mM KCl , 




dNTPs 25µM 0.5 µl 
TOD 1:10 diluted Unknown  2 µl 
Sterile H2O (Fisher) N/A 38.5 µl 
Mouse DNA 1:10 diluted Unknown 3 µl 
Final Volume - 50 µl 
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b) Itga5-specific programme 
 
Denaturation at 95°C for 5 min 
  95°C for 45sec  
Annealing     at 60°C for 45 sec      30 cycles 
Extension      at72°C for 1:30 min  
  72°C for10 min 
   4°C for 15 min 
 
c) mdx-specific programme 
 
Denaturation at 95°C for 3 min 
  95°C for 45sec  
Annealing     at 56°C for 45 sec      40 cycles 
Extension      at72°C for 1:30 min  
  72°C for10 min 
   4°C for 15 min 
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Pr imer  
Number 
Descr iption Sequence 
1 A7 - 981.rev CCA GAA TCG ATG GAG AAA CC 
5 A7 - 3588.rev GAT CGT CGA CTC TAG AAG ATG TTA GGC AGT GGC TGG 
6 A7  3206.seq 
 
CTC AGA GAT GCA TCC ACA GTG 
 
7 A7 - 719.seq TTC TGT GAG GGG CGC CCC CAG 
12 HSA.seq GCA CTA CCG AGG GGA ACC TG 
13 MCK.seq TCA CAC CCT GTA GGC TCC TC 
43 A7.39.seq GAG GGG TGC TGA GGT GAA AG 
44 A7.264.rev GCC GGT GGT AAG AAC AGT CC 
64 Cre UM15B.rev GAC GGA AAT CCA TCG CTC GAC CAG 
65 Cre UM19B.seq GAC ATG TTC AGG GAT CGC CAG GCG 
95 HT030-dwn GCA GGA TTT TAC TCT GTG GGC 
96 HT031-wt/flox-up TCC TCT GGC GTC CGG CCA A 
97 HT032-ko-up GAG GTT CTT CCA CTG CCT CCT A 
98 HT038-neodwn ACC GCT TCC TCG TGC TTT AC 
82 AM p9427.seq AAC TCA TCA AAT ATG CGT GTT AGT G 
83 AM p260e.rev GTC ACT CAG ATA GTT GAA GCC ATT TAG 
84 AM p259e.rev GTC ACT CAG ATA GTT GAA GCC ATT TAA 
 
134 Anxa5-Int2.seq TGG GGA GAG ACT TAG CCA AC 
158 Anxa5-Int Ex3.rev AATTAAACGTTACCCAAGCC 
159 Anxa5-LacZ.rev TGCGGGCCTCTTCGCTATTACG 
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Table 2.8: Oligonucleotides used for cloning 
 
 
2.4 Embryonic stem cells  
After preparing 100 µg of high quality plasmid for each construct they were 
linearised using NotI and sent for transfection of embryonic stem cells at the transgenic 
core facility at Dresden, Germany. Mouse ES cells which were transfected with the 
targeting vector and selected on Neomycin were receiv d in 96 well plates on dry ice 
and kept at 80°C. JM8N4 and 129Sv-derived R1 ES cells were used 
 
2.5 DNA extraction and screening of targeted clones 
For isolation of DNA the transfected ES cells were removed from -80°C and 
were thawed at 37°C for about 10 mins and transferred to 24 well plates containing 
feeder cells over night at 37°C, growth media was changed the following day. When 
confluent, cells were lysed with 500 µl PK lysis buffer and kept overnight at 37°C 
followed by addition of 500 µl isopropanol and plates were then left at 4°C for 4-6 
hours for formation of the DNA precipitate.  The visible precipitated DNA was 
transferred to 1.5 ml eppendorf tubes containing 100 µl sterile TE buffer (pH 8.0) using 




124 AnxA5-Cre-fus.rev ATC AAT CGA TGA GTT GCT TC 
125 AnxA5-Cre-fus.rev GCT TGA TAT CGG TTA CAG TGT GAA TAG TAC TAC CCT 
TCC TTT CAC AGG CTA CGA TGC CCA AGA AGA AGA GGA 
AG 
126 AnxA5-Ex6.rev TGG CAC TGA GTT CTT CAG GTG 
127 AnaxA5-Int5.Seq CGT GAT GAT CGG TTT ATT GGC 
131 Anxa5-int6.seq: AGT TCT TAG AGG AGG CTT CAG GA 
132 Anxa5-int6.rev CTT GAT GCA CTG TGA AAT GGT TA 
133 Anxa5-Ex3.rev GAA GTC AGT CAC AGT GCC TC 
134 Anxa5-Int2.seq TGG GGA GAG ACT TAG CCA AC 
135 Cre-A5KI.rev CAT GTC CAT CAG GTT CTT GC 
142 Anxa5-int6gPCR.rev TGT CTC TTC TCT ATG CCT GCT TC 
143 Anxa5KI-neopA.seq GAG GAT TGG GAA GAC AAT AGC AG 
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2.6 Southern blot analysis  
2.6.1 DNA gel treatment and membrane transfer 
Approximately 10µg of genomic DNA in TE buffer was digested overnight 
using the appropriate restriction enzyme in digestion buffer. The digested DNA was 
then separated on a 0.6% agarose gel, stained with ethidium bromide and viewed using 
UV light. The gels were then submerged in depurinatio  buffer (Table 2.9) for 10 
minutes. The solution was replaced with the denaturation buffer (Table 2.9). After 20 
minutes fresh buffer was added for a further 20 minutes. The same was repeated with 
the neutralisation buffer (Table 2.9). The gels were then placed over 20xSSC saturated 
filter paper placed in solution and the DNA was transferred onto a nylon membrane 
(Hybond XL, GE healthcare) by vertical diffusion of the 20xSSC buffer through paper 
towels overnight. The DNA was then fixed to the membranes using freshly prepared 
0.4N NaOH by placing them on saturated Whatman paper with the bound DNA facing 
upwards for 10 min. The membranes were then neutralised by transferring to 20xSSC 
(Table 2.9) for a further 10 min. For the membranes to be ready to use for radioactive 
labeling, they were heated at 55°C for 1-2 hours and kept at 4°C until use.   
Table 2.9: Reagents used in southern blot analysis 
 
 
2.6.2 Preparation of DNA probes 
For screening of Anxa5-KI-Cre transfected ES cells 3 DNA probes were 
generated. Probe 1, (3' probe, Figure 5.4) was amplified by PCR with primers #126 and 
#127 (table 2.8) using plasmid pX1-E2-7. The 700bp Neo probe  (Neomycin-specific) 
was obtained by restriction of plasmid pGem-Neo∆-EcoRI plasmid with Pst I. The 870 
bp probe 2 (5' probe, Figure 5.4) was obtained by restriction of plasmid pX3-EN-8-4 
(#197) with BamHI.  
Reagents Compositions 
Depurination buffer 0.25 M HCl 
Denaturation buffer 0.5 M NaOH, 1 M NaCl 
Neutralisation buffer 3 M NaCl, 0.5 M Tris/HCl (pH 7.4) 
20X SSC 3 M NaCl, 0.3 M Na Citrate (pH 7.0) 
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2.6.3 Radioactive random labelling of DNA probes  
50 ng of DNA fragment was labelled with 50 µCi α -dCTP32 using the “Prime it 
II” kit (Stratagene) according to the supplier's protocol, followed by purification using 
Illustra NICKTM columns (GE healthcare). The specific activity of 4 µl of the 400 µl 
elute was determined using a liquid scintillation counter (HIDEX). 2-3.106 cpm of 
labelled probe was denatured for 5 minutes at 95°C just before hybridization and kept 
on ice for 2 minutes  
2.6.4. Hybridisation using radio-labeled probes  
Nylon membranes containing DNA were placed into a hybridisation tube with 
the hybridised DNA facing inwards and prehybridised for 4-6 hrs at 42°C with 12.5 ml 
of pre-warmed hybridisation solution (Table 2.10) to which 100 µg/ml denatured 
salmon sperm DNA was added. The denatured radioactive probe was added with fresh 
hybridisation solution and incubated overnight at 37°C. The next day the membranes 
were washed at RT with washing solution (Table 2.10) for 10 min. A more stringent 
wash with pre-heated washing solution was carried out at 50°C depending on the 
radioactive signals picked up by a hand monitor andexposed to a BioMax MS-1 film 
(Kodak) together with an intensifying screen (Kodak) for amplification of the signal at -
80°C  






20x SSPE buffer 3M NaCl, 0.2M NaH2PO4 x H2O, 25mM 
Na2EDTA, 65mM NaOH, ddH20 (pH 
7.4). sterilised by autoclaving 
20 x SSC  3M Nacl, 0.3 M Na Citrate, H2O, pH 7.0 
Washing buffer 2 X SSC in 0.1% SDS 
Formamid buffer Formamid (Sigma), 20x SSPE buffer, 
10% SDS, 100 X Denhardt solution, 
ddH20 
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2.7 Generation of chimeric mice from targeted ES cells  
ES cells, which were identified as positive for homologous recombination were  
injected into host blastocysts and implanted into pseudo-pregnant foster mothers at the 
Transgenic Core Facility, Dresden, Germany.  
2.8 Cardiotoxin (CTX) injection 
Injury was performed by injecting 50µl of 10 µM CTX along the whole length 
of the TA muscle under general anaesthesia with isofluorane.  
2.9 Dissection of mice   
Mice were sacrificed by a schedule-1 method according to the Home office 
license guidelines. An incision was made over the hindlimbs (HL) to carefully remove  
the skin and expose the muscles of interest. Each muscle was individually isolated with 
the tendon and stretched on parafilm and secured with dissecting needles. It was then 
processed for post fixation in PFA or frozen for 1 minute in liquid nitrogen cooled 
isopentane.  
For isolation of embryos, the pregnant female was sacrificed and embryos were 
separated and washed in PBS solution. The hind limbs of the embryos were either 
processed for cryo sectioning or for paraffin embedding. The diaphragms of the 
embryos were care fully dissected and processed for wh le mount immunostaining. 
2.10 Histology 
2.10.1 Post fixation of tissue for cryo sectioning 
Muscles were incubated in 2% PFA solution for 4 hours at 40C. The PFA 
solution was replaced by PBS (Table 2.11), and incubated overnight with regular 
changes. The next day PBS was replaced by 5% sucrose in PBS solution for 2-4 hours 
with regular changes and then replaced by 20% sucroe s lution in PBS over night 
before freezing for cryo sectioning. 
 Table 2.11: Composition of Phosphate buffered Saline  
 
Reagent Composition 
Phosphate buffered Saline 10x pH 7.4 
 
1.37M NaCl, 27mM KCl, 100mM 
Na2HPO4, 18mM KH2PO4, 5mM 
MgCl2·6H2O 
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2.10.2 Cryosectioning 
Frozen tissues from mice were mounted with OCT to the specimen holder.  The 
temperature of the sample was maintained at -24 while t e blade temperature was 
maintained at -26 and 10µm thick sections were colle ted on TESPA (3'aminopropyl-
triethoxy silane) coated slides. Every fifth section was collected onto an independent 
slide, which was used to obtain an overall representatio  of the muscle. 
2.10.3 Preparation of Diaphragm for paraffin embedding 
After isolating the diaphragms from Itga5cKO and contr l mice at post natal day 
3 (P3), they were washed with PBS and were dehydrate  through the series of 
increasing concentrations of ethanol at RT. At the beginning, the samples were 
immersed in 30% ethanol for 1-2 hours changing to 50% ethanol and finally to 70% 
ethanol. The diaphragms were stored in 70% ethanol u ti processed for paraffin 
embedding. 
2.10.4 Paraffin embedding of diaphragms 
Diaphragm which were stored in 70% ethanol were then placed in the plastic 
cassettes and set up in a tissue preparation machine (LEICA TP1020) on the pre set 
program. 
   90% ethanol  1 hr 
   95% ethanol  1 hr 
   100% ethanol  1/2 hr 
   100% ethanol  1/2 hour 
   100% ethanol  1/2 hour 
    
Diaphragms were then cleared of any remaining ethanol by immersing in 
histoclear (Fisher) solution for 30 minutes and repeating it for 3 times before adding it 
to molten paraffin. Samples were then rotated through 3 metal containers containing 
molten paraffin at 650C. Once this process is over the diaphragms were embedded on 
embedding station (Microm EC350-2). All cassettes were placed in a wax bath in the 
embedding station and removed from their cassettes individually before placing into 
wax blocks. A mold was half filled with hot wax and the tissue was orientated within 
the wax and the base mould is placed on the cold plate to set. Paraffin blocks were 
stored at 40C before sectioning on microtome (Microm HM355S). 
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2.10.5 Microtome sectioning 
To set up the microtome the machine is filled with dH2O to warm to 400C small 
amount of “STA-ON”, a tissue section adhesive from Surgipath was added to improve 
the tissue collection on the precoated slides. Paraffin block was placed on the pre cooled 
tissue holder before sectioning at 10-µm thicknesses. Slide was left to air dry before 
storing them at room temperature. Samples were then stai ed with Hematoxylin and 
Eosin dyes. 
 
2.10.6 TESPA (3'aminopropyl-triethoxy silane) coating of the slides 
Slides were pre-coated with the adhesive TESPA (Sigma) as described in Table 
2.12. Slides were then dried at 550C and stored at RT until used. 
Table 2.12: TESPA coating solutions 
 
2.10.7 Hematoxylin and Eosin staining 
Eosin Y (Sigma-Aldrich) was freshly prepared by making a 0.1% solution in 
distilled water and adding a few drops of glacial acetic acid; Mayer’s hematoxylin 
(Merck) was 1:1 diluted with ddH2O. Sections were submerged in freshly filtered 
hematoxylin for 3 minutes. The sections were then washed with cold running tap water 
for 10 minutes before they were submerged into freshly filtered eosin for 30 seconds to 
1 minute before dehydration with increasing ethanol concentration. Samples were then 
treated twice in histoclear for 7 to 10 minutes and mounted using DPX (Fisher), 
protected with a cover slip and left to air dry for15 to 20 minutes.  
 
 
Reagents Incubation per iod 
Acetone 30 sec 
2% TESPA in acetone 1 min 
Acetone Quick immersion 
Acetone Quick immersion 
ddH2O Quick immersion 
 
   
  Chapter 2 
82 
2.10.8 Oil Red O staining 
Oil Red O staining was performed to confirm the deposition of adipose tissue in 
and around the muscle tissue.  The stock solution was prepared by dissolving 300mg of 
Oil red O powder in 100mls of 60% isopropanol over night. The stock solution is stable 
for up to one year and sored at 40C until to be used for staining. The working solution 
was made by mixing 3 parts of Oil Red O stock soluti n with 2 parts of ddH2O, which 
was then incubated at RT for 10 min. Working solutin was then filtered through a 
0.2µm filter before using it for staining. 10µm thin muscle sections were immersed in 
working solution of Oil Red O and incubated for 10-2 minutes at 600C before washing 
under the running tap water for 10 min. The slides were then rinsed with 
60%isopropanol and mounted using Galvatol mounting medium. 
2.10.9 X-gal staining for detection of LacZ 
X-gal staining for β-galactosidase activity was used to detect expression of the 
LacZ fusion gene. X-gal staining was carried out on muscle sections of various 
thickness (10µm -20µm).  Muscle sections were fixed for 30 minutes in fixation buffer ( 
Table 2.13) before washing them in wash buffer (Table 2.13) for 15 minutes for 3 times. 
Fresh X-gal staining solution was prepared from core X-gal buffer (Table 2.13) by 
addition of X-gal stock solution at the concentration of 50mg/ml. the solution was 
filtered before use on the sections. Muscle sections were then incubated at 370C untill 
the LacZ staining was visible. Staining was stopped by washing the sections in wash 
buffer, before mounting with them with Gelvetol mounting medium.  
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Sections were rehydrated in PBS for 10 minutes before fixing with 1% 
paraformaldehyde (PFA) (Sigma) in PBS for 10 minutes at room temperature in a 
humid chamber. Three washes of PBS with 0.1% Tween-20 (PBS-T) for 5 minutes were 
performed after the PFA fixation. Slides were then p rmeabilised in methanol at -20oC 
for 8 minutes and then washed three times in PBS-T for 5 minutes. Non-specific 
binding was blocked using 5% Normal Goat Serum (NGS) (Invitrogen) diluted in PBS-
T for 90 minutes at 37oC in a humid chamber. Primary and secondary antibodies 
(Tables 2.14 (a) and (b)) were prepared and diluted in 2% NGS in PBS-T. 
 
Reagents Compositons 
0.1 M Phosphate buffer  NaH2PO4, Na2HPO4, ddH2O 
Fixation buffer 5mM EGTA, 2mM MgCl2, 0.2% 
glutaraldehyde, 0.1M phosphate buffer 
Wash Buffer  2mM MgCl2, 0.1M phosphate buffer 
X-Gal core solution 2mM MgCl2; 5mM K4Fe (CN) 6-3H20, 
5mM K3Fe (CN) 6-3H2O, 0.1M 
phosphate buffer 
X-gal Stock solution  500mg X-gal, 10 ml dimethylformamide 
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Table 2.14(a): Primary antibodies used for immunohistochemistry 
 








Protein of interest Pr imary antibody Dilution (in 2% NGS) Manufacturer 
Nidogen U13+ (anti-rabbit) 1:2000 In house 
Laminin α2 LNα2 1:20 Sorokin 
Integrin α7B U12+ (anti-rabbit) 1:400 In house 
Integrin α7B U31+ (anti-rabbit) 1:400 In house 
Integrin β1 U49+(anti-rabbit) 1:400  
Integrin β1D U30+(anti-rabbit) 1:400 In house 
Integrin α6 GOH3 1:10 In house 
Integrin α5 CD49e 2.5µg/ml Pharmingen 
Integrin αv CD51 5µg/ml Pharmingen 
Lectin FITC  1:500 Sigma 
 
Secondary antibody Dilution (in 2% NGS) Manufacturer  
Goat anti-rabbit Cy2 1:200 Jackons 
alpha SMA- mouse mAb-Cy3 1:400 Sigma 
Goat anti-rabbit Cy3 1:800 Jacksons 
Goat anti-rat 647 1:200 Jackons 
 




1:500 (1µg/µl) Sigma 
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2.10.11 Preparation of Gelvatol mounting medium  
10ml solution of 0.1M KH2PO4.H2O was adjusted to 7.2 by addition of 0.1M 
Na2HPO4.H2O. The resulting solution was then diluted 1:10 to make a 0.01M solution 
to which 20gms of Polyvinyl alcohol (Gelvatol, Type II. cold water soluble, Sigma P-
1836) and 0.65gm of NaCl (0.14M) were added. The mixture was left on the stirrer to 
mix over night before adding 40ml of Glycerin (Sigma). Next day the mixture was 
transferred in two 50ml falcons and centrifuged at 14000rpm for 15 minutes. 
Supernatant was collected and anti-bleaching agent DABCO (Sigma) was added at the 
concentration of 25µg/ml. Syringes were filled with the Gelvetol avoiding the formation 
of air bubbles and were stored at -200C until used for mounting. 
2.11 Microscopy 
Immunostained cryosections were analysed with a Zeiss upright fluorescent 
microscope. Images were captured with a monochrome camera (Axiocam HR). H&E 
stained images were captured using the colour camera (AxioCam HRc, Zeiss) 
usingAxiovision software version 4.8.2.  
 
2.12 Western blot analysis 
2.12.1 Preparation of Muscle Lysates 
GC (Gastrocnemius), TA (Tibialis Anterior), Sol (Soleus) and EDL (extensor 
Digitorum longous) muscles were dissected and snap frozen in liquid nitrogen and 
stored in -80 ºC. For preparation of muscle lysates, the tissue was immersed in 2ml pre-
cooled RIPA buffer (Table 2.15) and homogenised on ice. Tissue lysates were 
centrifuged for 5 minutes at 14000rpm. The supernatant was centrifuged for a further 60 
minutes at 35,000 rpm at 4°C. The protein concentration was quantified using the Pierce 
BCA Protein Assay kit using bovine serum albumin as a standard according to the 
supplier’s protocol. The samples were then stored at -80 ºC. 
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Table 2.15: Reagents used for western blotting 
 
2.12.2 Immunoblotting  
20µg muscle lysates in 1x sample buffer were denatured at 95°C for 5 minutes. 
SDS-PAGE 5-15% or 8-18% gradient gels were used to separate samples at 200V under 
non-reducing, or reducing (8-18%) conditions by the addition of 5% β-
mercapterethanol. Biorad broad range molecular range marker was used as standard. 
Transfer onto PVDF membranes was carried out in 10mM sodium borate overnight at 
200mA at 4°C.  Protein marker was identified by Ponceau S (2.5% Ponceau S in 5% 
Trichloroacetic Acid) staining. After blocking in 1x Sigma blocking Buffer B6429 (for 
quantification) or 2% NGS in PBS-T (all other), the appropriate affinity-purified 
polyclonal primary antibodies were applied at 1:1000 dilution in 1x Sigma block or 2% 
NGS PBS-T and incubated 1 hour at room temperature. Membranes were then washed 
three times in PBS-T and then incubated with IR-dye conjugated (for quantification 
blots) or goat anti-rabbit secondary antibodies conjugated to horseradish peroxidase 
(HRP) together with actin antibody as a loading control. Membranes were then washed 
two times with PBS-T and once in PBS. Protein bands were visualised with ECL using a 




Tris buffer saline (TBS) 10x pH 
7.6 
50mM Tris-Cl, 150mM NaCl 
RIPA buffer 5x 100mM Tris (pH 7.4), 750mM NaCl, 5% NP40, 
0.25% Triton-X 100 and 2.5% Na-
Deoxycholate 
Sample buffer 5x pH 6.8 5% SDS, 25% glycerine (v/v), 200nM Tris 
(v/v), and bromophenol blue  
Running buffer 10x 1.92M glycine, 0.25M Tris, and 1% SDS 
diluted in ELGA water 
Transfer buffer stock 10x pH 9.2 29.9g glycine, 58g Tris, and 3.7g SDS dissolved 
in ELGA water 
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Table: 2.16: Composition of gradient gels used during western blotting 
 
 
2.12.3 Quantification of Immunoblot 
Quantification of integrin α7, β1 and actin expression was calculated from 
immunoblots, using the Odyssey System. Two infrared fluorescent channels can be 
detected, meaning two target proteins can be detected simultaneously, in the same 
immunoblot. Actin was used in all cases as a loading control. For each sample, the 
fluorescence intensity of both the integrin α7/β1D and actin bands was measured by 
manually outlining the immunoblot band. The background was automatically subtracted 
from this measurement. All parameters were constant for all immunoblot band 
measurements. The integrin α7/β1D value was then divided by that of actin, to 
normalise any loading discrepancies. When quantifyig overexpression for the 
transgenic strains, all (normalised) values for integrin α7/β1D were then divided by the 
(normalised) value of the wild type. This gave the wildtype value an assigned value of 
1, and all overexpressing strains a fold increase from this value. Immunoblots samples 
were run for two mice from each strain and each was repeated at least three times and 
the average values were calculated.  
 Separating Gel Separating  Gel 
Components Source 5% (ml) 15% (ml) 8% (ml) 18% 
(ml) 
ELGA water Water polisher 16.9 6.9 13.9 3.9 
30% acryl-bisacrylamide BIO-RAD 5 15 8 18 
Separating buffer 4x 
1.5M Tris, 0.4% SDS 
pH8.8 
In house 7.5 7.5 7.5 7.5 
10% Ammonium 
persulfate 
Melford 0.06 0.05 0.06 0.05 
TEMED Fisher 
Scientific 
0.011 0.011 0.011 0.011 
 
 Stacking gel 
Components Source 3% (ml) 4.5% (ml) 
ELGA water Water polisher 13 12 
30% acryl-bisacrylamide BIO-RAD 2 3 
Stacking buffer 4x 
0.5 M Tris, 0.4% SDS pH 6.8 
In house 5 5 
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2.12.4 Immunoprecipitation of muscle lysates 
1mg of total protein extract was pre-cleared for 2 hours with 50µl of Protein 
Sepharose A (GE-Healthcare). The supernatant was used for precipitation with 
5µL/500µL of the appropriate affinity purified rabbit polyconal antibody in a total 
volume of 500µl 1X RIPA lysis buffer and left to rotate overnight. 50µl of Protein 
Sepharose A was added and incubated on a rotating wheel for 2 hours. Samples were 
briefly spun down and the supernatant discarded, the sepharose pellet was washed 3 
times in 500µl 1X RIPA buffer and briefly centrifuged. After final washing the 
supernatant was removed using a Hamilton syringe and the antigen was eluted with 
100µl freshly made treatment buffer. Samples were then d atured at 95°C for 5 
minutes and 5µl of sample was run on 5-15% or 8-18% SDS-PAGE gradient gels. 
Remaining samples were then stored at -20 ºC after quick freezing on dry ice. 
 
2.13 Animal maintenance  
Mice were handled in accordance with Home office regulations. All mouse lines 
were kept under specific pathogen-free conditions in individually-ventilated cages and 
were routinely screened for common mouse pathogens. Mice were weaned and genders 
were separated around 3 to 4 weeks of age. At this s age, they were ear tagged, and ear 
biopsies were used for genotyping. Mice that were not needed where humanely culled 
by a schedule 1 method. For genotyping embryos, pregnant female mice were sacrificed 
by schedule 1 method and the embryos were removed and analysed for phenotype. The 
tail tissue from embryos was taken for genotyping by PCR.  
 
2.14 Isolation of pericytes from mouse tissue 
This technique was performed in collaboration with Dr Zhou. ROSA-td Tomato 
mice were dissected under dissecting microscope and tissues from muscle and 
peritoneum were carefully isolated and washed with sterile PBS several times. Tissue 
samples were then sliced in to small pieces before incubating in to Collagenase (Col 
type II, 3mg/ml) for 20 minutes. The tubes containing tissue were gently agitated after 
every 5 minutes to facilitate complete dissociation of the tissue by Col type II. Samples 
were mixed by passing through 5ml pipette before incubating for further 20 minutes. 
After this process, disintegrated tissues were passed through 40µm cell strainer and 
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centrifuged at 1600 rpm for 20 minutes. Supernatant was discarded and cell pellet was 
suspended in DMEM 10% FCS medium before culturing them on gelatin-coated plates 
overnight. Next morning cells were washed by PBS to remove the loose cells before 
changing medium and incubated further until 100% confluence. Medium was changed 
on daily basis.  
2.15 Fluorescence Activated Cell Sorting (FACS) 
This technique was performed in collaboration with Dr Zhou. Cells were grown 
on gelatin-coated plates until they reach confluence. Cell were then detached from the 
plates using 5mM EDTA before splitting them in two 15 ml falcons, one will serve as 
control for FACS staining. Cells were centrifuged at 1000 rpm for 4 minutes, 
supernatant was discarded and cells were resuspended i  5ml PBS with 5%FCS for 
further centrifugation. Cell pellet were then resuspended in 100µl PBS with 5%FCS. At 
this stage one set of cells were stained with varied c ll surface markers (CD140b, 
CD31, CD45) conjugated with different fluorochroms, while second set was labeled 
with relevant IgG antibody to serve as a negative control. Cells were incubated for 45 
min on ice with intermittent mixing before washing twice with 5ml of 5% FCS in PBS. 
Cells were resuspended in 5% FCS in PBS before sorting them on FACS machine (BD 
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Chapter 3  
Integrin α5β1 in development and adult Skeletal Muscle 
 
Integrin α5β1 deficiency leads to embryonic lethality before muscle 
development begins, due to mesodermal defects, most pr minent in the posterior region 
of the embryo (Yang and Hynes, 1993). To study the function of integrin α5 in skeletal 
muscle we made use of conditional knockout (cKO) integrin α5 fl/fl and heterozygous 
integrin α5 +/- knockout mice in combination with Cre recombinase driven by the 
muscle specific promoters, Human α-Smooth muscle actin (HSA) and Pax3.  
 
3.1 Generation of integrin α5 conditional knockout in skeletal muscle. 
Integrin α5 mutant mice were a kind gift of Prof R.O Hynes (MIT, Boston, 
USA), which were generated in his laboratory with the gene targeting strategy described 
in figure 3.1. 
 
To generate integrin α5 fl/fl (Itga5), the targeting vector was designed in such a 
way that exon 1 was flanked by two LoxP sites, while the neomycin cassette was 
flanked by two frt sites. After homologous recombinat on in ES cells mice heterozygous 
for the targeted allele were generated and then crossed with Flp deleter mice to excise 
the Neo cassette. These α5 fl/fl animals are normal and used for cross breeding with 
mice in which Cre is driven by a tissue specific promoter. In addition we obtained mice, 







Figure 3.1: Design of the targeting vector for homologous recombination in integrin α5 mice. Genomic organisation of the integrin α5 knockout 
(Itga5KO) and Wildtype (Itga5WT) alleles is shown in the first two constructs (top wo). The targeting construct for the conditional integrin α5 knockout 
allele (middle) and the resulting targeted allele after homologous recombination (upper bottom) is shown. Mating with Flp recombinase transgenic 
mice removes the neomycin selection cassette located between frt sites (lower bottom). Breeding with Cre recombinase expressing mice will excise 
exon 1 which is flanked by two loxP sites, resulting in conditional loss of integrin α5  (Itga5cond KO) (bottom last). 
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3.1.1 Breeding strategies to generate integrin α5 conditional null mice 
In order to understand the role of integrin α5 in skeletal muscle, we decided to 
delete integrin α5 specifically in skeletal muscle. To obtain these animals we crossed 
heterozygous Itga5+/- mice with animals expressing Cre recombinase under the control 
of HSA promoter (figure 3.2 A), which becomes active at embryonic day 9.5  (Asante, 
E.A., et al., 1993) and predominantly active in differentiating skeletal muscle (Miniou, 
P., et al., 1999). This created Itga5 +/- HSA-Cre mice, which were then crossed with Itga5 
fl/fl females to obtain Itga5 fl/-HSA-Cre mice (figure 3.2 B). 
 
 
Figure 3.2:  The breeding strategy applied to obtain Itga5 cKO mice. (A) Itga5+/- mice were 
crossed with mice expressing Cre recombinase under the control of the HSA promoter to 
generate Itga5+/-HSA-Cre mice, which were then crossed (B) with Itga5 fl/fl mice to generate 









Itga5 +/-HSA-Cre Itga5 Fl/Fl  
Itga5 Fl /-HSA-Cre 
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3.1.2 Genotyping by PCR analysis of integrin α5 cKO mice 
Tail biopsies of the experimental mice were processed for preparing DNA 
lysates which were then used for genotyping by polymerase chain reaction (PCR) using 
primers HT030-dwn, HT031-wt/flox up, HT032-KO-up, HT038-Neo dwn (Table 2.7) 
and Figure 3.1). The primer combination HT032 and HT038 gave a 1KB band specific 
for the Itga5KO allele. The combination of HT030 and HT031 primers re ulted in a 
550bp band for the WT allele in integrin α5 heterozygous animals but detected also the 
presence of the floxed allele (fl) by the appearance of a 700bp band. Finally, excision of 
exon 1 by Cre- recombinase was confirmed by the presence of a 500bp band, which was 
the product of the primer pair HT030 and HT032 (Figure 3.3). Cre-specific primers 





Figure 3.3: Genotyping of Itga5cKO mice. Genotyping was carried out by touchdown PCR 
programme using primers HT030, HT031, HT032 and HT038. “Fl” = Floxed allele (exon 1 of 
Itga5 flanked by 2 loxP sites), while “WT” = wild type allele, M= marker (1KB ladder). After  




We observed a 500bp band corresponding to excised allele, which is likely due 
to small amounts of muscle tissue present in the tail biopsies. We therefore decided to 
perform the PCR on the DNA samples obtained from indiv dual muscle like GC, TA; 
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Figure 3.4: Representative PCR results from DNA isolated from individual muscle. DNA was 
isolated from GA, TA and Sol muscle isolated from Itga5fl/-HSA-Cre mice and PCR was carried 
out using the specific primer combinations. The KO allele was identified as a 1000bp band 
while the floxed allele (FL) was observed at 700bp. The wild type allele (WT) gave a 550bp 
band while the excised allele showed at 500bp.  
 
 
The amount of excision was quantified by calculating he ratio of the intensity of 
the floxed and excised allele by Image J analysis software. There was almost 50% 
excision observed in all the muscle in Itga5 fl/-HSA-Cre mice. The representative table 
with the actual values obtained from Image J analysis i  documented in table 
1(Appendix I) 
3.1.3 Histological analysis of adult integrin α5 HSA-Cre mice 
Itga5 fl/-HSA-Cre mice were born at the Mendelian ratio, and were viable and 
fertile. There was no apparent abnormality. It was therefore crucial to determine the 
effects of integrin α5 deficiency in muscle. To answer this question skeletal muscle of 
integrin α5 cKO and control mice were analysed by histology. As controls we choose 
the following genotypes, Itga5 fl/+ HSA-Cre, Itga5 fl/fl and Itga5 WT. Experimental mice 
were sacrificed at four weeks, three months and one year of age. Whole hind limbs (HL) 
were dissected and frozen for cryosectioning as described in materials and methods. 
Cryosections of 10µm of thickness were taken and analysed by Hematoxylin and Eosin 
(H&E) staining to visualise any signs of muscle damage. In addition we also analysed 
the diaphragm to observe any changes in phenotype. 
Often early signs of muscle degeneration are visible at four weeks of age. 
However, muscle sections of 4-week-old Itga5fl/-HSA-Cre mice had no obvious signs of 
muscle damage when compared with Itga5fl/+HSA-Cre littermate controls (Figure 3.5). At 
TA GC Sol M 
KO 
Fl  
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the age of three months the muscle phenotype did not change and the morphology of the 
muscles was comparable to that of controls. There was no obvious difference in muscle 
fibre diameter observed. However, we observed some centrally located nuclei (CLN) 
particularly in the GC muscle and therefore we decid to quantify the number of fibres 
with CLN in both Itga5cKO and control mice. These experiments were repeated for three 
different sets of mice at four weeks and three months of age to eliminate any biological 




Figure 3.5: Representative images comparing muscle sections of Itga5 cKO and littermate 
controls: H&E staining of 10µm cryosections of GC muscle revel d no major signs of muscle 
damage in Itga5 fl/-HSA-Cre mice at 4 weeks and 3 months of age (B, D) when compared with age 
matched Itga5 fl/+HSA-Cre mice (A, C). Bar, 50µm. 
 
 
The numbers of CLN were counted from sections, which were 100µm apart 
from each other. The mean of two values was then taken for statistical analysis. In GC 
muscle we observed a slight increase (0.8%) of fibres containing CLN compared to 
control mice (0.6%). However, there was no statistical significant difference between 
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both genotypes. In the TA and Sol muscles the number fi res with CLN (0.5%) was 




Figure 3.6: Graphical representations of fibres with CLN in Itga5cKO and control mice. Graph 
shows the percentage of fibres with CLN in GC, TA and Sol muscles of Itga5 fl/-HSA-Cre and 
fl/+ HSA-Cre mice. n=3 and p=0.9451 
 
 
As there were nophenotypic abnormalities observed in young mice, we decided 
to analyse another cohort of integrin α5HSA-cre mice at 12 months of age. Surprisingly 
Itga5fl/-HSA-Cre mice showed some signs of muscle degeneration. H&Estaining of the 
muscle cryosections of 12-month-old Itga5 fl/-HSA-Cre mice displayed centrally located 
nuclei and smaller fibre diameter when compared with age matched Itga5 fl/+HSA-Cre 
(Figure 3.7 A-F). Presence of calcification and fibrosis around the fibres was also 
prominent in muscle sections of some Itga5 fl/-HSA-Cre mice (Figure 3.7 C). However, 
these histological changes were prominent only at a loc lised area of the GC muscle and 

























 Figure 3.7: Representative images comparing muscle sections of Itga5 cKO and littermate controls. H&E staining of 10µm cryosections of 
 GC muscles revealed signs of the muscle regeneration in Itga5 fl/-HSA-Cre mice at 12months of age (A-C) when compared with age matched  
            Itga5 fl/+HSA-Cre mice (D-F). Bar,50µm.
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3.2 Investigating the conditional loss of integrin α5 at early stage of 
muscle development 
The results in adult mice can be due to either there is indeed no major muscle 
phenotype when integrin α5 is deleted when muscle differentiation occurs, or it is 
inefficiently deleted by Cre driven by the HSA promter. Since integrin α5 is down-
regulated after birth, between day5 and 10 postnatally (Blaschuk and Holland, 1994; 
Boettiger et al., 1995; Bronner-Fraser et al., 1992) but strongly present before, we 
decided to determine whether integrin α5 is efficiently deleted by Cre recombinase at 
early postnatal stages. 
 
3.2.1 Histological analysis of newborn integrin α5 fl/- HSA-Cre mice 
In order to evaluate the phenotype in newborn mice we generated postnatal day 
3 (P3) mice through time mating. Plugged females were s parated, monitored until they 
gave birth and pups were genotyped by PCR as describ d before. The HLs were frozen 




Figure 3.8: Representative images comparing muscle s ctions of Itga5cKO and littermate 
controls: H&E staining of 10µm cryosections of HL muscles revealed no signs of muscle 
damage in Itga5 fl/-HSA-Cre mice at postnatal day 3(P3)(A-C), when compared with age matched 
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As expected, there were no signs of muscle degeneration in P3 Itga5 fl/-HSA-Cre 
mice, due to the loss of integrin α5. The structure of all the muscles including GC, TA
and Sol was normal and there were no gross abnormalities observed when compared 
with littermate controls. (Figure 3.8, A-F). To confirm the absence of integrin α5 in 
these mice we performed immunostaining on cryosections from Itga5cKO and control 
mice (Figures 3.9-3.12).  
 
By double-immunofluorescence analysis we stained for integrin α5 in 
combination with integrin α7B (Figure 3.9), αv (Figure 3.10), β1D (Figure 3.11) and α6 
(figure 3.12) to observe if there was any change in the expression pattern of these 
integrin, because of the absence of integrin α5. All immunostainings were performed 
with secondary controls to avoid false positive results (data not shown). 
Immunostaining with integrin α5-specific antibodies on muscle sections of Itga5cKO 
mice confirmed the absence of integrin α5, whereas we observed a strong staining for 
integrin α5 at the MTJ of control mice (Figure 3.9), indicating that integrin α5 had been 
efficiently deleted.  Integrin α7B is strongly expressed at the MTJ but the expression 
level was not elevated in absence of integrin α5, when compared to control sections 
(Figure 3.9). Sections were also stained with integrin αv to analyse if there is any 
compensatory mechanism in place in the absence of integr n α5. However, it was 
difficult to draw a conclusion from these results as antibodies raised against murine αv 
are notoriously bad in immunostaining (Figure 3.10)  Strong expression of integrin β1D 










Figure 3.9: Representative images of immunostaining a ainst integrins α7B and α5 in muscle sections of Itga5cKO and control mice.   
Immunostaining of   10µm cryosections of HL muscles onfirmed absence of integrin α5 expression in Itga5 fl/-HSA-Cre mice (top row) at P3,  
while integrin α5 is strongly evident at MTJs (white arrow) in Itga5 Fl/+HSA-Cre mice (bottom row). The expression of integrin α7B remained 








Figure 3.10: Representative images of immunostaining against integrins αv and α5 in muscle sections of Itga5cKO and control mice.  
Immunostaining of 10µm cryosections of HL muscles confirmed integrin α5 expression in Itga5 Fl/+HSA-Cre mice (bottom row) at P3, while 
there was no evidence of expression of integrin α5 at MTJs (white arrow) in Itga5 Fl/-HSA-Cre mice (top row). The sections were co-stained 






 Figure 3.11: Representative images of immunostaining against integrins β1D and α5 in muscle sections of Itga5cKO and Itga5 control 
 mice.  Immunostaining of 10µm sections of HL muscles confirmed presence of integri  α5 in Itga5 Fl/+HSA-Cre mice along with the strong 
 expression of integrin β1D at MTJs (white arrow). The expression of integrin β1D was also strongly present at MTJs(white arrow) of Itga5 







 Figure 3.12: Representative images of immunostaining against integrins α6 and β1D in muscle sections of Itga5cKO and control mice. 
Immunostaining of 10µm sections of HL muscles confirmed the presence of integrin α6 at capillaries and β1D at MtJs in Itga5 Fl/+HSA-Cre 
mice at MTJs, which was not different to cKO mice. Bars, 20µm. 
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Integrin α6 is expressed in proliferating myoblasts during skeletal muscle 
development, but then down-regulated after myotube formation and completely lost in 
mice by P10 (Blaschuk and Holland, 1994; Nawrotzki et al., 2003). To visualise if there 
is any increase in expression of integrin α6 in integrin α5 cKO mice, we stained sections 
with antibodies against α6 and β1D (Figure 3.13). However, we did not see any 
difference in the expression of either α6 in the absence of integrin α5.  
This data suggests that there was no compensatory mechanism by other integrins 
observed in the absence of integrin α5.  
 
3.2.2 Histological analysis of adult diaphragm of integrin α5 HSA-Cre mice 
In chimeric analysis of integrin α5-/- ES cells it was shown that the diaphragm 
was affected (Taverna et al., 1998). We therefore analysed the diaphragm from adult 
mice to look for any abnormalities. Diaphragms from the adult mice were processed for 
paraffin embedding and sectioning. 10µm thick sections were then subjected to H&E 





Figure 3.13: Histological analysis of diaphragms of Itga5cKO and control mice. H&E staining 
of diaphragms from Itga5fl/-HSA-Cre mice (A-C) showed no obvious phenotypic changes when 
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This showed that there were no phenotypic abnormalities n the diaphragm of 
Itga5cKO when compared with control mice. Fibres appeared normal and of similar size 
and nuclei were located at the edge of the fibres (Figure 3.13). 
 
Results so far in to the analysis of integrin α5 conditional KO mice suggests that 
there was no obvious difference in the muscle phenotype when samples were compared 
at 4 weeks, 3 months and 6 months of age, but a mild dystrophic phenotype was 
observed at 12 months of age in the GC muscle. Thismade us think that there is a 
possibility that these mice when aged were unable to r generate the muscle upon stress, 
suggesting a deficit in the function of regeneration.  
 
 
3.3 Histological analysis of cardiotoxin (CTX) injected integrin           
α5 HSA-Cre mice 
 
To examine the possibility of delayed regeneration in 12 months old integrin α5 
conditional KO mice we decided to induce muscle regeneration using myotoxic agent. 
TA muscle of Itga5 fl/-HSA-Cre mice, and age matched littermate controls were injcted 
with the myotoxic agent cardiotoxin (CTX) and regeneration capacity was analysed 
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Figure 3.14: Schematic representation of the scheme followed for cardiotoxin (CTX) 
injections. To identify the defect in regeneration Itga5cKO and Itga5 control mice, CTX was 
injected at day 0 (D0) to mice in group 1, 2 and 3.. The muscle was left to recover for 30days. 
mice from group 1 were dissected and injured and non i jured muscles were isolated. The mice 
from group 2 and 3 were further injected with second dose of CTX and dissected at day 33 
(D33), day 36(D36).  
 
 
The muscle was left to recover for 30 days. The first set of Itga5 cKO and 
control mice were dissected at this stage and TA muscle was isolated for 
cryosectioning. The remaining sets of mice were injcted a second time with CTX. The 
mice were then sacrificed at day 33 and 36 and the TA was isolated for cryosectioning. 
Cryosections from Itga5 fl/-HSA-Cre and Itga5 fl/+HSA-Cre TA muscle from day 30-36 were 
analysed by H&E staining (Figure 3.15). 





 Figure 3.15: H&E staining of double injured Itga5 cKO and control TA muscles. H&E staining of 10µm transverse sections of TA muscles 
injured with CTX revealed signs of muscle regeneration in Itga5 Fl/-HSA-Cre (A-C) and Itga5 Fl/+ HSA-Cre (D-F) mice. Day30 represents the 
time point after the first dosage of CTX while Day33 and Day36 represent day 3 and 6 after the second CTX administration. Bar, 50µm
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30 days (Day 30) after CTX injection the TA muscle of Itga5fl/-HSA-Cre mouse 
showed signs of regeneration with centrally located nuclei (CLN) (Figure 3.15 A) and 
was not significantly different to Itga5fl/+HSA-Cre injured TA muscle (Figure 3.15 D). 
The TA muscles of both Itga5cKO and control mice displayed signs of dystrophy, such as 
fibrosis and smaller fibre diameter (Figure 3.15 B,C,E,F), but overall, there was no 
difference between the genotypes. However, we observed that there was possibly more 
fat deposited in cKO mice 30 days after the first CTX injection as compared to controls 
(Figure 3.15 A,D). These H&E results conclude that even there was a subtle difference 
between Itga5 cKO and control mice at day 30; there was no obvious difference in the 
phenotype of the muscle at day 33 and day36 when challenged twice with CTX injury. 
Data shown here is a representative from comparable regions from three injured 
muscles from both Itga5fl/-HSA-Cre and Itga5 fl/+HSA-Cre mice and thus we conclude that 
there was no obvious difference.   
 
Replacement of myofibre by fat is a classical sign of muscular dystrophy. To 
confirm increased presence of fat we performed oil red O staining. The muscle sections 
from both Itga5 fl/-HSA-Cre and Itga5 fl/+HSA-Cre mice showed comparable staining for Oil red 
O three and six days after the second CTX injection (Figure 3.16 B,C,E,F), while, as 
seen before by H&E staining, increased fat deposition was apparent in cKO sections 
(Figure 3.16 A,D). 
Consistent with the H&E results, the Oil red O staining also conclude that there 







Figure 3.16: Oil Red O staining of muscle sections of Itga5 cKO and littermate controls. Oil red O staining on 10µm cryosections of TA muscles 
injured twice show fat deposits in both genotypes (B,C,E,F) Day 30 after the first CTX injection cKO section (A) shower increased fat deposits as 
compared to controls (D). Bar, 50µm. 
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Histological analysis of Itga5cKO mice so far suggests that the loss of integrin 
α5 under the HSA promoter is not a useful model to study the importance of integrin α5 
in muscle development. It may be the case that, by he time HSA promoter is expressed, 
the expression of integrin α5 is already down regulated and very low amount of integrin 
α5 is present, which, after excision has no effect on later stages of muscle development. 
It is therefore necessary to knock down the expression of integrin α5 at very early stages 
of muscle development. This led us to consider the transcription factors, which are 
expressed at early embryonic stages of mouse developm nt.  
 
3.4 Conditional knockout of integrin α5 through the action of Pax3-Cre 
promoter 
 
In mice, Pax3 expression initiates at E~8.5 (Goulding et al., 1991). Therefore we 
decided to cross breed Itga5 +/- mice with Pax3Cre mice, in which Cre had been inserted 
into Pax3 locus (Engleka, K.A., et al., 2005). Itga5 +/- Pax3-Cre males were mated with 
Itga5 fl/fl females to obtain Itga5 fl/-Pax3-Cre mice.  
Genotyping of the F2 generation at weaning resulted in either fl/+, fl/- or fl/+Pax3-
Cre mice, but no conditional KO. In total we genotyped 35 mice at 3 weeks of age, 
without obtaining Itga5 fl/-Pax3-Cre mice. We then suspected that the conditional loss of 
integrin α5 under Pax3-Cre expression is either embryonic or postnatal leathal. To 
investigate this further we decided to analyse embryos from time-mated females.  
 
3.4.1 Isolation and visual observation of integrin α5 Pax3-Cre embryos 
In order to determine the reason behind the premature death of integrin α5 Pax3-
Cre mice, we analysed E18.5 embryos. The visual observation of these embryos showed 
a striking difference between the littermates. Genotyping confirmed a correlation 
between Itga5 fl/- Pax3-Cre genotype and posterior abnormalities. Itga5 fl/- Pax3-Cre 
embryos had a smaller (Figure 3.17 D) and curled tail compared to littermate controls 
(Figure 3.17 A, B). In addition the vertebral posture of embryos was strikingly different 
to controls (Figure 3.17 C).  
 
   





Figure 3.17: Representative images comparing E18.5 embryos of Itga5 cKO and control. 
Embryos from Itga5 fl/-Pax3-Cre and Itga5 fl/+Pax3-Cre were analysed for any abnormalities at 
E18.5. A) Itga5 fl/-Pax3-Cre display a defect at the posterior end of the embryo characterised by a 
curled tail. B) Itga5 fl/+Pax3-Cre embryos have stretched HLs C) Itga5 fl/-Pax3-Cre embryos are 
considerably smaller and deformed. D) Variation of tail length, in Itga5 Fl/-Pax3-Cre embryos     
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We also observed that yolk sacs of Itga5 fl/-Pax3-Cre embryo were filled with 
blood (Figure 3.17 E), which could suggest a hemorrhage. We also noticed one embryo 
with exencephaly (Figure 3.17 F). Closer observations also revealed slight 
abnormalities with the limb structure. The Hind imb of integrin α5fl/- Pax3-Cre mice were 
similar in size and curved inwards while in controls they were well stretched (Figure 
3.17 B). This observation corresponds with the published work of integrin α5KO mice 
(Yang and Hynes, 1993), where it has been shown that there were defects at the 
posterior trunk of the embryos between E8-10.5.These integrin α5 KO mice die at 
E10.5, unlike our conditional null integrin α5 mice, which survive until P2. To examine 
the reason behind the premature death of these mice we decided to isolate both hind 
limb and forelimb along with internal organs like hart, lung and diaphragm. Hind limb 
and forelimb were processed for cryosectioning, while eart, lung and diaphragms were 
processed for paraffin embedding.  
 
3.4.2 Statistical analysis of of integrin α5 Pax3-Cre embryos 
Statistical analysis for the Mendelian ratio from 104 embryos from crossing 
Itga5 +/-Pax3-Cre with Itga5 fl/fl mice between E18.5 and P2 showed that pubs are born at 
normal Mendelian ratio but none survived beyond P2. 
 






Genotype Expected %  Observed %   
  E18.5 E19.5 P1 P2 
Fl/- 25% 10 (15.625%) 4 (25%) 0 (0%) 5(27.77%) 
Fl/-Pax3-Cre 25% 15(23.4375%) 5(31.25%) 3(50%) 4(22.22%) 
Fl/+ 25% 18(28.125%) 3(18.75%) 1(16.66%) 6(33.33%) 
Fl/+ Pax3-Cre 25% 21(32.8125%) 4(25%) 2(33.33%) 3(16.66%) 
Total 100% 64 (100%) 16(100%) 6(100%) 18(100%) 
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3.4.3 Histological analysis of integrin α5 Pax3-Cre embryos 
Cryosections from HLs and FLs from both Itga5 cKO and controls at E18.5 
were analysed by H&E staining. The morphology of HLmuscles TA, EDL and GC 
were similar to that of controls. There were no differences observed in FL muscles 
either. There was no direct evidence of any developmental defect in muscle sections of 




Figure 3.18: H&E staining of muscle sections of Itga5 cKO and control embryos: H&E 
staining of 10µm cryosections from hindlimb and forelimb of Itga5 Fl/-Pax3-Cre (A,B) and Itga5 
Fl/+ Pax3-Cre (C,D) at E 18.5,embryos shows no striking difference in muscle morphology.. Bar, 
50µm 
 
This data indicate that there is no specific muscle ph notype in the HL and FL 
muscles of integrin α5Fl/-Pax3-Cre embryos. At this stage we are unable to understand the 
reason behind the early death in conditional KO of integrin α5Pax-Cre. As mentioned 
earlier, this project was a collaborative project with the team at MIT USA and we were 
limited to analyse the muscle phenotype as a possible neural crest phenotype was in the 
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We then switched our focus of research on integrin α5/α7 double knockout 
(DKO) mice.  
 
3.5 Generating integrin α5/α7 double knockout (DKO) mice 
We first wanted to analyse whether half dosage of integrin α5 on a homozygous 
null background of integrin α7 worsened the phenotype. To do this we crossed hetero- 
or homozygous Itga7 mice with heterozygous Itga7 mice, which were heterozygous for 





Figure 3.19: Breeding strategies to obtain α7-/-/α5+/- mice. Hetero- or homozygous integrin 
α7 mice were bred with females heterozygous  for bot integrin α7  and integrin α5. Resulting 
genotype combinations with the expected frequency is shown on the right. 
 
 
Itga7+/-//Itga5 +/-  
Itga7 +/-//Itga5+/+  
X 
Itga7 -/-//Itga5+/+  
Itga7+/+//Itga5 +/-  
Itga7+/+//Itga5 +/+  
Itga7+/-//Itga5 +/+  
Itga7+/-//Itga5 +/-  
Itga7-/-//Itga5 +/+  







Itga7+/-//Itga5 +/+  
Itga7+/-//Itga5 +/-  
Itga7-/-//Itga5 +/+  
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In figure 3.19 the expected genotypes are shown with at least 12.5% α7-/-/α5+/- 
mice. However, genotyping of more than 400 offspring failed to obtain any surviving 
adult mouse with Itga7-/- Itga5+/- genotype.  
 
At the same time we started to generate a conditional KO of integrin α5 in 
combination with the α7 null allele. Therefore we designed another breeding strategy 
where Itga7+/-//Itga5+/-HSA-Cre mice were crossed with hetero- or homozygous Itga7 
mice, homozygous floxed for Itga5 (figure 3.20).  
 
            
 
Figure 3.20: Breeding strategy to obtain α5/α7 DKO. Integrin α7//α5 heterozygous mice 
carrying Cre recombinase gene were bred with integrin α7 heterozygous or homozygous females 
both floxed for the integrin α5 allele. Resulting combinations of genotypes with the expected 
frequency are shown on the right. 
Itga7+/-//Itga5 +/-HSA-Cre 
Itga7 +/-//Itga5 fl/fl  
X 
Itga7 -/-//Itga5 fl/fl  
Itga7+/+      
Itga7-/-  
Itga5 fl/+  
Itga7+/-  
Itga7-/-  
Itga5 fl/+HSA-Cre  
Itga5 fl/-  
Itga5 fl/-HSA-Cre  
Itga7+/-  
Itga5 fl/+  
Itga5 fl/+HSA-Cre  
Itga5 fl/-  
Itga5 fl/-HSA-Cre  
4 X 6.25% 
4 X 6.25% 
2 X 12.25% 
4 X 12.50% 
4 X 12.50% 
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Figure 3.20 displays all the possible combinations a d the percentages of the 
expected genotypes. The most interesting genotype was Itga7-/-//Itga5 fl/-HSA-Cre. 
However, as described above, we never obtained a surving mouse with this genotype, 
clearly indicating that half dosage of integrin α5 on an integrin α7 knockout results in 
embryonic lethality. We therefore decided to study these mice at very early stages of 
development.  
In order to do so, we set up time matings and harvested embryos at E10.5.  using 
the breeding strategy shown in figure 3.19. We identifi d embryos with the genotype 
Itga7-/-//Itga5+/-. These embryos were smaller than littermates and all had 
haemorrhages in the heads, along the spine and in intersomatic vessels. Some of these 
embryos were pale with very little blood visible.  
3.5.1 Statistical analysis of the genotype from mice at embryonic day 10.5 (E10.5) 
We genotyped 358 embryos to calculate percentages in agreement with the 
Mendelian ratio (Table 3.2) and the Chi square analysis between the last two groups (-/-
//+/- Vs -/-//+/+) shows significant difference between the percentages of embryos with 
p<0.01. 
 
Table 3.2: Statistical analysis of genotypes for the breeding pair Itga7+/-//Itga5+/- X Itga7+/- or 




   Genotype 
(Itga7//Itga5) 
Number  of 
embryos 
Percentage expected Percentage observed 
+/-// +/+ 95 25% 26.53% 
+/+//+/- 60 12.5% 16.76% 
+/-//+/- 110 25% 30.72% 
+/+//+/+ 39 12.5% 10.89% 
-/-//+/- 19 12.5% 5.30% 
-/-//+/+ 35 12.5% 9.77% 
Total 358 100% 100% 
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The analysis in table 3.2 suggests that there is a low frequency for embryos with 
null alleles for integrin α7 and only one allele for integrin α5, suggesting the importance 
of both integrins during developmental stages of the mice. According to the data shown 
in table 3.2, the highest percentage of embryos had at least one functional allele for both 
integrins, while only 19 out of 358 embryos were idntified as Itga7-/-//Itga5+/-. This is 
still significantly lower than integrin α7 deficiency, for which it is known that 50% of 
the mutants die between E10.5-12.5, indicating that a more severe phenotype manifests 
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3.6 Discussion 
In this study we investigated the potential role of integrin α5 in skeletal muscle. 
Integrin α5 is known to be important during embryonic development and its deficiency 
causes death of the embryos at E10.5 due to defects in the development of mesodermal 
structures, mostly in the posterior part of the body (Yang et al., 1993). To study the 
function of integrin α5 in adulthood chimeric mice were derived from integrin α5 -/- 
embryonic stem (ES) cells (Taverna et al., 1998). These results. highlight the fact that 
the muscle fibres survive in α5-null chimeric mice by the fusion of -/- cells with WT 
myoblasts, suggesting that there is dosage effect of integrin α5, which is required for 
embryonic viability. In addition, their study indicates that α5 integrin is not essential for 
muscle development but necessary to maintain muscle fibr  integrity (Taverna et al., 
1998).  
This is the only known in vivo study, which focused on the function of α5 
integrin in skeletal muscle. However, the reason for the degenerative changes observed 
in the muscle deficient in integrin α5 remains unclear. To further investigate the 
involvement of integrin α5 in skeletal muscle development and maintenance we 
generated a muscle-specific KO of integrin α5.
 
3.6.1 Evaluating the outcome of integrin α5 conditional deletion in adult mice  
The data suggests that loss of integrin α5 under the control of the HSA promoter 
had no adverse effect on the muscle phenotype. The mic at different developmental 
stages (4 weeks, 3 months and 6 months) displayed normal muscle fibre size and no 
phenotypic abnormalities when compared to age matched ontrol mice. However, when 
we analysed older mice at the age of over 12 months, we saw signs of dystrophy in the 
HL muscle of Itga5 Fl/-HSA-Cre mice. We observed this phenotype in the GC muscle 
while other HL muscles showed normal muscle architetur . This could only be 
explained by the facts that firstly, integrin α5 is not efficiently deleted under the control 
of HSA-Cre system or secondly, there is a deficit in he regeneration process of Itga5 
cKO mice.  
To further investigate the first theory we decided to study Itga5 cKO and control 
mice at P3.  Integrin α5 is highly expressed during the muscle development and its 
expression is down regulated after birth, between day5 and 10 post-natally (Blaschuk 
and Holland, 1994; Boettiger et al., 1995; Bronner-Fraser et al., 1992).  Under the 
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control of the HSA promoter the deletion of integrin α5 was efficient as integrin α5 
immunostaining was absent in the cKO but present in co trols (figure 3.10, 3.11 and 
3.12). It is also important to bear in mind that HSA promoter becomes active at 
embryonic day 9.5 (Asante, E.A., et al., 1993) and is predominantly active in 
differentiating skeletal muscle (Miniou, P., et al., 1999). It may be the case that by the 
time the HSA promoter becomes active, the expression of integrin α5 is already down 
regulated and very low amount of integrin α5 is present, which, after excision has no 
effect on later stages of muscle development. This would also explain normal 
regeneration seen after CTX injection, as Cre will only be expressed at differentiation 
during the regeneration cycle, while activated satellite cells and proliferating myoblasts 
will be positive for the integrin subunit. At this point we decided to divert our attention 
to a different promoter, which will allow the omission of integrin α5 at early stages of 
development.  
 
3.6.2 Analysing the effects of loss of integrin α5 at early stages of muscle 
development 
The Pax family of transcription factors plays an important role in the 
development of several organ systems. Pax3 was a choice of promoter as Pax3 is 
expressed in mice from E8 onwards (Goulding et al., 1991). Skeletal muscle arise from 
myogenic progenitor cells present in the somites of the embryo. Pax3 is also expressed 
in somites. The expression of Pax3 coincides with the earliest stages of somitogenesis, 
expressed in the dorsal region of new somite. After differentiation into sclerotome and 
dermomyotome, Pax3 expression is restricted to the dermomyotome that will then 
contribute to the formation of limb muscles and body wall (Epstein, 2000).  
 
Pax3-Cre mice (Engleka, et al., 2005) were bred with Itga5 heterozygous mice 
and the resulting F1 generation males (Itga5+/- Pax3-Cre) were mated with Itga5 fl/fl 
females. Analysis of genotyping of the F2 generation at weaning resulted in fl/+, fl/- or 
fl/+Pax3-Cre genotype, but no conditional KO. This indicated that the conditional loss of 
integrin α5 under the control of the Pax3 promoter is embryonic r postnatal lethal.  
 
To further investigate our findings we harvested embryos at E18.5, where we 
identified surviving embryos with conditional loss of integrin α5. We observed a 
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striking difference between the littermates. Itga5 cKO embryos were smaller and with 
posterior defects resulting in a curved spine and short or curled tails. Some embryos 
exhibited exencephaly, a defect in which the brain is completely exposed or protrudes 
through a defect in the cranial vault. As Pax3 is involved in neural crest specification 
during development (Monsoro-Burg et al., 1996)., this data indicates that integrin α5 
has been deleted in the neural crest and the observed differences were the result of 
neural crest defects.  
 
To conclude, our observations correspond with the published work of integrin 
α5KO mice (Yang and Hynes, 1993), where it has been shown that these were defects at 
the posterior trunk of the embryos between E8-10.5. The only difference was that some 
of our Itga5cKO mice were able to survive till P2. It will be interesting to study these 
mice to understand underlying defects. Our work was a joint collaboration between 
Hynes lab at MIT, USA. As a possible neural crest phenotype was in the interest of our 
collaborator, we did not further analyse the cause of the perinatal death of these mice 
and concentrated on the muscle phenotype in the conditi al integrin α5 null mice.  
 
In order to investigate if these Itga5cKO embryos exhibit a muscle phenotype, 
we analysed HL or FL muscle from these embryos. H&E staining of HL muscles 
revealed no obvious abnormalities between Itga5 fl/-Pax3-Cre and Itga5 fl/+Pax3-Cre muscles 
(Figure 3.18), suggesting that there is no skeletal muscle phenotype. 
 
3.6.3 Studying skeletal muscle regeneration in Itga5 cKO and control mice 
To test if there is a possible deficit in muscle regeneration in Itga5cKO mice, we 
induced artificial muscle regeneration by administration of CTX. Upon first CTX 
injection, the TA muscles from both Itga5 cKO and control mice revealed active 
regenerating fibres with CLN (Figure 3.15 A,D) when a alysed 30 days post injury. 
However, there was some deposition of adipose tissue observed in Itga5 cKO muscle 
compared to controls (Figure 3.16 A,D). The muscle was given a second dose of CTX 
after 30 days of recovery and TA was analysed after day 33, and day 36. As expected at 
the peak of degeneration, TA muscle from both Itga5 cKO and control mice displayed 
massive infiltration of polymorphonuclear leukocytes. At day 36 TA muscle from Itga5 
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fl/-HSA-Cre and Itga5 fl/+HSA-Cre mice were regenerating muscle with some fat deposits 
(Figure 3.16). 
Adipose tissue is necessary for muscle regeneration nd appearance of it solely 
does not conclude the adverse phenotype. Due to time restrictions, we were able to 
analyse only one set of data and to draw the conclusion from this would not be 
appropriate. These experiments will need repetition on more sets of mice and it will be 
interesting to see what phenotype will be 15 days after the second CTX  injection (Day 
45). 
 
3.6.4 Investigating the role of integrin α5 and α7 in skeletal muscle 
From previous studies important insights have been gai ed into the pathological 
changes and molecular abnormalities associated with integrin α7-deficiency in mice 
(Mayer et al., 1997; Nawrotzki et al., 2003). The relationship between integrins α5 and 
α7 may be more specific than a simple competition as, de pite the presence of integrin 
α6 and α3 in integrin α7 knockout muscle, only the integrin α5 co-precipitated with 
integrin β1D (Nawrotzki et al., 2003). Evidence suggests thate retention of integrin 
α5β1 and its ligand fibronectin at the MTJ precedes the onset of muscle wasting. It has 
been proposed that the α5β1/fibronectin link is inferior to that of the α7β1/laminin 2 
link. This is potentially due to modifications in components of the junctional 
cytoskeleton, modulating signalling pathways downstream of integrins. By identifying 
signalling pathways active in myoblasts one will be able to study the role of integrin-
mediated signalling (Figure 3.21). 
 
   




Figure 3.21 Schematic representation of integrin α7β1 and α5β1 interactions. Diagram 
showing integin α7β1 and α5β1 connecting their respective ligands to the actin ytoskeleton. 
Exactly how they connect to the actin cytoskeleton and which intacellular signalling events they 
induce are unclear as is the cross talk mechanism, which occurs between the two receptors in 
skeletal muscle. (Modifided from Mayer 2003). 
 
The fact that the increase in integrin α5 does not appear proportional to the 
decrease in integrin α7 would further confirm the notion that the relationship between 
integrins α5 and α7 is more complex than a simple competition. To understand what 
drives the cross talk between these two transmembrane proteins, we decided to generate 






  signalling 
Intracellular 
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3.6.5 Analysing the effect of DKO of integrin α7 and α5 on skeletal muscle. 
As described in figure 3.19 we mated Itga7 mice with Itga5 heterozygous mice. 
The outcome of the F1 generation was somewhat surpri ing to our study. We were 
unable to see any surviving mice with the genotype of Itga7-/- Itga5+/-. As described by 
Mayer et al in 1997, 50% of integrin α7 KO mice die during embryonic development, 
so this indicated a dosage effect of the integrin α5 for survival. At the same time we 
were working on generating a conditional KO of integrin α5 on an integrin α7 null 
background  (refer to figure 3.20 for breeding strategy). Again, we did not obtain any 
viable pups with the genotype of Itga7-/-//Itga5 Fl/-HSA-Cre. This supported our previous 
notion of a dosage effect of integrin α5, and that integrin α5 is a requirement for 
embryonic survival of integrin α7-deficient mice. To identify what had caused 
embryonic lethality with full penetrance we analysed embryos at E10.5 from the parents 
of the combinations of genotypes described in figure 3.19. Genotyping by PCR 
confirmed that the Itga7-/- Itga5+/- indeed is embryonically lethal. Many of these 
embryos were resorbed, but haemorrhages in most of these embryos indicate that death 
is caused by a defective vasculature.  
During these experiments we also experienced a technical problem with the 
animal facility, because of which we had a very low success rate of females getting 
plugged. 50% of females, which were plugged, became never pregnant, and we also 
observed that a high number of wildtype embryos were resorbed. Due to all these 
technical difficulties and restricted time fame, we decided to discontinue the 
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Chapter 4: 
Could integrin α7β1 be a potential therapeutic target for 
DMD?   
 
4.1 Characterisation of transgenic mice overexpressing integrin α7 
splice variants  
 
Integrin α7 plays an important role in muscle development and fu ction (Song et 
al., 1993). The absence of integrin α7 leads to progressive muscular dystrophy, which 
was first described in mice as causing mild myopathy mainly in the Soleus muscle and 
affecting the MTJ (Mayer et al., 1997). Interest in integrin α7 has also arisen from its 
speculated potential to rescue the phenotype of DMD. Integrin α7β1 has been put 
forward as a promising candidate to treat DMD because it fulfills many of the functions 
of DGC, for example signal transduction, mechanical st bility, it is a laminin receptor 
and it is naturally elevated in DMD. In addition, published data indicated prolonged 
lifespan of dystrophin/utrophin double mutant mice when the level of integrin α7 was 
increased (Burkin et al., 2005). 
 
  Integrin α7 is alternatively spliced in its intra- and extra-cellular domains and 
the expression of these splice variants is developmentally regulated. However, very 
little is known about the function of these different splice variants during skeletal 
muscle development or in their suitability to ameliorate the muscle phenotype seen in 
dystrophin deficient mdx mice. To investigate the function of these splice variants, 
transgenic mice were generated overexpressing all four integrin α7 splice variants in all 
their intra- and extracellular combinations. They will ork as a tool to investigate the 
role of each α7 integrin splice variants in ameliorating the DMD phenotype by crossing 
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4.1.1 Generation of integrin α7 splice variant overexpressing mice 
Mice overexpressing integrin α7 were already generated in the Mayer lab using 
the strategy mentioned below. 
Plasmid corresponding to the four possible α7 intracellular and extracellular 
splice variant combinations had already been generated. Constructs were prepared 
expressing each integrin α subunit under the control of Human Skeletal α-Actin (HSA) 




Figure 4.1: Integrin α subunit constructs under the control of HSA promoter. Integrin α 
subunits were cloned into a cassette following the HSA (2239kB) promoter. Arrow marks the 
transcription start site. In addition the HSA construct contains an enhancer element (CAP) as 
well as a 5’ UTR and a part of the first HSA intron to enhance expression. At the 3’ end the 
PolyA sequence of bovine growth hormone is added 
 
 
The HSA promoter activity starts at embryonic day 9.5 and is predominately 
active in skeletal muscle (Chamberlain et al., 1985; Asante et al., 1992). Terminal 
differentiation is the end point of muscle development during which stage many 
changes occur in integrin expression. The HSA promoter is active prior to this process 
when cells terminally differentiate and thus the integrin expression induced via HSA 
promoter may have a significant effect on muscle development. 
 
The various constructs were digested from their vectors, purified and injected 
into the pronuclei of fertilised oocytes. Oocytes were then implanted into 
pseudopregnant females. DNA was extracted from the tail tips of the offspring born and 
PCR amplification was carried out using primers specific for the HSA promoter region 
and the integrin α subunit cDNA. This identified offspring positive for the transgene. 
 
Approximately 10% of the pups born after pronuclei injection were positive for 
the transgene. Each positive offspring is a so-called Founder Mouse, and each Founder 
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Mouse was named for ease of recognition. Because multiple copies of the DNA 
construct can integrate at random places within the genome after injection, the strains 
were established from a single mouse of the F1 generation.  The Founder was therefore 
crossed with a wildtype mouse and one mouse from this subsequent F1 generation 
positive for the transgene was chosen to establish the entire strain. In this way, all mice 
within an established strain are heterozygous for the transgene and were originally 
derived from the same mouse and so, should have the sam  expression level. The whole 
strain was named after the Founder mouse for simplification.  
 
4.1.2 Identifying protein overexpression in transgenic strains 
In order to establish the founder strain the pups born after the pronuclei 
injections were identified for the presence of the transgene. The tail biopsies were taken 
and processed for genotyping by PCR. The offspring born were checked for the 
transgene using primers specific for HSA promoter region, as well as integrin α subunit 
cDNA.  The PCR result confirmed the presence of the transgene for each positive 
offspring. 
 
The number of strains established for each construct varied. This is because the 
number of positive offspring born from each injection varied, and some of the positive 
strains were terminated because they did not overexpress the protein. The integrin α7 
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Table 4.1. Summary of integrin α7 splice variant overexpressing transgenic strains. Each 
construct corresponds to a combination of extracellular and intracellular splice variant as 




4.1.3 Identifying protein overexpression in transgenic strains 
The integration of the transgene into the genome dos not guarantee that the 
protein will be overexpressed; therefore not all positive offspring will overexpress the 
protein. To identify and quantify the integrin α7 splice variant overexpression, the mice 
were sacrificed and Gastrocnemius (GC) muscle was isolated. Protein extracts were 
prepared and separated by SDS-PAGE. After transfer to PVDF membranes the 
overexpression of the integrin α7 splice variants was compared to the wildtype by 
immunoblotting with antibodies specific for the intracellular A or B splice variants. 
 
The GC muscle lysates from the α7X1A (Judith, Lydia, Maria and Elke) and 
α7X2A (Susie and Chris) were separated under the non-reducing condition on 5-15% 
gradient SDS-PAGE gels.  The PVDF membranes were probed with α7A (U12+) 
antibody raised in rabbit. Immunoblots in figure 4.2 represents all strains that 
overexpress the integrin α7A intracellular splice variant and were further sub-divided 
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Figure 4.2: Integrin α7 levels in mice overexpressing integrin α7A splice variants. 
Immunoblotting of GC muscle lysates identified strains overexpressing the integrin α7A under 
the control of HSA promoter. Strains were named for ease of recognition as shown. Two mice 
from each strain were analysed. 20µg of total protein from GC muscle lysate were run under 
non-reducing conditions by SDS-PAGE on 5-15% gels. Antibodies specific for intracellular α7A 
variant and actin were used for immunoblotting. 
 
 
The expression of integrin α7A was increased in all the overexpressing stains 
compared to wild type (Figure 4.2). The expression of the integrin α7A was difficult to 
visualise in wildtype muscle, as the level of the A variant was low in wildtype muscle. 
The level of overexpression varied between strains overexpressing α7X1A (Figure 4.2 
right immunoblot) and α7X2A (Figure 4.2 left immunoblot). Variation in the l vel of 
overexpression was also apparent between strains expressing exactly the same 
construct. To take Lydia and Maria as an example, both overexpressing the α7X1A, yet 
Maria overexpresses less protein compared to Lydia. 
 
Similarly, the GC muscle lysates from the α7X1B (Karin and Xaver) and α7X2B 
(Max, Moritz, Fritz and Babette) were separated under the non-reducing condition on 5-
15% gradient SDS-PAGE gels. Immunoblots were probed with integrin α7B (U31+) 
specific antibody raised in rabbit (Figure 4.3). The protein levels of integrin α7B were 
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Figure 4.3: Integrin α7 levels in mice overexpressing integrin α7B splice variants. 
Immunoblotting of GC muscle lysates of 3 months old mice overexpressing two α7X1B and four 
α7X2B overexpressing strains. Strains were named for ease of recognition as shown. 20µg of 
total protein was run under non-reducing conditions on 5-15% gradient SDS-PAGE gels. 




The level of overexpression was found to be similar between Xaver (α7X1B) 
and Karin (α7X1B) (Figure 4.3 left immunoblot), but variation was observed between 
strains overexpressing α7X2B. Max, Fritz and Babette were strongly expressing α7X2B 
compared to Moritz (Figure 4.3 right immunoblot). 
 
It should be noted here that antibodies specific to the integrin extracellular splice 
variant X1 and X2 were not available and thus, only the blots with intracellular splice 
variants were feasible to do. 
 
To conclude, integrin α7 splice variant overexpression was achieved in all the 
strains, but some variation was observed between th transgenic strains expressing the 
same integrin variant. For further study only one strain per mouse was selected with a 
similar expression pattern. Accordingly, Susie (α7X2A) and Lydia (α7X1A) were 
chosen from α7A overexpressing mice, while Xaver (α7X1B) and Babette (α7X2B) 
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4.1.4 Quantification of protein overexpression in integrin α7 transgenic strains 
Integrin overexpression was quantified from immunoblots of muscle extracts 
probed with specific antibodies. However, when immunoblotting, instead of using ECL 
conjugated secondary antibodies, secondary antibodies conjugated to an Infra-Red Dye 
were used. The fluorescence generated from each immunoblot band was then quantified 
by a specialised scanner (Li-Cor Odyssey® scanner). Differences in immunoblot band 
intensity are often generated by experimental error, therefore it was necessary to 
normalise integrin expression to a protein remaining constant in all samples. Actin is a 
house keeping gene which was used to normalise the prot in values obtained when the 
spice variants were over expressed compared to wildtype protein expression (Figure 
4.3). The value assigned to each transgenic strain represents the fold increase in 
expression of the splice variant where the wildtype expression has been assigned the 
value of 1. 
 
Figure 4.4: Quantification of integrin α7 splice variant overexpression. The optical density of 
integrin α7 bands was determined using Odyssey sofware The relative expression level to the 
wildtype was calculated after normalisation to actin. 
 
 
The integrin α7A variants are overexpressed to a greater extent than he α7B 
variants compared to the respective intracellular splice variant in the wildtype (Figure 
4.4). This could be due to the natural high level of expression of the integrin α7B 
variant while the endogenous α7A variant expression is low within adult muscle. It was 
essential to confirm that the sub-strain chosen for each strain has similar protein 
expression in each hindlimb muscles. Therefore lysates were prepared from GC, TA, 
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PAGE. After transfer to PVDF membrane the expression of integrin α7 was compared 
to wildtype by immunoblotting (Figure 4.5) 
 
 
Figure 4.5: Integrin α7 levels in different muscles of transgenic mice. Proteins were extracted 
from gastrocnemius (Gc), soleus (Sol), extensor digitorum longus (EDL) and tibialis anterior 
(TA) muscles of the 4 representative strains overexpressing α7A and α7B integrins. 
Immunoblots were probed with specific antibodies for each overexpressing integrin. Actin was 
used as a loading control. Top, α7X1A and α7X2A; Bottom, α7X1B and α7X2B. It is evident that 
the integrin level is increased at least 10fold as compared to WT and similar in all the muscles 
of each strain. 
 
 
The integrin level is increased at least 10fold in both α7A and α7B 
overexpressing mice as compared to wildtype and is similar in all four muscles analysed 
(Figure 4.5).  
 
From the above results it is clear that the integrin α7 splice variant expression is 
elevated in the respective mice but it was important to see where in muscle the 
expression of these proteins is localized. To further confirm the localization of α7A and 
α7B immunofluorescence staining were performed on sections of the hindlimb (HL). 
 
Mice were sacrificed at 3 months and HLs were dissected and cryo-embedded. 
Sections were cut at 10µm and stained with antibodies raised against the intracellular 
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Figure 4.6: Localisation of integrin α7 splice variants in transgenic overexpressing mice. 
Representative muscle sections taken from WT, integr  α7X1A, α7X2A, α7X1B and α7X2B 
transgenic mice were immunostained for integrin α7A and α7B. Integrin α7A is restricted to the 
MTJ in WT whereas it is additionally expressed at the sarcolemma and the sarcoplasm in 
integrin α7A transgenic mice. The inset (top row, middle and right) shows the expression of 
protein at MTJs in both α7A expressing strains. In WT, α7B is strongly expressed at the MTJ 
and a patchy staining of the sarcolemma is seen. In integrin α7B transgenic mice, α7B is 
strongly increased at the sarcolemma and is also found in the sarcoplasm. Bar, 50µm. 
 
In wild type muscle integrin α7A is expressed at the MTJ and can barely be seen 
at the sarcolemma. In the transgenic strain Lydia-α7X1A and Susie-α7X2A, very 
strong overexpression of the α7A intracellular variant is seen at the sarcolemma and in 
the sarcoplasm. In addition, the MTJs also displayed high level of expression of the 
protein. In the wild type, integrin α7B is also expressed at the MTJ but in contrast to the 
α7A intracellular variant is additionally expressed at the sarcolemma. In Xaver-α7X1B 
and Babette-α7X2B overexpression is also confirmed and integrin α7B expression is 
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4.1.5  The effect of integrin overexpression on integrin β1 
Integrins function as αβ heterodimers, so any increase in an integrin α7 splice 
variant will only be relevant if there is a concomitant increase in the functional 
heterodimer. To assess whether total integrin β1 increases when α7 is overexpressed, 
immunoblotting was repeated on the transgenic GC muscle lysates, with an antibody 




Figure 4.7 Integrin β1 expressions in integrin α7 splice variant overexpressing mouse 
strains. 20 µg of total protein from GC muscle lysates were separated under non-reducing 
conditions on 5-15% gels. Antibodies raised against the extracellular domain of integrin β1 and 
GAPDH were used for immunoblotting. 
 
 
The level of β1 varied widely between different strains. The leve of integrin β1 
increased slightly in transgenic mice compared to wild type controls. As shown in 
figure 4.7, Susie (α7X2A) and Chris (α7X2A) both display increased expression of β1 
compared to Lydia (α7X1A), Elke (α7X1A), Maria (α7X1A) and Judith (α7X1A). The 
same is true for the strains expressing integrin α7B. Xaver and Karin (α7X1B) appeared 
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The increased integrin β1 levels seen in strains overexpressing integrin α7 splice 
variants would infer that the amount of functional αβ integrin heterodimer is also 
increased. If this can be established then any effect of overexpression seen on muscle 
can be attributed to an increase in integrin α7β1 function, rather than a non-specific 
effect of protein overexpression. As the β1D variant is the predominant splice variant in 
adult skeletal muscle, heterodimer formation was investigated by immunoprecipitation 
of integrin β1D followed by immunoblotting for the overexpressed integrin α7 splice 
variant. This was carried out on a selection of transgenic strains (Figure 4.8). Polyclonal 
antibodies raised in the lab against the cytoplasmic domains of both integrin α7A and B 
and integrin β1D were used for precipitation. 1 mg of total protein was used from GC 
muscle lysates in all cases.  
 
Figure 4.8: Analysis of integrin heterodimer formation in integrin α7 overexpressing 
strains. Immunoprecipitation experiments were carried out using GC muscle lysates 
and 1mg of protein per strain. Strains were subdivided in to those expressing α7A and 
α7B integrin. (A) Strains overexpressing α7A variant. Integrin α7A was precipitated 
and samples were separated by SDS-PAGE under reducing conditions followed by 
immunoblottin for the precipitated integrin α7A (i) as a positive control. Reverse 
immunoprecipation with integrin β1D antibodies followed by immunoblotting for β1D 
(ii) or α7A (iii). An increase in αβ heterodimer formation is only seen in α7X2A 
overexpressing strains. (B) Strains overexpressing the integrin α7B intracellular 
variant. i. and ii . Immunoblotting for either α7B (i) or β1D (ii) was conducted in the 
strains overexpressing the α7B intracellular variant as a positive control for 
precipitation. The β1D precipitates were separated by SDS-PAGE and blotted for 
integrin α7B to determine the extent of heterodimerisation (iii). An increase in αβ 
heterodimer formation is only seen in α7X2B overexpressing strains 
This image cannot currently be displayed.
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As a positive control for this experiment, the integrin α7 splice variant being 
overexpressed was precipitated, separated by SDS-PAGE under reducing conditions 
and then immunoblotting for the precipitated variant was performed (Figure 4.8 Ai. and 
Bi.). Integrins were cleaved into their respective heavy and light chains on the blots by 
the reducing conditions as shown. As the α7A and α7B antibodies are both raised 
against the respective cytoplasmic domains, only the integrin α7 light chain (30kD) is 
recognised. Most of the overexpressed integrin α7 is correctly processed, however 
unprocessed integrin running at 120kD can also be seen on these blots. This is probably 
a result of the high level of integrin α7 overexpression exceeding the cells capabilities 
to process all of the integrin correctly, leaving some without a proteolytic cleavage site. 
These integrin β1D control blots confirm successful precipitation ad the pattern of 
integrin α7 overexpression seen previously by direct immunoblotting. 
The precipitation was repeated, this time using antibodies raised against the 
adult, muscle specific variant of integrin β1, integrin β1D (Figure 4.8 Aii. and Bii.). 
Samples were again run under reducing conditions and immunoblotting for integrin 
β1D was performed to confirm precipitation. βME reduction induces separation of the 
150kDa IgG band into its heavy and light chains which prevents the integrin β1 bands 
from being obscured. However, this has the unfortunate effect that the peptide 
antibodies raised against β1A and β1D have a reduced affinity to their epitopes, the 
reason for which is unknown. This means that these blots confirm successful integrin β1 
immunoprecipitation, but the subsequent integrin β1 immunoblotting of the reduced 
samples should not be relied on for comparisons of the level of integrin β1D between 
strains. 
For this reason, integrin α7β1D heterodimerisation was investigated in the 
transgenic strains by blotting for the overexpressed integrin α7 splice variant on integrin 
β1D precipitates (Figure 4.8 Aiii. and Biii.), as the integrin α7 epitope is unaffected by 
reduction.  
In the integrin α7A overexpressing strains (Figure 4.8 Aiii), integrin β1D 
precipitates were blotted using an antibody raised against integrin α7A. An increase in 
the amount of α7Aβ1D in all strains overexpressing the α7X2A variant was seen as 
compared to the wildtype. However, no increase in α7Aβ1D was seen in strains 
overexpressing the α7X1A variant. 
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Similarly, in strains overexpressing the α7B intracellular variant (Figure 4.8 
Biii), an increase in α7Bβ1D was seen compared to the wildtype in the α7X2 
overexpressing strains. Yet, the strains, which overexpress the α7X1, again show no 
increase in the level of integrin α7X1β1D as compared to the wildtype. This increase in 
dimerisation of integrin α7X2 with integrin β1D appears completely independent of the 
intracellular variant expressed or the level of integrin α7 overexpression. As even when 
very high overexpression of the α7X1 variant is achieved, as seen in for Lydia (α7X1A) 
no increase in α7β1D heterodimerisation is seen.  
 
4.1.6 Analysis of integrin β1D expression 
Overexpression of integrin α7 splice variants resulted in an increase in total 
integrin β1 which is relative to the extent of integrin α7 overexpression. Yet, only 
overexpression of the integrin α7X2 extracellular variant resulted in increased 
association with integrin β1D, the isoform of integrin β1 present in adult skeletal 
muscle. The levels of integrin β1D present in the muscle could not be reliably deduc  
from the immunoprecipitation experiments. Therefore, to investigate any changes to the 
levels of integrin β1D expression, GC muscle lysates were immunoblotted directly with 
antibodies specific to the integrin β1D intracellular variant (Figure 4.9). 
Immunoblotting showed an increase in integrin β1D levels in strains 
overexpressing the integrin α7X2 extracellular variant in combination with either the A 
(Figure 4.9 A,B) or B intracellular variant (Figure 4.9 C,D). In stark contrast, strains 
overexpressing the integrin α7X1 extracellular variant either in combination with the A 
(Figure 4.9 B) or the B intracellular variant (Figure 4.9 C) showed no increase in 
integrin β1D. 
Overexpression of the α7X2 extracellular splice variant resulted in an increase 
of the total level of integrin β1 and an increase in integrin β1D expression.  As one 
would expect, this results in increased heterodimer formation. Although the 
overexpression of the X1 extracellular variant of integrin α7 resulted in an increase in 




   




Figure 4.9: Analysis of integrin β1D expression in integrin α7 overexpressing mice. 
Immunoblotting of GC muscle lysates were separated under non-reducing conditions by SDS-
PAGE on 5-15% gels. Antibodies raised against the intracellular D variant of integrin β1 and 
actin were used for immunoblotting. 
 
 
The apparent lack of integrin β1D heterodimerisation with integrin α7X1 could 
be logically explained if this integrin α7 splice variant instead specifically dimerised 
with an alternative integrin β1 splice variant. Integrin β1A is expressed in muscle 
during myogenesis, but is replaced by the D variant on terminal differentiation. It is 
therefore not present at detectable levels in adult skeletal muscle. However, as the α7X1 
is also predominantly expressed during myogenesis it is feasible that it may dimerise 
with integrin β1A. 
To investigate this possibility, direct immunoblotting of the same GC lysates 
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Figure 4.10: Analysis of integrin β1A expression in integrin α7 overexpressing mice. 
Immunoblotting of GC muscle lysates were run under non-reducing conditions by SDS-PAGE 
on 5-15% gels. Antibodies raised against the intracellular A variant of integrin β1 and actin 
were used for immunoblotting. 
 
 
Overexpression of integrin α7 splice variants resulted in a slight increase in 
integrin β1A in the strains expressing X1 extracellular integrin variant when compared 
to wildtype controls. From the data it also seems that he mice overexpressing integrin 
α7X2 variant also display higher levels of expression of integrin β1A. 
 
4.1.7 In vivo analysis of integrin β1D expression and effect of dimerisation  
 
Heterodimer formation is a pre-requisite of cell surface expression. To further 
investigate integrin α7β1D heterodimer formation, immunostaining of muscle sections 
was performed. Mice were sacrificed at 3 months and hi limbs were dissected and 
cryo-embedded. Sections were cut at 10µm and stained with antibodies raised against 


























































   




Figure 4.11: Expression of β1 subunit in transgenic muscle. Muscle sections taken from WT, 
integrin α7X1A, X2A, X1B and X2B variant mice were stained for integrin β1 (CD29, clone 
9EG7, Pharmingen, and polyclonal antibody against the extracellular domain and recognises 
activated form of integrin β1) and β1D (rabbit polyclonal) in comparable regions of the GC 
muscle. Bar, 100µm 
 
Integrin β1D is expressed at the MTJ of wildtype muscle and can also be seen, 
although weakly, at the sarcolemma (Figure 4.11 bottom row). In all four transgenic 
strains the staining pattern for β1D is similar to that seen in the wildtype. In contras ,  
β1staining is more intense and concentrated at the sarcolemma when the X2 variant is 
overexpressed, while the overexpression of the α7X1 variant results in an integrin β1 
staining pattern similar to the wildtype.   
 
In summary, only an increase in integrin α7X2 resulted in an increase in the 
amount of integrin β1D present (immunoblotting and staining) and in the formation of 
α7β1D integrin dimerisation (Figure 4.7 and 4.8). When integrin α7X1 is 
overexpressed, it is however localized to the MTJ and sarcolemma (Figure 4.11) 
suggesting it is able to heterodimerise with integrin β1. Yet, immunoprecipitation and 
immunoblotting would suggest this is not with integrin β1D. It may indicate that 
integrin β1A could be an alternative dimerisation partner for α7X1, but the mechanism 
behind their binding remains to be elucidated. 
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To conclude, increased expression of integrin α7X2 variant appears to cause 
increased β1 integrin expression, which could result in reduced sarcolemmal stability 
and therefore contribute to the phenotype observed in the α7X2 overexpressing mice 
(see below). 
 
4.1.8 Muscle histology of transgenic strains overexpressing integrin α7 
The role of integrin α7 splice variants in adult skeletal muscle is clearly intricate 
and complex. It is seen that association with integrin β1D is dependent on the 
extracellular splice variant expressed, and that localization and competition are 
dependent on the intracellular variant overexpressed. Of particular interest when 
considering this is whether these factors have any effect on the muscle itself. As one of 
the reasons these mice were generated was to investigat  he potential of integrin α7 in 
rescuing the mdx/DMD phenotype. 
 
To investigate the role of integrin α7β1 in skeletal muscle and its potential to 
rescue the phenotype in mdx mice, we first needed to understand muscle histology of 
the transgenic overexpressing strains. It is important to determine whether the 
overexpression of the individual splice variant of integrin α7 in vivo caused any 
phenotypic changes to the muscle tissue. To investigate the muscle histology, the mice 
were sacrificed at four weeks, three months and six months of age. The hindlimbs were 
dissected and cryo-embeded. 10 µm sections were cut and slides were stained for 
Haematoxylin and Eosin (H&E) staining. Four muscles r presenting a variation of 
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Figure 4.12: Histological analysis of integrin α7 overexpressing mice. Representative muscle 
sections from wildtype and integrin α7X2A (Susie), α7X1A (Lydia), α7X1B (Xaver), and α7X2B 
(Babette) overexpressing mice at three months of age. Sections were stained with haematoxylin 
and eosin. Centrally located nuclei are marked with an asterisk. The soleus muscle is spared in 
all transgenic strains (lower panel). Bar, 20µm. 
 
 
In the wild type all muscle fibres are of similar diameter and all the nuclei are 
located at the edge of the fibre, close to the sarcolemma. In the muscle sections of the 
mice overexpressing integrin α7X1A and α7X1B (Lydia and Xaver), the muscle 
histology is almost similar to that of the wild type control. Muscle fibers are of similar 
diameter and all the nuclei are located at the edge of the fiber. A similar 
phenotype/genotype correlation was seen at four weeks and six months of age. 
Interestingly, H&E staining of transverse cryosections of mice overexpressing integrin 
α7X2A and α7X2B showed a myopathic phenotype. Large number of muscle fibers 
showed centrally located nuclei indicating that themuscle has undergone regeneration 
following degeneration. This suggests that overexprssing these two splice variants has 
actually caused damage to the muscle. Intriguingly, the soleus was protected in all the 
strains (figure 4.12). It seems that the Soleus has a specific protection with no centrally 
located nuclei present as seen in the GC, TA and EDL of either integrin α7X2A or 
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4.1.9 Quantification of centrally located nuclei (CLN) in transgenic mice 
H&E staining data indicated a clear phenotypic difference between the strains 
overexpressing the integrin α7X1 and X2 extracellular splice variants. To furthe 
investigate these differences, the number of centrally located nuclei (CLN) was 
quantified and this was carried out for three different age groups of mice in order to 
follow the progression of the disease phenotype. During muscle regeneration following 
the muscle injury, satellite cells of the muscle fibre become activated and enter the cell 
cycle. In order to repair the damaged muscle fibre, th se SCs fuse with the muscle fibre 
and their nuclei can be seen at the centre of the fibr . The percentage of muscle fibres 
with CLN is used as an indicator of muscle damage. 
 
Muscle sections at four weeks (fully developed muscle), three months (early-
mid adult stage), and six months (adult stage) was analysed and compared to wildtype 
muscle at all ages. The number of muscle fibres was counted for CLN using the H&E 
images in IMAGE J software and the percentage of muscle fiber with CLN was 
calculated (Figure 4.13).  
 
 
Figure 4.13 Quantification of CLN in integrin α7 transgenic mice. The degree of de- and 
regeneration was assessed in H&E stained transverse sections of six-month-old Wildtype and 
transgenic mice. Data are expressed as % of fibers with centrally located nuclei. One-way 
ANOVA statistical analysis was performed in StatView 5 for Windows. Data are expressed in 
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Wildtype muscle usually has approximately 2% of fibres with centrally located 
nuclei. In all strains analysed, the GC, TA and EDL all had a very similar severity of 
phenotype. In strains overexpressing the integrin α7X1A (Lydia) and α7X1B (Xaver) 
the muscle phenotype did not differ from the wildtype (Figure 4.13). Muscle 
overexpressing the integrin α7X2A (Susie) and α7X2B (Babette), however, had an 
increase in the percentage of muscle fibres with centrally located nuclei.  
 
Quantification of the percentage of muscle fibres with centrally located nuclei 
(CLN) of the GC, TA, EDL and Sol muscle confirms the difference in phenotype 
between the X1 and X2 overexpressing strains. As early as 4 weeks of age, strains 
overexpressing the X2 variant had between 5 and 15% of centrally located nuclei (data 
not shown). This phenotype gets progressively worse with age, whereby at 6 months of 
age approximately 35-40% of muscle fibres were affected (Figure 4.13). The percentage 
shown is an average from all mice analysed (four mice from each strain).  
By 6 months of age an increase in muscle degeneration nd regeneration can be 
seen in muscle overexpressing the integrin α7X2A subunit (Susie) and α7X2B subunit 
(Babette). In contrast, and as seen previously, α7X1 overexpressing strains showed less 
than 5% of muscle fibres with centrally located nuclei and are thus very similar to the 
histology observed in wildtype muscles. 
Surprisingly, the Soleus muscle appeared to be protected and there was only a 
slight increase in centrally located nuclei for theintegrin α7X2 overexpressing strains 
and this was true at all ages analysed (Figure 4.13 and data not shown). The percentage 








   
  Chapter 4 
145 
4.1.10 Summary of integrin α7 splice variant overexpressing strains  
Strains were generated to overexpress integrin α7 splice variants. A large 
number of strains successfully overexpressed the splice variants and the HSA promoter 
provided substantial protein overexpression.  
 
The overexpression of integrin α7 splice variants in transgenic mice models has 
revealed many significant differences between them. Integrin β1D preferentially 
heterodimerises with integrin α7X2 and not integrin α7X1. Increasing levels of integrin 
α7X2 in association with either intracellular splice variant resulted in increased integrin 
α7X2β1D and this caused a dystrophic phenotype. The dystrophic phenotype resulted 
in a considerable increase in muscle fibres with CLN, with the specific protection at the 
MTJ (data not shown) and soleus muscle. In contrast, completely normal muscle 
histology was seen on overexpression of the α7X1 extracellular splice variant. The 
phenotypic effect of integrin α7 splice variant overexpression was independent of the 
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4.2 Investigating the effects of integrin α7 overexpression on mdx 
phenotype 
To determine the contribution of integrin α7 splice variants in rescuing 
dystrophin deficiency, integrin α7 overexpressing mice were crossed with dystrophin-
deficient mdx mice. Tail biopsies were taken from offspring to is late the DNA for 
genotyping. PCR was performed using primers specific for the transgene and for mdx.  
 
4.2.1 Integrin α7 splice variant’s overexpression in mdx mice 
 
To identify and quantify integrin expression in mdx transgenic (mTg) mice we 
sacrificed the mice and hindlimb muscles were isolated. Protein extracts were prepared 
from the largest muscle, GC and separated by SDS-PAGE (Figure 4.12). The 
immunoblots were probed with rabbit polyclonal antibodies specific for the integrin 
α7A, integrin α7B and integrin β1D. GAPDH was used as a loading control. 
 
 
Figure 4.14: Integrin α7 splice variant expression in mdx mice. Immunoblots of lysates from 
Gc muscle of mice overexpressing integrin α7X1A, α7X2A, α7X1B, α7X2B on the mdx 
background and WT muscle as control. At least 3 mice per splice variant were lysed in RIPA 
buffer and submitted to immunoblotting with rabbit polyclonal integrin antibodies. GAPDH 
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Integrin α7 splice variant overexpression was achieved in mtg-Susie (mdxα7X2A), 
mtg-Lydia (mdxα7X1A), mtg-Xaver (mdxα7X1B) and mtg-Babette (mdxα7X2B). Immunoblot 
clearly shows overexpression of integrin α7A in mtg-Susie (mdxα7X2A) and mtg-Lydia 
(mdxα7X1A) (Figure 4.14 top row) when compared to the wildtype and mdx littermate. 
Similarly in mtg-Xaver (mdxα7X1B) and mtg-Babette (mdxα7X2B) the expression of integrin 
α7B was shown to have increased (Figure 4.14 middle row) noticeably when compared 
against the controls. At the same time the heterodimer formation was analysed by 
probing the immunoblots with the antibody raised against β1D. The presence of the β1D 
protein in all the mdxtg strains was confirmed by the appearance of a 150 kD band in all 
the analysed samples.  
 
4.2.2 Protein quantification of alternative splice variants in mdxα7tg mice 
An effect of the transgene on the endogenous alterntive splice variant in 
transgenic mice was analysed by quantifying the protein levels of α7A in mdxα7B and of 
α7B in mdxα7A mice by Western blotting and immunostaining. The membranes were 





Figure 4.15: Quantification of integrin α7 splice variant overexpressionin mdx mice. The 
optical density of integrin α7 bands was determined using ImageJ software. The relative 
expression level to the wildtype and mdx was calculted after normalisation to GAPDH. 
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It was observed that the levels of α7A, α7B and β1D were increased by 1.5, 2.5 
and 3 fold respectively in mdx mice, but were not significantly different from wildtype 
mice. As expected in mdxα7tg mice, integrin levels were increased by ~5fold for α7A and 
~8- ~16fold for α7B as compared to wildtype mice (Figure 4.15). Different to the 
transgenic lines, the level of β1D was high in all transgenes and not only restricted to 
the α7X2 splice variants.  
 
4.2.3 Muscle histology of mdx transgenic (mdxtg) mice overexpressing integrin α7 
splice variants 
 
H&E staining of integrin α7 splice variant overexpressing mice suggested that 
mice expressing the extracellular X2 splice variant have a myopathic phenotype. It is 
therefore important to investigate the effect of α7 splice variant overexpression on mdx 
mice in vivo. In order to do this, mice were sacrificed at four weeks, three months and 
six months. The hind limbs were dissected and cryo-embedded. 10µm sections were cut 
and slides were stained for H&E staining. The GC muscle from mdx mice showed a 
typical dystrophic phenotype with fibrosis and many fibres containing CLN. The 
morphology of muscle sections from dxα7tg mice is somewhat similar to mdx mice 
with many fibers undergone a degeneration-regeneration cycle. Interestingly, mdx mice 
expressing the α7X2 variant seemed to have larger areas of muscle damage compared to
mdxα7X1 mice in GC muscle. (Figure 4.16) 
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Figure 4.16: Histological analysis of integrin α7 overexpressing mdx mice. H&E staining of 
10 µm thick cryosections of GC muscle from WT (D) mdx (A) and integrin mdxα7X2A (C), 
mdxα7X1A (B), mdxα7X1B (E), and mdxα7X2B (F) overexpressing mice at three months of age revals 
signs of muscle regeneration in mdx as well as mtg mice. Appearance of CLN was pronounced in 
mdxα7X2B and mdxα7X2A muscle compared to mdx and WT mice. Bar 50µm  
 
 
Figure 4.17: Quanification of fibres with CLN in mdxtg mice. Percentage of fibers with 
centrally located nuclei in GC muscles of mdx and mdxα7tg mice. Areas of degeneration were 
excluded. Overall, the percentage of fibres with centrally located nuclei in GC muscle is not 
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It was therefore important to count the percentage of fibers with CLN in GC 
muscle of mdx and mdxα7tg mice. Surprisingly, the overall percentage of fibres 
containing CLN in mdxα7X2 was not significantly different compared to mdxα7X1 and mdx 
mice. These results demonstrate that mdx mice expressing integrin α7 variants are not 
histologically different than mdx control mice (Figure 4.17).  
 
In addition, immunostaining of muscle sections from mdxtg mice for integrin α7 
intracellular splice variant and the laminin α2 was performed.  As shown in figure 4.18, 
this showed a strong staining of the respective overexpressed splice variant in muscle 
sections of mdxtg mice at the sarcolemma (Figure 4.18 Bi, Ci, Di andEi).  
 
Closer inspection of the sections revealed the interes ing finding that some of the 
muscle fibres overexpressing integrin α7 were actually protected against muscle 
damage. There were no CLN in most of the fibres expressing integrin α7X1A (Figure 
4.18 Biii) and α7X1B (Figure 4.18 Diii). However, in α7X2A (Figure 4.18 Ciii) and 
α7X2B (figure 4.18 Eiii) muscle sections the ratio of overexpressing fibres with CLN 
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Figure 4.18: Investigating expression and localisation of integrin α7 splice variants in mdxtg 
mice. Representative muscle sections taken from mdx, mdxα7X1A, mdxα7X2A, mdxα7X1B and mdxα7X2B 
mice were immunostained for integrin α7A and α7B. Integrin α7A is restricted to the MTJs in 
mdx mice whereas it is additionally expressed at the sarcolemma and the sarcoplasm in 
transgenic mice. Integrin α7B is found at the sarcolemma and the sarcoplasm in mdxα7B 
transgenic mice. Laminin α2 (LN α2 in yellow) stained the BM and DAPI was used to mark the 
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4.2.4 Analysis of membrane damage in mdxα7tg mice using Evan’s blue dye 
 After the H&E staining results it was clear that the muscles of mdxα7X2 mice 
showed a more severe dystrophic phenotype compared to m x and mdxα7X1 mice. In mdx 
mice one of the dystrophic features is membrane damage, which can be detected with 
the help of Evans Blue Dye (EBD).  
 
In order to evaluate the protection offered by each integrin α7 splice variant, 
mdx, mdxtg and α7 transgenic mice were injected with EBD six hours prior to dissection. 
Mice were sacrificed and hindlimbs and diaphragms were isolated. Evans blue positive 
fibers were visualized and scanned at low magnificat on using the Odyssey machine 
(Li-Cor) (Figure 4.19) and at higher magnification using Zeiss Axioplan fluorescent 






Figure 4.19: Membrane damage in mdxα7tg mice using Evan’s blue dye. Membrane damage 
was assessed by injection of Evan’s Blue Dye. Hindlimbs were harvested from mdx and mdxα7tg  
mice, 6 hours post-injection and cryosections were scanned at 700nm using the Odyssey Imager 
(Li-Cor). Scanned images of the EBD injected hindlimbs show membrane damage in all 
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The α7 transgenic mice did not show any EBD uptake, while al  mdxα7tg mice 
displayed signs of membrane damage. Some muscles wer  spared and in some muscles 
the morphology was improved compared to mdx muscles, most often in Peroneus. 
However, this result was variable between individuals of the same genotype. In order to 
evaluate if the α7 splice variants really improve the dystrophic phenotype of mdx mice, 
we analysed the most affected muscle, the GC. The scanned images of the hindlimb 
sections revealed that there is no difference in EBD incorporation in mdx and mdx α7tg 
mice (Figure 4.19). In fact mdx α7X2, especially mdxα7X2B mice had more areas of 
membrane damage compared to mdx and mdxα7X1 transgenic mice. We therefore 




Figure 4.20: Membrane damage in diaphragms of mdxα7tg mice using Evan’s blue dye. 
Membrane damage in diaphragms of α7X2A, mdx and mdxα7X2A mice 6 hours post-injection with 
EBD. Fibres in the diaphragm of mdxα7XA2 mice have more uptake of EBD compared to that 
dissected from mdx  and α7X2A transgenic mice. 
 
It clearly shows that the fibres in the diaphragm of mdxα7X2A mice has more 
uptake of EBD compared to the diaphragm of  mdx mice.   α7X2A transgenic mice did 
not show any signs of membrane damage. Together, this data argue that overexpression 
of α7X2 variants worsen the phenotype of mdx mice. However, more work is need into 
analysis of the effect of α7X1 variants on muscle stability in mdx mice. 
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4.3 Discussion 
Integrins play an important role during skeletal muscle development. The 
integrin α7β1 is the only β1 integrin present throughout the muscle development and 
adulthood, and deficiency of α7 leads to congenital myopathies in mice and human 
(Mayer, 1997, Hayashi et al, 1998). Integrin α7 share a similar function as the DGC by 
connecting the cytoskeleton to the extracellular matrix. Transgenic expression of the 
adult isoforms of integrin α7β1 has shown improvement of the phenotype in mice 
deficient in dystrophin and its analogue utrophin (Burkin et al, 2001). This data suggests 
that integrin α7β1 could play a role in ameliorating the phenotype caused by the 
dystrophin deficiency. However, integrin α7 expression is developmentally regulated 
and the complexity has increased with the existences of intra- and extracellular splice 
variants. In order to evaluate the importance of developmental splice variants of integrin 
α7, we generated transgenic mice overexpressing all four possible combinations of these 
splice variants. These mice were then crossed with the dystrophin deficient mdx mice to 
analyse the importance of integrin α7 overexpression. 
 
4.3.1 Integrin α7 overexpression and its effect on muscle phenotype 
Transgenic mice overexpressing integrin α7 splice variants were generated to 
provide insight into the possibility and efficiency of increasing integrin α7 splice 
variant protein expression i vivo. In addition, the mice were generated to compare the 
roles of the different integrin α7 splice variants. Offspring positive for each of the 
integrin α7 splice variant transgenes were born healthy and viable.  
 
The expression of the transgene was controlled by the HSA promoter and thus 
expression will be specifically in skeletal muscle. Variation in the level of protein 
overexpression in the different transgenic strains is to be expected, as there is no control 
on where the transgene will integrate into the genome. In addition, although a measured 
amount of DNA is injected, the copy number of the transgene will vary between 
injections and therefore strains.  
Protein overexpression was verified by immunoblotting and immunofluorence 
and then quantified. Integrin α7A and B transgenic mice showed a strong 10 fold 
increase in α7 expression and immunostaining results showed localization of the protein 
at MTJ and at the sarcolemma. There was also an ectopic presence of integrin in the 
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sarcoplasm, suggesting that the protein is produced in a larger mount than the cell is 
capable to translocate it to the sarcolemma. 
 
4.3.2 Integrin β1D association with the integrin α7X2 variant 
An increase in integrin α7 is only relevant if there is a concomitant increase in 
the integrin α7β1 heterodimer. Changes to integrin α7 and β1 splice variant expression 
in skeletal muscle have been documented (Song et al., 1992;Belkin et al., 1996;  van der 
Flier et al., 1995; Song et al., 1993; Hodges and Kauffman, 1996; Collo , Starr and 
Quaranta, 1993; Ziober et al., 1993; Velling et al., 1996; von der Mark et al., 2002; 
Ziober, Chen and Kramer, 1997; Kaariainen et al., 2002) , but there has been no 
evidence to suggest that either of the β1 cytoplasmic splice variants has a specific 
preference for any of the α7 integrin isoforms in terms of heterodimer formation. It was 
therefore surprising to find that enhanced dimer formation with  integrin β1D was only 
observed when the α7X2 splice variants were overexpressed. In addition, the total 
amount of integrin β1D present only increased when the α7X2 variant was 
overexpressed. In contrast, integrin β1D does not increase when integrin α7X1 variants 
are overexpressed.    
This is even more surprising, when one considers that the integrin α7X2 specific 
association with integrin β1D is completely independent of whether the A or B 
intracellular variant is present. That is to say the extracellular domain of integrin α7 has 
a specificity for an intracellular domain of integrin β1.  
 
The α7X2β1D splice variant-specific pairing is in line with t e expression 
pattern of these two splice variants. Integrin α7X2 and integrin β1D are both the 
predominantly expressed isoforms of these two integrin subunits in adult skeletal 
muscle, so it makes sense that they would preferentially form a heterodimer.  
 
The role of integrin α7X1 in adult muscle is less straightforward. Increasing the 
amount of the integrin α7X1 variant did not result in an increase in the α7X1β1D 
heterodimer, even though it is known that the α7X1 and β1D integrins can form a 
heterodimer (Yeh et al., 2003). Overexpressing the integrin α7X1 variant did result in 
an increase in the total amount of integrin β1 present. It was hypothesised that this could 
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be because the integrin α7X1 variant was forming an association with integrin β1A. 
Yet, levels of integrin β1A remained undetectable in the integrin α7X1 overexpressing 
muscle as for the wildtype. Possible explanations of this discrepancy include that the 
increase in integrin β1A was too slight to be detected by immunoblotting, or 
alternatively, the integrin β1A specific antibody is not as efficient as the integrin β1D 
antibody. A further reason to suggest that the lack of integrin β1A detection is a 
problem of the technique is the fact that integrin α7X1 is localised to the sarcolemma of 
transgenic muscle, and surface expression of integri s requires αβ heterodimerisation. 
In other words, integrin α7X1 must be associated with integrin β1 to be expressed at the 
sarcolemma, and as shown by the immunoprecipitation experiments this was not the 
integrin β1D variant. This phenomenon does require further investigation, perhaps if 
antibodies were unable to identify integrin β1A, in situ hybridisation could be employed 
to verify the presence or absence of the β1A subunit.  
The splice variant specific pairing of integrin α7 and β1 is a significant 
indication that the integrin α7 splice variants clearly play very different roles in skeletal 
muscle. This may have implications for their potential use in the treatment of DMD. 
 
4.3.3 Integrin α7 extracellular splice variants and their effect on adult muscle 
integrity  
The integrin α7 transgenic mice were developed mainly to investigate the 
potential of integrin α7 to treat Duchenne Muscular Dystrophy. In the initial 
characterisation of the overexpressing mice, many interesting and unexpected findings 
were made, that even expressing these constructs on a wildtype background gave much 
insight into the functional differences of these α7 integrin splice variants. However, 
these findings may be different when the splice variants are expressed in the context of 
a muscular dystrophy, be it in the α7 integrin knock-out or the mdx mouse.  
 
The most surprising finding was that the overexpression of the integrin α7X2 
splice variant caused a muscular dystrophy, yet the overexpression of the α7X1 variant 
did not. In α7X2 integrin overexpressing mice, a progressive increase in the number of 
fibres with centrally located nuclei was seen, reaching up to 40% at 6 months of age. In 
stark contrast, the overexpression of the integrin α7X1 variant appeared to have no 
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detrimental effect on adult muscle integrity. The difference in phenotypes when 
extracellular variants are overexpressed is surprising as the integrin α7X2 variant is 
naturally the predominantly expressed isoform in adult skeletal muscle. The phenotype 
was also completely independent of the intracellular variant present.  
 
It has previously been suggested that integrins α7X2 and β1D provide a strong 
connection to the ECM required in adult muscle (Belkin and Retta. 1998; Kaariainen et 
al., 1998). In contrast, integrins α7X1 and β1A are transiently co-expressed at the early 
stages of muscle regeneration following injury (Kaari inen et al., 2002). It may 
therefore be postulated that these integrins fullfil specific requirements of regenerating 
muscle by providing a weaker and more dynamic connection to the ECM. The fact that 
the integrin α7X1 and integrin β1D do not form a heterodimer in adult skeletal muscle 
makes sense when one considers the requirements placed on the ECM-cytoskeletal 
connection in adult muscle. An increase in this link could therefore result in a stiffened 
muscle, which is more susceptible to mechanically induced damage. Even though we 
observed an increase in the fibres with CLN in three months old α7X2 overexpressing 
mice, no fibres appeared positive for membrane damage when analyzed for EBD 
uptake. Also there was no sign of fibrosis, calcificat on or fat deposition in the analyzed 
muscle sections. These results point to the fact that t e phenotype observed in α7X2 
overexpressing mice is a result of contraction- induced damage.  
 
Integrin α7 expression increases in regenerating muscle (Kaariainen et al., 
2002). The proliferation and fusion of satellite cells (muscle stem cells) is a feature of 
muscle regeneration. Therefore, a simple explanatio of the increase in centrally located 
nuclei seen would be that integrin α7X2B and α7X2A had specifically activated muscle 
proliferation. This does not seem to be the case because if satellite cells were 
continuously proliferating and fusing to existing muscle fibres, they would become 
hypertrophic and this was not observed. It therefore appears that the overexpression of 
integrin α7X2B and α7X2A has actually caused damage to the muscle resulting in 
degeneration, which was then followed by regeneration. The question is therefore why 
increasing the expression of the integrin α7X2 damages adult skeletal muscle whereas 
the α7X1 splice variant does not.  
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This question is complicated as the Soleus muscle and MTJs were protected 
from an α7X2 induced dystrophic phenotype. In the integrin α7 knockout mouse the 
only affected muscle was the Soleus muscle and there was also a severe phenotype at  
the MTJs (Mayer et al, 1997). The findings of this thesis therefore support this previous 
conclusion that these are the two sites at which integrin α7 is localised and concentrated 
and plays a vital and unique role. Therefore, perhaps the protection of these two sites is 
simply because they are in some way adapted to elevat d levels of integrin α7.  
 
There is further evidence to suggest that the study of the Soleus muscle in 
particular may provide important clues as to how integrin α7X2 expression could still 
have a potential role in a gene therapy treatment of DMD. The Soleus muscle is 
primarily made up of the oxidative slow-twitch type I and fast-twitch type IIa fibres and 
it has been known for many years that these fibre typ s are affected the least by the 
degenerative effects of Duchenne Muscular Dystrophy (Karpati, Carpenter and Prescott, 
1988; Webster et al., 1988). In support of this notion, the increase in the proportion of 
‘slower’ type IIA fibres seen in the ADR-mdx double mutant mice resulted in the 
improvement of muscle fibre integrity and mdx disease phenotype (Heimann et al., 
1998; Kramer et al., 1998). It seems more than coincidental that there is a high level of 
integrin α7 in the Soleus muscle and that this muscle in particular is protected from 
DMD.  
 
One could hypothesise that the integrin α7β1 complex and the DGC play very 
similar roles in skeletal muscle but at complimentary sites. The integrin α7β1 would 
reside at the sarcolemma of the soleus and all MTJs and the DGC at the sarcolemma of 
all other muscles. Transgenic overexpression of the int grin α7 at the sarcolemma 
would then cause a disruption to the DGC-laminin link causing a muscular dystrophy. 
In contrast as the integrin α7β1-laminin link is predominant at the MTJ and perhaps the 
sarcolemma of the Soleus, there is no disruption to the DGC and therefore no disease 
phenotype. However, this would still suggest that the integrin α7β1-laminin link is 
inferior to the DGC-laminin link as when it acts in its place a dystrophic phenotype is 
caused. In order to provide an insight into the effct of integrin α7β1-laminin link in the 
mdx mouse, when DGC function is lacking, we crossed the integrin α7 splice variant 
overexpressors with mdx mice.  
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4.3.4 Effect of integrin α7 overexpression on dystrophin deficient muscle 
Dystrophin deficient mice were crossed with α7β1 overexpressing strains to 
study the potential of its splice variants in rescuing the dystrophic phenotype. 
Morphological analysis of mdxtg mice revealed a more severe muscle phenotype 
compared with mdx mice when the X2 extracellular splice variant was present, which 
was pronounced in the GC muscle Similarly, EBD injected muscle sections showed 
more membrane damage in mdxα7X2 mice compared to controls. GC was the muscle then 
chosen to calculate the fibres positive for the cytoplasmic α7 splice variants with or 
without the CLN. The overall proportion of CLN in GC was similar in mdx and mdxtg 
muscle. Overexpression of α7 integrin splice variant made no difference in the 
proportion of the fibres with CLN and thus offers no protection against the disease. 
 
In the previous study on mdx/utr -/- double mutant mice, it was shown that 
overexpression of integrin α7X2B rescued the phenotype observed (Burkin et al., 2001). 
This is conflicting with the results observed in this study. A possible explanation is that 
the mdx/utr double mutant mice display a more severe phenotype compared to 
dystrophin deficiency alone. It is also interesting to note that in the mdx/utr double 
mutant study the overexpression of α7X2B was controlled by the MCK promoter, 
which is activated during the differentiation from the myoblast to myotubes, and in 
mice only becomes active around birth. In the current study protein overexpression was 
driven by HSA promoter, which is active at a similar stage in muscle differentiation but 
already expressed at early stages of skeletal muscle development (Sassoon, Garner and 
Buckingham, 1998). 
In our study, overexpression of α7X2 variant modified the structure of the 
muscles, but the soleus which was protected in all WT α7 transgenic strains. An 
opposite effect has previously been observed in α7-/- mice in which the loss of integrin 
α7 causes myopathic changes mainly in the soleus (Hayashi et al., 1998 ;Mayer et al., 
1997; Miosge et al., 1999). We have evidence that te integrin α7 subunit is 
predominantly expressed in type I and IIa, moderately in IId but not detectable by 
immunostaining in type IIb fibers (unpublished data). The slow-twitch soleus is 
naturally extremely rich in integrin α7. Increased amount of integrin does not perturb 
the integrity of the muscle; however its absence has dramatic consequences. Also 
overexpression of α7 showed no beneficial effect of integrin α7 trangenic expression in 
mdx mice soleus. This result differ from previous studies showing that integrin α7B 
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transgenic ADR/mdx mice induce a fibre-type switch from integrin α7B-non-expressing 
type IIb fibres into integrin α7B-expressing type IIa fibres, inducing an ameliorat n in 
the phenotype of these mice that exhibited less severe dystrophic symptoms than mdx 
mice (Heimann et al., 1998 ;Kramer et al..1998). This suggests that the absence of 
protection of the soleus in mdx in our study could be explained by the fact that 
transgenic expression of α7 did not cause any fibre-type switch. In transgenic mice 
overexpressing α7B (WT background), most of the fibres overexpressed th  transgene. 
Fewer fibres are overexpressing the α7A transgene but there was no correlation between 
fibre-type and fibres which preferentially expressed α7 transgene. Although there was 
no obvious change in fibre type in most muscles, only the EDL occasionally expressed 
MHCI. In mdxtg, no switch in fibre-type had been observed either; owever, while 90% 
of the fibres are positive for α7B, α7A overexpression is restricted to type IIa/d fibres. 
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4.4 Future work 
The initial characterisation of the transgenic strains raised so many interesting 
findings that within this study there was not enough time to cross the transgenic 
overexpressing mice into the integrin α7 knockout mice. This next step will no doubt 
shed further light on whether the integrin α7X1 can improve the dystrophic phenotype.  
 
The study of splice variant expression in the integrin α7 knockout mice will also 
be of interest, particularly for the study of the integrin α7X1 and A variants, whose role 
and function was difficult to define on the wildtype background. Perhaps this was due to 
the endogenous expression of integrin α7X2 and B, which masked the more subtle 
effects, the X1 and A variants likely have. It will a so be of interest to see if there is any 
difference between the integrin α7 splice variants in their ability to rescue the 
MTJ/Soleus specific phenotype. 
 
One aspect of integrin function that has received little attention is the 
mechanism by which splicing is controlled. Perhaps one very significant area of future 
study may lie in elucidating what factors control the spatial and temporal specific 
splicing of integrin α7 and β1 isoforms. It is for example known that extracellular 
signals can play a significant role in this (Weg-Remers et al., 2001;Xie and Black, 2001; 
Matter, Herrlich and Konig, 2002; Konig, Ponta and Herrlich, 1998). Ras, Protein 
Kinase C and Ca2+ / calmodulin-dependent pathways have all been implicated showing 
that splicing could indeed be controlled by extracellular signals and in response to 
changing physiologic conditions. Such elucidation may also bypass the need to 
overexpress protein; perhaps all that is required is to shift the balance of splice variants 
present. The foetal pattern of integrin expression, that is clearly specialised to the 
proliferative, regenerative and dynamic connections a d signalling pathways that may 
be able to repair the damaged muscle. Furthermore, if the pathways specifically 
controlling integrin splicing could be elucidated, small molecule inhibitors/activators of 
the pathways could be used transiently and easily according to need and so avoiding the 
complications associated with a gene therapy treatmnt. 
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Chapter 5  
Do pericytes contribute to skeletal muscle regeneration? 
 
In recent years, several markers have been identifid that define subpopulations 
of pericytes, like desmin, smooth-muscle-actin (α-SMA), NG2-proteoglycan (Ozerdem 
et al., 2001), PDGFR-β or the GTPase-activating protein RGS5 (Gerhardt and 
Betsholtz, 2003). It became also clear that pericytes and vascular smooth muscle cells 
are subsets of a continuum of vascular cells with phenotypic plasticity (Nehls and 
Drenckhahn, 1993). The lack of specific markers limited the analysis of pericytes, as 
pure cell populations could not easily be purified from tissues. In most studies, authentic 
pericytes had to be isolated from larger species to obtain sufficient cell numbers, by 
methods that used selective adhesiveness of cells to substrates (Hirschi and D'Amore, 
1996).  
 
Until recently, no adequate method was available to purify pericytes from mouse 
tissues, a prerequisite for using modern mouse genomics and proteomics. Therefore, we 
used a mouse model (Anxa5-LacZ), which will help us identify these cells through 
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5.1 Analysis of Anxa5-LacZ reporter mouse  
Anxa5-LacZ mice were generated in the laboratory of Dr Poschl by homologous 
recombination resulting in deletion of exon 4 and fusion of LacZ in frame with exon 3 
(Figure 5.1) (Brachvogel et al., 2003). Deficiency of this protein causes no obvious 
phenotypes, likely due to compensation by other members of the protein family 
(Brachvogel et al., 2001; Brachvogel et al., 2003). 
 
The Anxa5-LacZ gene was found to be intimately associated with the 
developing vasculature in the yolk sac and meningi from adult mice, but detailed 
analysis showed that the vascular Anxa5-LacZ expression is restricted to perivascular 





Figure 5.1: Strategy for the generation of Anxa5-LacZ reporter mice The top picture shows 
the structure of the WT allele of Anxa5 gene in the 129SvJ (E14) genome with the integrated 
MuERV element (Rodriguez-Garcia et al., 1999). The top bottom picture shows the targeting 
construct. The mutated allele containing the LacZ reporter fused to exon 3 together with a 
neomycin resistance cassette, resulting in deletion of intron 3 and exon 4 after homologous 
recombination in ES cells is shown in the middle. The bottom shows the Anxa5 locus in C57Bl6 
mice. Probe and resulting bands after Southern blotting are indicated in grey and exons are 





   




Figure 5.2: Characterisation of Anxa5-LacZ-positive perivascular cells. (A) Anxa5-LacZ-
positive pericytes are detected in meningi of Anxa-5-LacZ mice. (B,C) Cell sorting of cells from 
brain meningi of wild-type (Anxa5+/+ ) and AnxaLacZ mice after staining with the vital LacZ 
substrate FDG and PI. Vital FDG+PI- cells are shown in the square. (D-F) Isolated Anxa5LacZ    
perivascular cells express α-smooth muscle actin (SMA), NG2 proteoglycan (NG2), but not 
endothelial- specific PECAM. (Brachvogel et al., 2005) 
 
 
This result was further confirmed by the co-expression of pericyte-specific 
markers (NG2 proteoglycan, PDGFR-β or α-SMA). The presence of the Anxa5-LacZ 
reporter enabled them to isolate pericytes from various mouse tissues by fluorescence-
activated cell sorting (FACS) by detecting β-galactosidase activity with fluorescent 
substrates in vital cells (Figure 5.2) (Brachvogel et al., 2005). Using this method they 
were able to characterise mouse pericytes in vitro for differentiation behaviour and 
molecular signature (Brachvogel et al., 2007). Brachvogel et al (2003) also showed that 
the Anxa5-LacZ fusion gene is highly restricted to perivascular cells in embryonic and 
adult tissues. More importantly, isolated perivascular Anxa5-LacZ-positive cells 
express pericyte and stem cell-specific markers, differentiate into chondrogenic, 
osteogenic and adipogenic lineages and can be cultured for extended periods without 
undergoing senescence. In addition, in other studies, isolated pericytes were 
successfully used to ameliorate the muscular dystrophy phenotype in the golden 
retriever. Together, these results strongly suggest that pericytes could represent a novel 






   
  Chapter 5 
165 
5.2 Analysing the role of pericytes during skeletal muscle regeneration 
Pericytes isolated from human muscle biopsy samples were recently shown to 
efficiently participate in muscle regeneration after intra-arterial injection into immuno-
tolerant SCID-mdx mice, an animal model for human Duchenne muscular dystrophy 
(DMD) in which the dystrophin gene is mutated (Dellavalle et al., 2007). This has 
opened a promising area of stem cell-based therapies for DMD patients. However, 
although the differentiation potential of these cells has been well documented, the 
question still remains as to the fate of endogenous pericytes in the muscle tissue and 
whether or not they contribute to muscle regeneration. In order to address this question 
we crossed the Anxa5-LacZ reporter mice with dystropin deficient mdx mice, and 





Figure 5.3: Localisation of Annexin V expressing cells in the diaphragm. (A-B), Whole mount 
LacZ staining of the diaphragm highlights the vascular bed in wild-type-Anxa5-LacZ mice (A), 
and the stripe- like staining along the muscle fibres in mdx-Anxa5-LacZ mice (B). (C) Eosin-
counterstained longitudinal section of LacZ-stained m x-Anxa5-LacZ diaphragm showing the 
fibre-like dimension of the LacZ-positive cells. (D), Teased muscles fibres of LacZ-stained mdx-
Anxa5-LacZ diaphragm showing a blue-stained fibre and positively labelled cells that are 
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Whole mount staining of the diaphragm marked the widespread vascular bed in 
the diaphragm of wild-type mice, heterozygous for the Anxa5 mutation. In contrast, a 
strong stripe-like staining parallel to the muscle fibres was observed in mdx-Anxa5-
LacZ mice, which was more prominent than the blood vessel-associated staining 
(Figure 5.3 A and B). Sectioning of diaphragm muscle  further confirmed these results, 
but it remained unclear whether or not LacZ-positive staining associated with muscles 
fibres (Figure 5.3 C). We therefore analysed enzymatically and mechanically teased 
muscle fibres. Some blue-stained fibres were obvious next to unlabeled muscle fibres, 
suggesting that endogenous pericytes participate in muscle regeneration. However, 
some cells that closely associated with the muscle fibr s were also LacZ positive, yet, 
their identity still remains elusive (Figure 5.3 D).  
To further investigate the process of regeneration, HL muscle sections were also 
analysed by immunofluorescence, using antibodies against nidogen-1, α-Smooth 
Muscle Acitn (α-SMA) and DAPI (Figure 5.4). 
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Figure 5.4: Immunofluorescence staining of muscle sctions from mdx/Anxa5-Lacz mice. HL 
sections of mdx-Anxa5LacZ/LacZ mice display varied staining pattern of α-SMA at affected region 
of the HL muscle. Pictures A and B were taken at x10 magnification while C and D were taken 




Immunofluorescence results from the HL muscle of mdx-Anxa5LacZ/LacZ mice 
confirm the extent of regeneration that has occurred in some regions of HL muscles. 
Affected regions of the muscle shows a strong staining of α-SMA within the fibres 
particularly the smallest, still growing fibres (Figure 5.4 B and D), suggesting the 
likelyhood for this protein in muscle regeneration, likely for the fusion of myoblasts and 
formation of early myotube structure and organisation (Springer, Ozawa and Blau, 
2002). Nidogen-1 labeled the basement membrane, while DAPI marked the nuclei. 
Although these results from LacZ staining are very intriguing, we may have in 
addition missed cell populations into which pericytes potentially differentiated as the 
Anxa5 promoter could have been turned off in these cells. 
This preliminary data suggested a potential role of pericytes during muscle 
regeneration. But the Anxa5-LacZ mouse model has some limitations such as the LacZ 
mdx // Anxa5LacZ/LacZ 
 Hindlimb 
less affected regions 
 Hindlimb 
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staining can only be done by histological analysis and thus prevent some information 
about the role of pericytes in tissue remodelling. In addition LacZ activity is only 
expressed when Anxa5 promoter is active and therefore when Anxa5 promoter is 
repressed in pericyte descendants, we may miss the identification cells into which 
pericytes differentiate and thus cannot lineage trace the descendants.  
 
To address these concerns we generated a mouse model wher  Cre recombinase 
gene is fused in frame with the Anxa5 promoter in the mouse genome. This mouse 
strain will allow us to activate the expression of any reporter gene in pericytes and any 
descendants can then be identified thereafter. To generate the pericyte reporter mouse, 
we first designed the strategy to engineer the Anxa5-Cre targeting vector. After 
homologous recombination in ES cells the mouse strain w s established and crossed 
with the ROSA-26 reporter mouse strain to address the overarching aim of the project, 
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5.3 Generation of targeting vector for Anxa5-Cre knock-in mouse 
To generate Anxa5-Cre-Knock-in mice we first designed a targeting vector to 
create a knock-in allele in which Cre recombinase activity will be controlled by the 
endogenous Anxa5 promoter (Figure 5.5). Several laboratories had tried to generate an 
Anxa5 mutant mouse strain but failed due to the exist nce of a murine endogenous 
retrovector (MuERV) in intron 4 of the Anxa5 gene in the 129Sv strain, which is 
commonly used for homologous recombination in embryonic stem (ES) cells but absent 
in the C57BL/6 genome (Figure 5.1) (Brachvogel et al., 2003 and Rodriguez-Garcia et 
al., 1999). We therefore used existing plasmids, which were previously used to generate 
the Anxa5-LacZ strain (Brachvogel et al., 2003). Wefused part of Anax5 intron 2 and 
exon 3 with the sequence for Cre recombinase, including a nuclear localisation 
sequence (Cre-NLS) (Appendix II) by designing specific primers 124 and 125 (table 
2.7). This PCR fragment was then cloned into Anax5-X3-EV/BHI plasmid cut with ClaI 
and EcoRV (Appendix II) in order to combine the rest of exon 3 of the Anax5 gene 
(Figure 5.5). Exon 5 and the phosphoglycerate kinase neomycin (PGK-Neo) resistance 
cassette were then cloned into the Sal I / Kpn I restriction sites. The PGK-Neo cassette 
was flanked by two Frt sites and was inserted downstream of the Cre recombinase 
cassette (Figure 5.5). The selection cassette was removed from heterozygous mice by 
breeding with mice expressing Flp recombinase (Figure 5.5). By this way we avoided 
the negative impact of the PGK promoter on the regulation of the Anxa5 promoter 
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Figure 5.5: Strategy for the Anxa5-Cre knock-in targeting vector. Partial genomic 
organisation of the Anxa5 gene in the C57BL/6 genome and the targeting vector (middle) and 
the resulting targeted allele after homologous recombination is shown. Mating with hACTB-
FlpO transgenic mice removes the neomycin selection assette located between frt sites (lower 
bottom). The 5’- probe (Probe 1 in blue), Neo probe (Green) and 3' probe (Probe 2 in Orange) 
were used for Southern blotting (explained in figure 5.5). Main restriction sites are indicated by 
symbols, Neo:PGK-neomycin cassette. 
 
5.3.1 Embryonic stem cell transfection 
100 µg of the targeting vector was linearised with the restriction enzyme Not I 
and purified by phenol/chloroform and ethanol precipitation. The precipitated DNA was 
washed once more with 70% ethanol and dissolved in TE buffer. Transfection of ES 
cells was then performed at the transgenic core facility in Dresden, Germany and the 
positive clones were picked, expanded and sent to us to isolate genomic DNA. To 
identify the clones in which the homologous recombination has occurred, Southern 
blotting after Eco RV restriction was performed. 
 
5.3.2 Screening of the targeted allele by Southern blot 
Homologous recombination occurs between identical sequences of the targeting 
vector and genomic DNA. To screen for homologous recombination we designed three 





















 Figure 5.6: Relative positions of the probes designed for Southern blotting. 5' probe (Probe 1 in blue) was designed outside the arms of 
homology and will generate 11.7kb or 6.6 kb band in the WT or mutated alleles, respectively, after EcoRV and XbaI digestion. The Neo Probe 
(indicated in green) was designed to span the region associated with the Neo cassette, and generates a 9.2kb band in the mutated allele only 
after EcoRI restriction. The 3' probe (Probe 2, orange), also designed to bind outside the arms of homol gy generates a 8.63kb or 9.2kb band 
in the WT or mutated alleles, respectively, after EcoRI restriction. 
XbaI: 11.7kb 
EcoRV: 6.2kb 
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The 3’-probe (Probe 1 in blue, Figure 5.6) was designed to hybridise outside of 
the targeting vector to distinguish between homologus recombination and random 
insertion. When genomic DNA is digested with EcoRV, probe 1 will hybridise to a 6.6 
kb band in C57 BL/6 genomic DNA when homologous recombination has taken place, 
whereas in the non-targeted allele it hybridises to a 6.2 kb fragment (Figure 5.6). This 
initial screening identified 16 ES cell clones for homologous recombination. These 
selective ES cell clones were further tested with Probe 1 after restriction digestion with 
XbaI and resulted in a 11.7kb fragment in the WT while in the targeted allele the 
fragment was reduced to 6.6kb (Figure 5.7). To exclude additional random insertion of 
the targeting vector, neomycin was used as internal probe (Neo probe) for Southern 
blotting after EcoRI digestion and resulted in a single band of 9.2kb. A 5’ probe (probe 
2, Figure 5.7), was also designed to prove correct homologous recombination on either 
side of the targeting vector. This probe hybridised upstream of the inserted EcoRI 
restriction site for detection of homologous recombination on the long arm of homology 
resulting in a 9.2 kb fragment after EcoRI digestion of genomic DNA, representing 
homologous recombination and a 8.6kb fragment in the WT allele. The design and by 
which method the probes were prepared and checked on C57 BL/6 genomic DNA is 





 Figure 5.7: Southern blot analysis of the ES cell cones. A) and B) represents the blots hybridised with the 3' probe (Probe 1-indicated 
in blue in figure 5.5) after restriction digestion with EcoRV or XbaI, respectively. After EcoRV digestion 6.6Kb fragment and 6.2Kb 
fragments were obtained representing KI and WT allele. Similarly restriction with XbaI resulted in 6.6Kb fragment for KI allele while 
11.7 Kb for WT allele. C) Represents the blot hybridised with the 5' probe (Probe 2- indicated in orange in figure 5.5resulting in 9.2 Kb 
fragment for KI allele and 8.6 Kb fragment for WT allele. while D) represents the blot hybridised with the Probe Neo (indicated in green 
in figure 5.5). 
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5.3.3 Screening the targeted allele by PCR 
After the initial screening of ES cells by Southern hybridisation, 12 clones were 
selected and analysed by PCR using primers designed to amplify the regions were Cre 
recombinase had been inserted. Two different sets of primer combinations were used to 
test these clones for the presence of the neomycin cassette and for homologous 
recombination (Figure 5.8). The primer combination 142/143 was to screen for 
homologous recombination with primer 142 being located outside the targeting vector, 
while 143 being specific for neomycin. The primer combination 133/134/135 was to 
amplify fragments located within the targeting vector and which differentiate between 
the mutated and the WT alleles, resulting in a 453bp and a 344 bp band for the mutated 
and WT allele, respectively (Figure 5.8 C). Primer combination 142/143 resulted in the 
identification of 3 clones from C57 BL/6 ES cells, which were previously recognised as 















































































Figure 5.8: PCR analysis of ES cell clones. A) Represents the WT construct (top), targeting 
vector (middle) and targeted construct (bottom) with the relative position of primers 142, 143 
(blue), 133, 134 and 135 (indicated in purple). B) Represents the DNA gel after the PCR 
amplification with primer combination 142x143, resulting in 1.8kb fragment in the targeted 
allele. Plasmid DNA of the targeting vector was used positive control resulting in a 300bp 
fragment, while genomic DNA from 129Sv and C57BL/6 mice did not produce any fragment. C) 
Represents the DNA gel after PCR amplification with primers 133x134x135 resulting in a 
453bp fragment for the targeted allele and a 344bp fragment for the WT allele. Only the 
positive ES cell clones are labelled as well as control DNA and 1kb ladder. 
 
 
5.3.4 Generation of the Anxa5-Cre-knock-in mouse strain 
The heterozygous C57 BL/6 ES cell clones were injected into albino C57BL/6 
blastocysts.  The resulting male chimeras were mated with C57 BL/6 females, which 
were transgenic for recently generated Flpo recombinase (Flpo) (Kranz et al., 2010). 
With this crossing we combined germline transmission of the Anax5-Cre knock-in and 
germline excision of the neomycin cassette located b tween two Frt sites. The correct 
genotypes were confirmed by PCR analysis with primers specific for the individual 


















5.4 Investigating the fate of pericytes during skeltal muscle 
regeneration 
 
As discussed previously there are limitations of using the Anxa5-LacZ mouse 
model to study muscle regeneration and thus to detect th  potential fate of pericytes in 
muscle regeneration a marker is needed, which is independent of muscle specific down-
regulation. To resolve this issue, we decided to focus on two main strategies by which it 
is possible to study the progeny of pericytes during muscle regeneration. 
 
1) Use of ROSA26 reporter strain: In this approach theAnxa5-mediated 
expression of Cre recombinase mediated activation of ROSA26 reporter gene 
expression.  
2) Use of isolated pericytes: Using muscle regeneration as a model, we isolated 
pericytes from skeletal muscle and the peritoneum from homozygous 
ROSA26-tdTomato reporter strain to compare their signature and their 
potential to contribute to muscle regeneration. Theactivation of tomato gene 
expression was achieved by in vitro transduction via an Adeno virus 
expressing Cre recombinase. Pericytes isolated from these mice induced 
angiogenic differentiation of endothelial cells, but also retained stem cell-like 

















5.4.1 Analysis of the Anxa5-Cre-KI: ROSA26-LacZ mouse strain 
To generate mice in which the expression of LacZ is conditionally regulated, we 
crossed the Anxa5-Cre-KI mice with the ROSA26-LacZ reporter strain. In these mice 
Cre recombinase leads to excision of the stop cassette flanked by two LoxP sites 





Figure 5.9: Schematic representation of ROSA26-LacZ reporter cassette for lineage tracing. 
In the ROSA26-LacZ reporter mouse, a stop cassette flanked by loxP sites was inserted just 
downstream of the transcription start site at the ubiq itously expressed ROSA26 locus, but 
before the reporter gene. When intact, this cassette prevents expression of β -galactosidase (β-
gal) from the downstream LacZ coding sequence. The stop cassette is excised upon exposure to 
Cre recombinase, which mediates recombination between the LoxP sites, thus permitting 
expression of the lacZ reporter. All progeny derived from these parent cells will carry this 
mutation and be marked by β-gal expression that can be detected by microscopy in tissue 
sections. (Modified from Kretzschmar and Watt, 2012). 
 
 
This will allow the ROSA26 promoter to drive the expression of the LacZ 
reporter gene. The expression of β-gal will be present in cells, in which the Anxa5 
promoter is active and all their decendants, allowing us to lineage trace Anxa5 positive 
pericytes.   
 
To analyse the β-gal activity in the muscle tissue in Anxa5+/Cre//ROSA-LacZ 
mice, three months old mice were sacrificed and TA muscle was isolated and processed 
for cryosectioning. 20µm sections of TA muscle were then fixed with glutaraldehyde 
and processed for X-gal staining. Anxa5LacZ/LacZ mice were used as a control and TA 
muscle sections from these mice were stained with X-gal in parallel (Figure 5.10). 
Rosa26 






Figure 5.10: Representative images of muscle sections from Anxa5-Cre//ROSA-LacZ and Anxa5-LacZ mice: 20 um sections of TA muscle from 
both Anxa5+/Cre//ROSA-LacZ (A-C) and Anxa5LacZ/LacZ (D-E) were fixed with glutaraldehyde and stained with X-gal substrate. All LacZ positive cells 
are associated with blood vessels, which are indicated with small triangles in figure A, D and E. We also observed entire myofibres staining blue (D 
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Anxa5+/Cre//ROSA-Lacz mice displayed strong X-gal staining throughout the 
muscle section (Figure 5.10 D-E). All the blood vessel  around the fibres were stained 
blue and some fibres showed intense staining of X-gal (Figure 5.10 D and F). However, 
the TA muscle sections of the control Anxa5LacZ/LacZ mice showed only certain areas of 
X-gal positive blood vessels (Figure 5.10 A-C). The int nsity of the X-gal staining was 
also weak compared to the conditional KI strain. This may be because in Anxa5-LacZ 
mice Anxa5 promoter drives the expression of LacZ gene, whose expression varies in 
development. On the other hand, LacZ expression is conditionally activated in 
Anxa5+/Cre//ROSA-LacZ mice thereby labelling all pericytes and their decendants with 
the LacZ marker.  
 
In addition, whole mount staining of the diaphragms of Anxa5+/Cre//ROSA-LacZ 
and Anxa5-LacZ mice was performed. Similarly to theTA muscle, LacZ activity was 
found in blood vessels of the diaphragm of both mice, but the intensity of the stain 
varied. Anxa5-LacZ mice displayed weaker X-gal stain compared to Anxa5+/Cre//ROSA-
LacZ mice (data not shown). In addition in conditionally activated Anxa5+/Cre//ROSA-
LacZ mice, some of the fibres close to the blood vessels stained positive for X-gal.  
 
This data suggests that the conditional activation of the LacZ gene was 
successful and was able to mark pericytes, thus suitable to trace their fate. In order to 
verify that these pericytes contribute to muscle regeneration we decided to induce 
muscle regeneration in Anxa5+/Cre//ROSA-LacZ and Anxa5 LacZ/LacZ mice.  This was 
done by intramuscular injections of the mytotoxic agent cardiotoxin (CTX). TA muscles 
from three-month-old Anxa5+/Cre//ROSA-LacZ and Anxa5 LacZ/LacZ mice were injected 
with 50µl of 10µM CTX and left to recover for 10 days before dissection. The 
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Figure 5.11: Representative images of muscle sections from Anxa5+/Cre//ROSA-LacZ and 
Anxa5 LacZ/LacZ mice. Cryosections from TA muscle of Anxa5+/Cre//ROSA-LacZ and Anxa5 
LacZ/LacZ mice were stained with LacZ and nuclear red. A-C and G-I represents the non-injected 
TA while D-F and J-L represents CTX injected side from Anxa5+/Cre//ROSA-LacZ and Anxa5 
LacZ/LacZ mice, respectively. The intensity of the LacZ stain is largely evident in Anxa5+/Cre//ROSA-
LacZ muscle tissue when comaped with Anxa5 LacZ/LacZ tissue. 40x magnification.  
 
 
10 days after the injury, muscles were dissected an processed for 
cryosectioning which were then analysed for LacZ staining. Nuclear red staining was 
used to mark the nuclei (Figure 5.11 A-L). 
From figure 5.11 it was clear that there was a difference between the LacZ 
staining of the muscle sections from Anxa5+/Cre//ROSA-LacZ and Anxa5 LacZ/LacZ mice. 
As seen before (Figure 5.10), in the non-injured muscle from Anxa5+/Cre//ROSA-LacZ 
mice many fibres were seen with cells at the pericyte location marked with LacZ 
(Figure 5.11 A-C). The same was true in Anxa5 LacZ/LacZ mice but the LacZ staining was 
much weaker in some areas (Figure 5.11G). In Anxa5+/Cre//ROSA-LacZ mice we also 
observed many fibres stained for LacZ and most of them were at the periphery of the 
muscle section. On the other hand control mice did not show any signs of LacZ stain 
inside the myofibre (Figure 5.11 G-I).  
The CTX injected muscle sections from Anxa5+/Cre//ROSA-LacZ displayed 
regenerating fibres with CLN marked by nuclear red stain. These myofibres were 
strongly stained with LacZ, indicating a possible fusion of pericytes with the fibre 
during muscle repair. In contrast in Anxa5 LacZ/LacZ muscle sections weak patchy blue 
staining was evident inside the regenerating fibres. Some LacZ staining was also 
observed around the blood vessels of non-injured muscle sections. 
In addition to the LacZ staining we also stained the 20 µm of CTX injected TA 
muscle with PECAM 1, α-SMA and Nidogen (figure 5.12). PECAM 1 stainins 
endothelial cells thus identifing the location of capillariesAffected regions of the 
muscle shows strong staining of α- SMA within the fibres. Nidogen antibody was used 
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Figure 5.12: Representative images of muscle sections from Anxa5-Cre//ROSA-LacZ  
mice: 20 µm sections of TA muscle from Anxa5+/Cre//ROSA-LacZ were fixed with 
glutaraldehyde and stained with X-gal substrate (A and D). All LacZ positive cells are 
associated with blood vessels, which are indicated with white arrow in A and D, 
Additionally the LacZ staining was observed at nuclear position in fibres with CLN (A 
and D , yellow arrow).The sections were further stained by PECAM 1 and α-SMA (B 
and E ) to locate the capillaries and the CTX injured sites respectively. The basement 
membrane was stained by nidogen (Nd1) antibody (C and F). Dapi was used as nuclear 




To conclude the data from LacZ staining from Anxa5+/Cre//ROSA-LacZ and 
Anxa5 LacZ/LacZ mice suggests that there is a difference in the LacZ staining. To 
overcome the limitations from LacZ staining and to trace pericytes using a fluorescent 
marker, we made use of other reporter stains. We therefore crossed Anxa5-Cre-KI mice 
with ROSA26-EYFP and ROSA26-tdTomato reporter strains. 
 
5.4.2 Analysis of the Anxa5-Cre-KI: ROSA26-EYFP mouse strain 
To expand our possibilities to lineage trace pericytes we made use of the 
ROSA26-EYFP strain (Shrinivas et al., 2001), made avail ble by Dr S.Shrinivas from 
the University of Oxford. The mouse strain was generated using homologous 
recombination using a targeting vector into ROSA26 locus. 
 
This strain has been successfully used in many high-profile publications for 
lineage tracing of precursor cells and long-term tracking of their progeny and shown to 
be useful for localisation of YFP in tissues and unbiased isolation of cells through 
FACS analysis (Schwarz et al., 2008; Rivers et al., 2008; Kuang et al.,, 2007; Geoffroy 
and Raineteau, 2007;Clayton et al., 2007). We then crossed Rosa26-EYFP mice with 
Anxa5-Cre mice to generate Anxa5-Cre-EYFP mice, which should express YFP in 
Anxa5 positive pericytes and its descendants.   
 
First, we isolated pericytes from muscle and peritoneum tissue and sorted them 
by FACS analysis (figure 5.13) to enrich the CD140b+/YFP+/CD31- pericyte 
population. CD140b, also known as PDGFRβ and is expressed by pericytes as a surface 
marker, while CD31 is a cell surface marker expressed by endothelial cells.  
 




Figure 5.13: FACS sorting of pericytes isolated from muscle and peritoneum of ROSA26-
EYFP mice. Cells from muscle and peritoneum were labeled with CD140b and CD31 before 
loaded into sorting machine. P1 indicates vital cell population from debris. P2 shows CD140b 
positive population of P1, which was further enriched by P4 gating (Cd31-/YFP+) to isolate the 




The isolated YFP+ pericytes could be easily identified in FACS analysis and 
maintained the marker for more than 10 passages. The isolated PVCs from peritoneum 
and muscle were co-cultured with HUVEC (Human Vascular Endothelial Cells) and 
showed pro-angiogenic effects compared to HUVEC mono culture in a 3D tube 
formation assay in collagen gel (Data from Dr Zhou, not shown). These EYFP+ 
pericytes stained positive for several tested PVC markers but the YFP signal was too 
weak to be detected by epifluorescence. We therefore used the much stronger tandem 
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5.4.3 Analysis of Anxa5-Cre-KI- ROSA26-td-Tomato mouse strain 
We crossed the Anxa5-Cre-KI mice with ROSA26-tdTomato mice. Offspring 
showed a very strong expression of td-Tomato and the specificity of the expression was 
hard to define. The entire mouse appeared red and we were unable to use these mice for 
any experiments to elucidate the role of pericytes in muscle regeneration. We therefore 
focused our attention on inverse strategy, in which we isolated pericytes from ROSA26-
tdTomato silent mice and activated expression of the Tomato gene by in vitro induction 
of Cre recombinase via viral delivery. 
 
5.4.4 Approach 2: Transplantation study 
5.4.4.1 Efficiency of pericytes in skeletal muscle regeneration 
In order to study the role played by pericytes in muscle regeneration, we decided 
to transplant Tomato-positive pericytes isolated from muscle and peritoneum. The 
expected outcome from these experiments is summarised n figure 5.14. These 
experiments were carried out in collaboration with Dr. E. Poschl and Dr. Z. Zhou 
For the isolation of pericytes they used a silent ROSA-td-Tomato mice in which 
the expression of Tomato gene is inactive. Upon the in vitro induction of Adeno-Cre 










Figure 5.14: Schematic representation of the expected outcome from transplantation 
experiments. Silent ROSA-td-Tomato mice were injected with cells expressing td-tomato after 
being transduced with Adeno-Cre virus. The cells could contribute to muscle regeneration and 
find their niche in the blood vessels. Upon the cardiotoxin (CTX) induced muscle regeneration, 
it is expected to see the recruitment of these pericyt s to regenerated fibres.  
 
 
Before these cells can be injected in to the mouse hindlimb muscles, FACS was 
used to isolate a pure pericyte population (Figure 5.14 A-C). These cells were then 
varified for expression of specific markers.  
 
5.4.4.2 FACS analysis of PVC isolated from muscle and peritoneum tissue 
Pericytes were isolated from muscle and peritoneum of ROSA26-tdTomato -/- 
mouse. The cells were then cultured as described in methods and maintained in 100% 
confluence. These cells were then sorted using FACS for CD140B+, CD45-, CD31- 
(Figure 5.15). The P1 population was gated to distinguish between the real cell 
population and debris (Figure 5.15 A) which was furthe  gated against CD140B, CD45 
and CD31 as shown in the histograms (Figure 5.15 B). A clear peak of the cells positive 
for CD140B was evident in the histograms in both muscle and peritoneum cell 
population. P3 population was gated against CD140b, CD31, suggesting this is a pure 
pericyte population expressing pdgfr-β. 
 
 
Rosa-tdTomato x AdCre 
Direct contribution to regeneration 
•  Recruitment to blood vessel 
• Reprogramming to tissue-specific phenotype 
•  Recruitment for regeneration 
+CTX 
ROSA-td-Tomato 
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Figure 5.15: FACS sorting for pericyte populations. Pericytes (CD140b+/CD31-/CD45-) were 
isolated from muscle and peritoneum from ROSA-td-Tomat  mice. A) Shows the gating strategy 
(P1) to distinguish between the cell population and debris. B) Shows the histogram for the cells 
stained for CD140b (top row), CD45 (middle row) and CD31 (bottom row). P2, CD45 negative 
population was gated for further sorting. C) P3, CD140b+ and CD31- population were isolated 
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To avoid immune rejection red-labeled pericytes were injected in the hindlimb 
TA muscle of congenic ROSA26tdTomato mice. To elucidate the role played by 
pericytes in muscle regeneration, we injected cardiotox n (CTX) into the TA muscle 20 
days after cells had been transplanted. This time point had been determined in initial 
experiments to be best for obtaining Tomato-positive pericytes in capillaries. The non-
injected TA muscle from the contralateral side was used as a control. The scheme of the 




Figure 5.16: Transplantation scheme for injecting cells in silent ROSA-td-Tomato mice:  
Cells were isolated from muscle and peritoneum of ROSA-td-Tomato mice and FACS sorted for 
various pericyte-specific markers. These cells were then transduced with Adeno-Cre (Ad-Cre) 
virus before injecting in the TA muscle. Muscle injury by CTX was carried out on day 20 post 
transplantation and mice were sacrificed on day 35. TA muscle from injured and non-injured 
side was isolated and processed for cryosectioning showing pericytes labeled by td-Tomato 
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15 days post CTX injection, TA muscles were dissected and 10µm thick 
cryosections were stained with Lectin to highlight endothelial cells, and DAPI (Figure 
5.17).  
 
Tomato-labeled muscle fibres were present in sections injected with muscle 
(Figure 5.17-Ai, Aiii and Bi, Biii) and peritoneum-derived (Figure 5.17-Ci, Ciii Di, 
Diii) pericytes both in non-injured and injured TA muscle. Even though the injection 
site is not visible after 35 days, one could see th spread of these tomato-labeled muscle 
pericytes is along the path of injection (Figure 5.17-Ai). The same was true on the 
injured side (Figure 5.17-Bi). In addition, these pricytes were found to be located in 
blood vessels and capillaries as evidenced by lectin staining (Figure 5.17 Aii and Bii). 
In the injured side some fibres had CLN (Figure 5.17 Biv) but none of them was 
strongly positive for Tomato. On the other hand there were few tomato positive fibres 
with CLN visible in the injured side when peritoneal-derived pericytes were injected 
(Figure 5.17 Div). The distribution of tomato-positive fibres in the non-injured side was 
similar when compared with section from TA muscle transplanted with muscle 
pericytes (Figure 5.17 Ci). Co-localisation with lectin staining was also evident in both 
injured and non-injured muscles injected with peritoneal pericytes, indicating their 
presence in capillaries (Figure 5.17 Di).  
This data indicate that both muscle- and peritoneum-derived pericytes can 
contribute to muscle regeneration. However, there was still the possibility that the 
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Figure 5.17: Localisation of transplantated tomato-labelled pericytes in the TA muscle of 
ROSA-tdTomato mice. TA muscles of ROSA26-tdTomato mice were injected with tomato-
labelled pericytes isolated from either muscle (Ai- iv and Bi- B iv) or peritoneum (Ci-Civ and 
Di-Div). In each mouse one TA was injured with CTX, while the other TA served as a non-
injured control. Tomato-labelled pericytes are visible in red, Lectin BS1 staining in green marks 
the pericyte location in capillaries, while DAPI (blue) marks the nuclei. Scale bars, 100µm (A-
Di), 20µm (Aii-Div). 
 
 
Previously, Dellavalle et al. (2011) described that the tissue non-specific 
alkaline phosphatase ALPL is specifically expressed by a subset of vessel-associated 
cells in skeletal muscle, but not in myogenic cells and myofibres. They generated  an 
inducible Alkaline Phosphatase CreERT2 mouse strain with which they could show that 
these ALPL-positive pericytes are distinct from endothelial and satellite cells. In 
addition, they showed evidence that these ALPL-positive pericytes contribute to muscle 
regenerating. We therefore decided to FACS sort our m scle- and peritoneum-derived   
pericytes with ALPL, to exclude a possible contamination of our initial cell population 





Figure 5.18: ALPL FACS sorting of pericytes isolated from muscle and 
peritoneum.CD140b+/CD45-/CD31- pericytes were isolated as before. These cells then 
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FACS sorting demonstrated that around 10-20% of our pericyte populations 
were positive for ALPL (Figure 5.18). These cells were then injected intramuscularly 
into the TA muscle of ROSA26-tdTomato mice as described in figure 5.16. 
Cryosections from the isolated muscles were immunostained with Lectin BS1 and DAPI 
while tomato positive fibres were visualised in thered channel (Figure 5.19). 
 
The immunostaining data from the muscle sections of ROSA26-td Tomato -/- 
mice transplanted with muscle or peritoneum PVCs additionally sorted for ALPL 
(Figure 5.19) gave a similar result as before seen with the non-ALPL-sorted pericyte 
populations (Figure 5.17). Sections from the injured and non-injured side showed 
Tomato-positive fibres with varying intensity. Interestingly, most fibres that were 
positive for tomato also showed co-localisation of T mato with lectin BS1-positive 
endothelial cells in capillaries, though this is difficult to see due to the intensity of the 
signal inside the muscle fibres (Figure 5.19 Aii-Div). In some cases a spider web-like 
structure of Tomato-positive blood vessels was visible (Figure 5.19 Ciii, Diii). In 
sections from the injured sides Tomato-positive fibres that had CLN were visible, 
indicating that pericytes had fused with the regenerating fibre (Figure 5.19 Biv) 
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Figure 5.19: Localisation of transplanted ALPL-sorted tomato-labelled pericytes in the TA 
muscle of ROSA-tdTomato mice. TA muscles of ROSA26-tdTomato mice were injected with 
ALPL-positive tomato-labelled pericytes isolated from either muscle (Ai- Aiv and Bi- B iv) or 
peritoneum (Ci-Civ and Di-Div). In each mouse one TA was injured with CTX and the other  
served as a non-injured control. Tomato-labelled pericytes are in red, lectin BS1 staining in 
green marks the pericyte location in capillaries, while DAPI (blue) marks the nuclei. Scale bars, 
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5.5 Discussion 
Pericytes are essential constituents of blood vessels and act as important 
regulators of vessel development, stabilisation and contractility. It has been suggested 
that pericytes and vascular smooth muscle cells (vSMCs) are phenotypic subtypes of a 
continuous perivascular cell (PVC) population that m y have the capacity to give rise to 
each other (Brachvogel et al., 2005). It has been dmonstrated that these PVCs 
constitute a population of mesenchymal stem cells (MSCs) associated with the 
vasculature (Brachvogel et al., 2005) and with the ability to differentiate in to 
chondrocytes, osteoblasts and adipocytes. Additionally, pericytes show myogenic 
potential distinct from satellite cells (Dellavalle et al., 2007), however, the contribution 
of PVCs to tissue and repair in situ remains uncertain. With an increased interest in the 
field of these PVCs, the process of studying and unerstanding the complexity of this 
versatile and intriguing cell types has just begun. 
 
5.5.1 Perivascular cells and mesenchymal stem cells 
As there has been a remarkable increase in knowledge in the field of stem cell 
biology in the past decade, much effort has been devoted to understand the molecular 
mechanisms that regulate adult stem cells, or the stem cell/progenitor cells derived from 
adult bone marrow (BMSCs), and developing ways to exploit their potential for 
therapies. The notion that PVCs are recruited from stromal cells (where MSCs were 
originally isolated from) by mutual contacts with endothelial cells has been indicated in 
several studies (Caplan et al., 2008; 2011; Crisan et al., 2008). In this study we tried to 
answer some of the basic questions regarding the role of these PVCs.  
 
5.5.2 Anxa5-based reporter mouse models to identify perivascular cells 
While there are still many unanswered questions about pericytes today, several 
techniques were developed and additional cellular mkers identified that now allow 
isolation of PVCs and in vivo studies in mice. Markers like α-SMA, NG2 proteoglycan, 
desmin and pdgfr-β are now regularly used to identify populations of perivascular cells 
in vitro and in vivo (Bergers and Song, 2005), but the most significant of all appears to 
be that of the annexin A5 protein that has proved pivotal in increasing the detection, 
isolation and characterisation of these cells (Brachvogel et al., 2003; 2005; 2007). In 
this study, we provide additional support that highlights this protein as a distinct marker 
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of pericytes. Through use of the Anxa5-LacZ mouse model developed by Brachvogel et 
al., 2005, we have been able to visualise and observe the distribution of pericytes 
through detection of LacZ expression. The mouse model has proved fundamental in 
identifying the distribution of pericyte-like cells along and in close association with the 
microvasculature of postnatal tissue. In our study we made use of the Anxa5-LacZ 
mouse model to study the role of pericytes during muscle regeneration by crossing them 
with mdx mice, a mouse model for DMD. Our data clearly shows a close relationship 
between regenerating fibres and the PVC population, which are wrapped around the 
blood vessels close to the fibre (Figure 5.3 C and D) 
 
The Anxa5-LacZ model has been instrumental in increasing our knowledge of 
pericytes. A large body of evidence further indicates hat all mesenchymal stem cells 
(MSCs) are pericytes (Caplan, 2008). Adult mammalian bone marrow has been shown 
to harbor not one but two discrete adult stem cell lines. While the hematopoietic stem 
cells generated in the bone marrow responsible for maintaining life long production of 
blood cells are certainly well characterised, the biological characteristics and properties 
of the second bone marrow resident population of stem cell are much less understood. 
This lack of understanding has been compounded, until relatively recently, by the 
shortage of specific antibody reagents to facilitate the isolation and enrichment of these 
mesenchymal stem cells (Short et al., 2004). In 2003 Baddoo et al., used a combination 
of plastic adherence and in vitro culture to establish a bone marrow stromal cell culture. 
They then removed any contaminating hematopoietic clls by negative selection using 
antibodies to a number of hematopoietic-specific antige s. The remaining stromal cells 
were shown to exibit osteogenic, adipogenic, and chondrogenic differentiation potential 
in vitro and expressed no markers of hematopoietic or vascular endothelial cells 
(Baddoo et al., 2003). They did however, express SCA1, much like a candidate 
osteoprogenitor population in mouse bone marrow as demonstrated by Falla et al., back 
in 1993 (Falla et al., 1993). Most recently in 2007, Brachvogel et al., demonstrated that 
a population of Anxa5-LacZ+ PVC isolated from mouse meningeal vasculature 
expressed SCA1- and it is now a common marker used for the characterisation and 
purification of mesenchymal stem cells.  
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For many in the field it is still remains to be unequivocally proven that all MSCs 
are in fact pericytes. Certainly, all pericytes arenot MSCs; it has been documented that, 
while pericytes do not differentiate into hematopoietic or neural cell in adults, the 
vasculature/perivascular location of hematopoietic and neural stem cells in early foetal 
tissue implies that other stem cells too inhabit the perivascular niche (Caplan, 2008; 
Hirschi and D’amore, 1996). But unfortunately, while there still remains much to 
discover about the complex ontogeny and function of pericytes, the proposal that all 
pericytes are MSCs will continue to be a somewhat open question rather than a proven 
statement. Nonetheless, advances such as the Anax5-LacZ and the Anxa5-
Cre//ROSA26-LacZ models give hope that we may be abl to provide a definite answer 
to this question in the future. 
 
5.5.3 Role of pericytes as myogenic precursors 
In regards to in situ functions of pericytes several doubts still remain. The most 
topical enquiring is into the potential contribution f these cells to tissue repair and 
regeneration, through their differentiation into various lineages (Caplan, 2008; Crisan et 
al., 2008). Our study had in mind the specific role f pericytes as myogenic precursors, 
and aimed to uncover any intimation towards the involvement of these perivascular 
cells giving rise to the muscle lineages in skeletal muscle regeneration. Our data 
suggests that there is a direct involvement of pericytes in myofibre regeneration. In 
mdx//Anxa5-LacZ muscle sections the α-SMA positive cells were evident inside the 
regenerating fibres indicating the location of pericytes. But this piece of data alone does 
not support that pericytes are a stem cell population, which can contribute to muscle 
repair. To support our findings we generated the Anxa5-Cre-KI mouse model, which 
provided us a tool to follow the fate of these pericytes during muscle regeneration in 
combination with various reporter strains such as ROSA26-LacZ and ROSA26-td-
Tomato. Preliminary data from our experiments on Anxa5-ROSA26-LacZ mice (Figure 
5.9 and 5.10) suggests that LacZ-positive pericytes or pericyte-like cells have 
contributed to muscle regeneration, which was evident by strong LacZ staining inside 
fibres with CLN. To further investigate these findigs it was necessary to lineage trace 
this stem cell like population. This led us to our hypothesis described in figure 5.19, 
where we propose the possibility of these cells to differentiate into a different lineage 
even after committed to one cell lineage due to their phenotypic plasticity. A feature 
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that distinguishes the MSC from that of the hematopoietic stem cell lineage is that 
differentiation pathways are not strictly delineated, since even apparently fully 




Figure 5.20: The mesenchymal stem cell system. Factors shown at the exit of the MSC 
compartment are those used in (osteogenic, chondrogenic, and adipogenic) or compatible with 
(VSMC differentiation) culture conditions. Double arrows indicate plasticity. The potential 
sequence of events occurring in the MSC compartment is shown.(Modified from Dennis & 
Charbord ,2002) 
Potential sequence of events occurring in the MSC compartment is shown in Abbreviations: MSC = mesenchymal stem cell; TGFβ 
= transforming growth factorβ; PDGF = plateletderived growth factor; ASMA = αsmooth muscle actin; TSP1 = 
thrombospondin1; EDa+FN = fibronectin comprising the EDa domain; 1E12 = smooth muscle αactinin recognized by the 1E12 
monoclonal antibody; h1Calp = h1calponin; hCald = hcaldesmon; mV = metavinculin; SM1 = SM myosin heavy chain of 204 
kDa; Des = desmin; Dex = dexamethasone; IBMX = isobutylmethylxanthine; IM = indomethacine; βgp = beta
glycerophosphate; aP = ascorbate2phosphate; NRO = Nile red O stain; vK = von Kossa stain; Coll = collagen I  
 
 
At the same time we also realised the limitation of using the Anxa5-Cre-Ki 
mouse model. One major drawback of this model is that, after somatic differentiation all 
decendants will be labeled with the reporter gene. To avoid this dilemma we have tried 
to develop an inducible Cre mouse model, Anxa5-Cre-ERT2. In order to do so we 
designed the targeting construct and transfected ES cells. Unfortunately, we failed to get 
any homologous recombination in ES cells twice. During the same time Dellavalle et 
al., used the ALPL-Cre-ERT2 mouse model (Dellavalle et al., 2011). Their data 
Anxa5-ROSA-LacZ PVCs Muscle ?? 
Pericytes : 
 mesenchymal stem cell compartment  
 restricted differentiation capacity 
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suggested that ALPL-positive pericytes, but not endothelial cells, fuse with developing 
myofibres and enter the satellite cell compartment during unperturbed postnatal 
development. This contribution increased significantly during acute injury or in 
chronically regenerating dystrophic muscle. This data indicates that pericytes, resident 
in small vessels of skeletal muscle, contribute to muscle growth and regeneration during 
postnatal life.  
To further investigate the involvement of pericytes as a stem cell we decided to 
follow an inverse approach. Instead of using the inducible Cre system in vivo, we 
isolated and purified perivascular cells from tdTomato reporter mice and induced 
reporter expression i  vitro by viral delivery of Cre recombinase. 
 
5.5.4 Investigating the contribution of pericytes in regenerating muscle by 
transplantation experiments 
 
To investigate the potential of pericytes as a stem c ll population we isolated 
and purified pericytes from ROSA-td-Tomato mice in which the expression of Tomato 
is silent and induced reporter expression in vitro by transduction with Adeno-Cre virus. 
Our data indicates that the isolated pericytes population from muscle and peritonium 
contributed to muscle regeneration. After intramuscular injection of these pericytes in 
ROSA26-tdTomato congenic mice we observed many fibres in regenerating areas 
expressing td-Tomato indicating the possible fusion of pericytes with the regenerating 
fibre. The intensity of the expression varied between fibres. This can be explained by a 
possible dilution effect when pericytes fuse with pre-existing fibres, as the reporter has a 
cytoplasmic location. Surprisingly in non-injured muscle we found more Tomato-
positive fibres. This can be explained by several possibilites. Firstly, there are more 
pericytes surviving in the un-injured situation, and, as there is still constant homeostasis 
in skeletal muscle up to six months of age (G. Kardon, personal communication) more 
pericytes could be recruited to the muscle fibres. Secondly, there could have been a 
possible carry over of the virus. To address this issue we injected these pericytes in WT 
C57/BL6 mice (Figure 5.21). If there was an issue of carrying the virus over then 
muscle cells, which became infected should turn red in the ROSA26 reporter stain, but 
not in C57/BL6 mice.  
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Figure 5.21: Transplantation of Tomato-labelled pericytes into TA muscle of C57BL/6 mice. 
TA muscles of C57BL/6 mice were injected with Tomat- l belled pericytes isolated from either 
muscle (Ai- Aiv) or peritoneum (Bi-Biv). Tomato expression is in red, endothelial cells marked 
with lectin BS1 in green, DAPI in blue to mark nuclei. Images were taken at x20 magnification. 
 
 
From these immunostaining results it was evident that Tomato-positive pericytes 
from both muscle and peritoneum were in fact able to fuse with muscle fibres (Figure 
5.21 Aii and Bii). Tomato-positive spider web-like structures along the blood vessels 
were again visible, identical to the results when we used the ROSA26-tdTomato mouse 
strain. Some fibres were positive for Tomato and haalso CLN (Figure 5.21 Biii). 
These regenerating fibres were not due to induced injury, but normal wear and tear of 
the muscle.  Together, our data showed unequivocally that the presence of red fibres 
was not due to viral contamination of our pericytes.  
 
 These findings support the hypothesis that in respon e to focal injury pericytes 
are activated and released from their position on the vascular tube to migrate/proliferate 
to the site of injury and contribute to the regeneration process. Support for this 
hypothesis is the fact that degradation products of extracellular matrix (ECM) proteins 
are chemotactic for progenitor cells, and pericytes show strong migration towards both 
papain and pepsin digested ECM (Crisan et al., 2008; Reing et al., 2008). 
Lectin Tomato Merged Ai  A ii  A iii  DIC 
Lectin Tomato Merged Bi  B ii  B iii  DIC 
A iv  
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Figure 5.22: Schematic representation of proposed hypothesis: A) Indicates the involvement of 
satellite cells (pink) in muscle regeneration upon activation. The pericytes are shown in blue 
wrapped arround the blood vessels surrounding the myofibre. B) Demonstrates the proposed 




Based on the results shown in this study we propose the working hypothesis, 
which is displayed in figure 5.22. The schematic representation of a well-known 
standard model of muscle regeneration can be seen in figure 5.22, where the role of the 
satellite cells in regeneration is shown. Alternatively, the model (Figure 5.22 B) shows 
the involvement of pericytes in myofibre regeneration. As therapy by isolated myoblasts 
is considered to be insufficient to rescue damaged muscle (Tedesco et al., 2010), 
isolated pericytes may become a potential therapy for muscle disease. 
 
In our study we have shown that annexin A5 is a distinct and significant marker 
for pericyte cells resident in the vasculature. It has been clearly demonstrated that 
pericyte-like stem cells can differentiate into myogenic lineages (Dellavalle et al., 
2007), and our results further support that notion by showing that not only pericytes 
isolated from skeletal muscle but also from the peritoneum can contribute to skeletal 
muscle repair. Whether pericytes from all tissues ar  similar in their molecular signature 








Peri-vascular niche  
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Chapter 6 Summary 
 
Major players in maintaining the muscle integrity during development and in adult 
skeletal muscle are integrins. Presented in this the is is the initial characterisation and 
investigation of the use of transgenic mice overexpssing integrin α7 splice variants and 
the conditional KO of integrin α5 in muscle. These mice were generated with the eventual 
aim to increase the knowledge and understanding of the role of integrins in adult and 
developing muscle and their potential role in in muscle wasting disease. 
The loss of integrins from skeletal muscle has been shown to result in muscle 
wasting diseases, but for the first time it has been presented that an increase in integrin α 
subunits can also cause a dystrophic phenotype in adult skeletal muscle. The onset and 
progression of this phenotype varies between different locations within muscle and 
correlates with the level of the integrin α subunit expression and the specific alternative 
splice variant of the subunit.  
Increasing the levels of integrin α7 results in an increase in the level of integrin β1 
and integrin α7 splice variants can compete with each other for integrin β1 association to a 
certain extent, but there are controls in place to nsure that the specific localisation and 
therefore function of certain receptor combinations are preserved. 
To elucidate the function of integrin α5 in skeletal muscle, it is important to knock 
down the expression of Itga5 gene. Knocking out integrin α5 is embryonically lethal and 
conclusions drawn from the α5 -/- chimeric mice were limited. An ideal tool in the 
investigation of the role of integrin α5 during muscle development would be to generate a 
conditional knock out of integrin α5 where, the expression of Cre is driven by a muscle-
specific promoter. Here we have shown that knocking down integrin α5 conditionally by 
the HSA-Cre promoter does not lead to a muscular dystrophy, however, loss of integrin α5 
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Integrin α5 is vital to skeletal muscle development and has a close relationship with 
integrin α7 (Yao et al., 1996; Taverna et al., 1998; Nawrotzki et al in 2003). In normal 
postnatal muscle integrin α5β1 expression is detected at MTJs, which is then switched by 
presence of integrin α7β1 two weeks after birth. However, the observations made by 
Nawrotzki et al in 2003, suggests that in integrin α7-deficient muscles, the expression of 
integrin α5β1D persists into adulthood. This leads to the accumulation of fibronectin in 
place of laminin at the junctional basement membrane of the muscle fibre. This link 
between α5β1D/fibronectin is inferior to the α7β1D/ laminin link at the normal MTJ, and 
this possible gain-of-function phenotype could be leading to the onset of muscle wasting in 
α7-deficient mice.  
Here we have shown the effect of loss of both the int grins by breeding integrin α7 
heterozygous or homozygous mice with integrin α5 heterozygous mice to generate integrin 
α7KO mice carrying only one allele of integrin α5. To our surprise none of these mice 
survived the postnatal stage and analysis of embryos at E10.5 suggests that these is an 
dosage effect of integrin α5 which is needed in order to compensate the effect of loss of 
integrin α7 at early stages of development and there is a possible role of these integrins in 
vascular development. 
Apart from gene therapy the stem cell based therapis are getting more interest in 
the field of regenerative medicine. For muscle related diseases, the potential candidates are 
stem cell population from muscle itself called, satellite cells (SCs), yet by nature they 
exhibit a number of characteristics that limit their ffectiveness as discussed before. In 
2007, Dallavalle et al demonstrated other cell types, which behave like stem cell 
populations and have the capacity to differentiate in o skeletal muscle. One such stem cell 
population included in this study is the cells associated with the microvasculature of 
skeletal muscle.  
Of particular relevance as a promising candidate for future cell therapy, pericytes 
may represent as embryonic mesangioblst present after birth, but by disparity do not 
express the endothelial markers found in these cells. In addition, they have a number of 
unequivocal characteristics that distinguish them from SCs, including a different 
anatomical niche and growth requirements. Unlike SCs, they do not express mitogenic 
factors such as Pax7, Myf5 and MyoD (Kassar-Duchossoy et al., 2004; 2005) until terminal 
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differentiation, but instead express a number of other markers. In recent years, several 
markers have been identified that define subpopulations of pericytes, like desmin, smooth-
muscle-actin (α-SMA), NG2-proteoglycan (Ozerdem et al., 2001), PDGFR-β or the 
GTPase-activating protein RGS5 (Gerhardt and Betsholtz, 2003) and non tissue-specific 
alkaline phosphatase (ALPL). By this it became also clear that pericytes and vascular 
smooth muscle cells are subsets of a continuum of vascular cells with phenotypic plasticity 
(Nehls and Drenckhahn, 1993). The lack of specific markers limited the analysis of 
pericytes, as pure cell populations could not easily be purified from tissues. Until recently, 
no adequate method was available to purify pericytes from mouse tissues, a prerequisite for 
using modern mouse genomics and proteomics. Therefor , we used a mouse model 
(Anxa5-LacZ), which helped us to identify these cells with the help of Anxa5 driven LacZ 
expression. Anxa5-LacZ fusion reporter mice have been shown to be a valuable tool for the 
identification, isolation and characterisation of perivascular cells/pericytes from tissues 
(Brachvogel et al., 2003; 2005; 2007). However, LacZ staining can only be done by 
traditional static histological analysis, and therefo  lacks any information about the 
dynamics of pericytes in tissue remodelling. Additionally, it is very likely that the Anxa5 
promoter is not active in pericyte descendants and so we may miss the identification of 
cells into which pericytes differentiate. In this study we demonstrate the potential fate of 
the pericytes in muscle regeneration by generating co ditional KI mice (Anxa5-Cre-KI).  
Dallavalle et al proposed these pericyte-derived cells as a second myogenic 
precursor present within postnatal skeletal muscle, distinct from SCs yet similar myogenic 
potency (Dallavalle et al., 2007).  In this study we demonstrate the potential fate of the 
pericytes in muscle regeneration by transplanting fluorescently labeled pericytes into the 
TA muscle of congenic mice. Upon muscle injury we wre able to trace the lineage of these 
transplanted cell and have shown here that these cell do contribute towards new myofibre 













Figure 6.1 Therapeutic possibilities for Duchenne Muscular Dystrophy. (A) Intramuscular 
injection of fluorescently labeled pericytes, isolated from muscle or peritoneum in order to follow 
the fate of these cells during muscle regeneration. (B) A schematic representation of the 
dystrophin/glycoprotein complex and the integrin/laminin-mediated attachment of muscle cells to 
the surrounding extracellular matrix. Upregulation of integrin α7 may compensate for the 
functional loss of dystrophin (Modified from Seale, Asakura and Rudnicki, 2001) 
 
 
Over all in this study we tried to evaluate possible therapies for DMD. As explained 
above the integrin α7β1 would be a candidate for gene therapy (Figure 6.1), but as 
discussed in the results chapter it might not be eff ctive as seen in mdx mice. While on the 
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